

	Espacio reservado para el adhesivo de radicación
---	--

DIRECCIÓN DE NUEVAS CREACIONES
Procedimiento acelerado de exámenes de patente (PPH)

1	NÚMERO DE SOLICITUD ANTE LA SIC	NC2019/0004672	
2	GLOBAL - PPH ☐ PAÍS	3	PCT – PPH ☐ PAÍS
4	PROSUR ☐ PAÍS	5	Alianza del Pacífico (AdP) ☐ PAÍS
6	OFICINA DE PRIMERA PRESENTACIÓN (OPP) ☒	7	OFICINA DE EXAMEN ANTERIOR (OEA) ☐
8	NÚMERO DE SOLICITUD O PUBLICACIÓN DE LA SOLICITUD (OPP) ☒ NÚMERO DE SOLICITUD EN OFICINA DE EXAMEN ANTERIOR (OEA): ☐ NÚMERO DE SOLICITUD PCT: ☐	US 15/807,426	
9	☐ REPRESENTANTE LEGAL ☒ APODERADO		
APELLIDOS DAZA MONTALVO		NOMBRES Carolina Mercedes	IDENTIFICACIÓN C.C.66783790 T.P.141563 CSJ
DIRECCIÓN	Carrera 11 No. 86-53 Piso 3	No. TELÉFONO	6181088
CIUDAD	Bogotá D.C.	CORREO ELECTRÓNICO	notificaciones@clarkemodet.com.co
PAÍS	COLOMBIA	No. RADICACIÓN O PROTOCOLO DE PODER GENERAL	NC2018/0007839
10	CONDICIONES PARA ACCEDER A ESTE PROCESO:		
10.1. DATOS DE PRIORIDAD ☐ SI ☒ NO			
(33) PAÍS DE ORIGEN 1.Estados Unidos de América 2.		CÓDIGO PAÍS US	(31) NÚMERO 62/419,062 (32) FECHA (AAAA/MM/DD) 2016/11/08
10.2. DATOS SOLICITUD INTERNACIONAL PCT ☒ SI ☐ NO			
Solicitud Internacional No.		PCT/US2017/060690	Fecha 2017/11/08
Publicación Internacional No.		WO2018/089532	Fecha 2018/05/17
*El solicitante presenta una copia de la(s) reivindicación(es) patentable(s) u otorgable(s) de la solicitud de la Oficina de Primera Presentación que profirió el examen de patentabilidad, junto con una traducción al castellano. ☒ SI ☐ NO			
*El solicitante presenta los resultados de búsqueda de la Oficina de Examen Anterior, junto con una traducción al castellano ☒ SI ☐ NO			
REQUISITOS PARA EL RECONOCIMIENTO DE LOS RESULTADOS DE EXÁMENES DE PATENTABILIDAD EFECTUADOS A SOLICITUDES EXTRANJERAS			
Para que la Superintendencia de Industria y Comercio pueda reconocer los resultados de exámenes de patentabilidad producidos por otras Oficinas de Propiedad Industrial se debe cumplir con las siguientes condiciones:			
(a) Al momento de solicitar el examen de patentabilidad, si el solicitante pide que se reconozcan exámenes de patentabilidad de otras oficinas extranjeras, deberá aportar junto con el pago de la tasa correspondiente, los siguientes anexos:			
(i) Copia de las resoluciones, fallos o decisiones que han sido relevantes para la determinación de la patentabilidad de la(s) solicitud(es) en la Oficina que haya proferido el examen de patentabilidad que contienen reivindicaciones patentables u otorgables que son la base de la petición, y si es del caso, su traducción al castellano. ☒ SI ☐ NO			
(ii) Copia de todas las reivindicaciones determinadas como patentables u otorgables en la Oficina que profirió el examen de patentabilidad y, si es del caso, su traducción al castellano. ☒ SI ☐ NO			
(iii) Copia de los antecedentes, información o documentos citados por el examinador de la Oficina de Primera Presentación del examen de patentabilidad, en las resoluciones, fallos o decisiones correspondientes, incluyendo la literatura no patente. Los documentos de patente deberán presentarse siempre y cuando no estén disponibles para la Superintendencia de Industria y Comercio mediante el simple acceso a bases de datos gratuitas. ☒ SI ☐ NO			
(iv) Una tabla de correspondencias de las reivindicaciones que han sido determinadas como patentables u otorgables en la solicitud de la Oficina que haya proferido el examen de patentabilidad. ☒ SI ☐ NO			
11	FIRMA DEL SOLICITANTE, DEL APODERADO O DEL REPRESENTANTE LEGAL Junto a cada firma, indicar el nombre del firmante y su calidad (si tal calidad no es obvia al leer el petitorio)		
 CAROLINA DAZA MONTALVO			

10 (iv)	TABLA DE CORRESPONDENCIA DE REIVINDICACIONES		
Reivindicaciones en la solicitud en Colombia		Reivindicaciones otorgables en la solicitud internacional	Explicación sobre la suficiente correspondencia ó Comentarios que explican la correspondencia
1. Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une al receptor de leptina humana (LEPR), CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende: (a) las regiones determinantes de complementariedad (CDR) de una región variable de cadena pesada (HCVR) que comprende una secuencia de aminoácidos establecida en un SEQ ID NO seleccionado del grupo que consiste en la SEQ ID NO: 2, SEQ ID NO: 42, y SEQ ID NO: 58 y (b) los CDRs de una región variable de cadena ligera (LCVR) que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 10.		1. Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une al receptor de leptina humana (LEPR), en el que el anticuerpo o fragmento de unión a antígeno del mismo comprende: (a) las regiones determinantes de complementariedad (CDR) de una región variable de cadena pesada (HCVR) que comprende una secuencia de aminoácidos establecida en una SEQ ID NO seleccionada del grupo que consiste en SEQ ID NO: 2, SEQ ID NO: 42 y SEQ ID NO: 58 y (b) los CDRs de una región variable de cadena ligera (LCVR) que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	<i>Sustancialmente iguales</i>
2. El anticuerpo aislado o fragmento de unión a antígeno del mismo de acuerdo con la reivindicación 1, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende: una LCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 14, y una LCDR3 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 16; y una región variable de cadena pesada que comprende: (i) un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8; (ii)		2. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende: una LCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 14, y una LCDR3 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 16; y una región variable de cadena pesada que comprende: (i) un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8; (ii)	<i>Sustancialmente iguales</i>

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 44; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:46; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48; o (iii) un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:62; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.	un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 44; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:46; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48; o (iii) un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:62; y un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.	
3. El anticuerpo aislado o fragmento de unión a antígeno del mismo de la reivindicación 2, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 2 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	3. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 2, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 2 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	<i>Sustancialmente iguales</i>
4. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 2, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 42 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	4. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 2, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 42 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	<i>Sustancialmente iguales</i>

5. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 2, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 58 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	5. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 2, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 58 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.	<i>Sustancialmente iguales</i>
6. Una composición farmacéutica, CARACTERIZADA porque comprende el anticuerpo o fragmento de unión a antígeno del mismo de una cualquiera de la reivindicación 1, y un vehículo o diluyente farmacéuticamente aceptable.	6. Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno del mismo según la reivindicación 1, y un vehículo o diluyente farmacéuticamente aceptable.	<i>Sustancialmente iguales.</i>
7. El anticuerpo según la reivindicación 3, CARACTERIZADO porque la región variable de la cadena pesada está unida a un IgG4 Fc humano.	7. El anticuerpo según la reivindicación 3, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.	<i>Sustancialmente iguales</i>
8. El anticuerpo según la reivindicación 4, CARACTERIZADO porque la región variable de la cadena pesada está unida a un IgG4 Fc humano.	8. El anticuerpo según la reivindicación 4, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.	<i>Sustancialmente iguales</i>
9. El anticuerpo según la reivindicación 5, CARACTERIZADO porque la región variable de la cadena pesada está unida a un IgG4 Fc humano.	9. El anticuerpo según la reivindicación 5, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.	<i>Sustancialmente iguales</i>
10. Una composición farmacéutica CARACTERIZADA porque comprende el anticuerpo según la reivindicación 7, y un vehículo o diluyente farmacéuticamente aceptable.	10. Una composición farmacéutica que comprende el anticuerpo según la reivindicación 7, y un vehículo o diluyente farmacéuticamente aceptable.	<i>Sustancialmente iguales</i>
11. Una composición farmacéutica CARACTERIZADA porque comprende el anticuerpo según la reivindicación 8, y un vehículo o diluyente farmacéuticamente aceptable.	11. Una composición farmacéutica que comprende el anticuerpo según la reivindicación 8, y un vehículo o diluyente farmacéuticamente aceptable.	<i>Sustancialmente iguales</i>
12. Una composición farmacéutica CARACTERIZADA porque comprende el anticuerpo según la reivindicación 9, y un vehículo o diluyente farmacéuticamente aceptable.	12. Una composición farmacéutica que comprende el anticuerpo según la reivindicación 9, y un vehículo o diluyente farmacéuticamente aceptable.	<i>Sustancialmente iguales</i>

13. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4; - un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; - y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8.	13. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4; - un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; - y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8.	<i>Sustancialmente iguales</i>
14. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de la cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en la SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 44; un - HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 46; y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48.	14. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de la cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en la SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 44; un - HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 46; y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48.	<i>Sustancialmente iguales</i>

15. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, CARACTERIZADO porque el anticuerpo o fragmento de unión a antígeno del mismo comprende una región variable de cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y - una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 62; y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.	15. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 1, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende: - una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12; - una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y - una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y - una región variable de cadena pesada que comprende: - un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 62; y - un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.	<i>Sustancialmente iguales</i>
16. El anticuerpo según la reivindicación 7 CARACTERIZADO PORQUE la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	22. El anticuerpo según la reivindicación 7 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	<i>Sustancialmente iguales</i>
17. El anticuerpo según la reivindicación 8 CARACTERIZADO PORQUE la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	23. El anticuerpo según la reivindicación 8 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	<i>Sustancialmente iguales</i>
18. El anticuerpo según la reivindicación CARACTERIZADO PORQUE la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	24. El anticuerpo según la reivindicación 9 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.	<i>Sustancialmente iguales</i>



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

154565 7590 10/08/2019
FisherBroyles, LLP/Regeneron/CW
26844 E. Quarto Pl.
Aurora, CO 80016

EXAMINER

SHAFFER, SHULAMITH H

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 10/08/2019

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/807,426	11/08/2017	Jesper Gromada	09774.271US1/10271US01	8661

TITLE OF INVENTION: ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	01/08/2020

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

154565 7590 10/08/2019
FisherBroyles, LLP/Regeneron/CW
26844 E. Quarto Pl.
Aurora, CO 80016

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/807,426	11/08/2017	Jesper Gromada	09774.271US1/10271US01	8661

TITLE OF INVENTION: ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$1000	\$0.00	\$0.00	\$1000	01/08/2020

EXAMINER	ART UNIT	CLASS-SUBCLASS
SHAFFER, SHULAMITH H	1647	424-139100

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,

1 _____

(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

2 _____

3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☐ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☐ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: (Please first reapply any previously paid fee shown above)

☐ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☐ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____

Date _____

Typed or printed name _____

Registration No. _____



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
15/807,426	11/08/2017	Jesper Gromada	09774.271US1/10271US01	8661
154565	7590	10/08/2019	EXAMINER	
FisherBroyles, LLP/Regeneron/CW			SHAHER, SHULAMITH H	
26844 E. Quarto Pl.			ART UNIT	
Aurora, CO 80016			PAPER NUMBER	
			1647	
DATE MAILED: 10/08/2019				

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b) (Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Notice of Allowability	Application No. 15/807,426	Applicant(s) Gromada et al.	
	Examiner SHULAMITH H SHAFER	Art Unit 1647	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 2/28/19.
☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on ____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on ____; the restriction requirement and election have been incorporated into this action.

3. ☒ The allowed claim(s) is/are 4-8,11 and 18-35. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to PPHfeedback@uspto.gov.

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a) ☐ All b) ☐ Some *c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. ____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: ____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date ____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892) 2. ☒ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date <u>2/28/19</u> . 3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____. 4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.	5. ☒ Examiner's Amendment/Comment 6. ☐ Examiner's Statement of Reasons for Allowance 7. ☐ Other _____.
---	--

/SHULAMITH H SHAFER/
Primary Examiner, Art Unit 1647

Detailed Action

Notice of Pre-AIA or AIA Status

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Status of Application, Amendments, And/Or Claims:

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 28 February 2019 has been entered.

Claims 4-8, 11, and 18-35 are pending and under consideration in the instant application.

Information Disclosure Statement:

The Information Disclosure statements (IDS) submitted on the 28 February 2019 has been considered. The signed copy is attached.

Conclusion:

Claims 4-8, 11, and 18-35 are allowed for reasons set forth in Notice of Allowance of 3 December 2018.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHULAMITH H SHAFER whose telephone number is (571)272-3332. The examiner can normally be reached on M-F 8AM-5PM.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an

interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, JOANNE HAMA can be reached on 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/SHULAMITH H SHAFER/
Primary Examiner, Art Unit 1647

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

What is claimed is:

1 – 3 (cancelled).

4 (previously presented). An isolated antibody or antigen-binding fragment thereof that binds human leptin receptor (LEPR), wherein the antibody or antigen-binding fragment thereof comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) that comprises an amino acid sequence set forth in a SEQ ID NO selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 42, and SEQ ID NO: 58 and (b) the CDRs of a light chain variable region (LCVR) that comprises the amino acid sequence set forth in SEQ ID NO: 10.

5 (currently amended). The isolated antibody or antigen-binding fragment thereof of claim 4, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12; an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14, and an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16;
and

a heavy chain variable region comprising:

(i)

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 4;
an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 6;
[[,]] and
an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 8;

(ii)

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 44;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO:

46;[[,]] and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 48;

or

(iii)

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 60;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO:

62;[[,]] and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 64.

6 (previously presented). The isolated antibody or antigen-binding fragment thereof of claim 5, which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

7 (previously presented). The isolated antibody or antigen-binding fragment thereof of claim 5 which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 42 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

8 (previously presented). The isolated antibody or antigen-binding fragment thereof of claim 5 which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 58 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

9 - 10 (cancelled).

11 (currently amended). A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 4 [[1]], and a pharmaceutically acceptable carrier or diluent.

12 - 17 (cancelled).

18 (previously presented). The antibody of claim 6 wherein the heavy chain variable region is linked to a human IgG4 Fc.

19 (previously presented). The antibody of claim 7 wherein the heavy chain variable region is linked to a human IgG4 Fc.

20 (previously presented). The antibody of claim 8 wherein the heavy chain variable region is linked to a human IgG4 Fc.

21 (previously presented). A pharmaceutical composition comprising the antibody of claim 18, and a pharmaceutically acceptable carrier or diluent.

22 (previously presented). A pharmaceutical composition comprising the antibody of claim 19, and a pharmaceutically acceptable carrier or diluent.

23 (previously presented). A pharmaceutical composition comprising the antibody of claim 20, and a pharmaceutically acceptable carrier or diluent.

24 (new). The isolated antibody or antigen-binding fragment thereof of claim 4, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:
an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;
an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14;
and
an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16;
and a heavy chain variable region comprising:
an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 4;
an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 6;
and
an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 8.

25 (new). The isolated antibody or antigen-binding fragment thereof of claim 4, wherein

the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;

an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14;

and

an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16;

and

a heavy chain variable region comprising:

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 44;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 46;

and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 48.

26 (new). The isolated antibody or antigen-binding fragment thereof of claim 4, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;

an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14;

and

an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16;

and

a heavy chain variable region comprising:

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 60;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 62;

and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 64.

27 (new). An autoinjector that comprises the antibody of claim 6.

28 (new). An autoinjector that comprises the antibody of claim 7.

29 (new). An autoinjector that comprises the antibody of claim 8.

30 (new). A pen delivery device that comprises the antibody of claim 6.

31 (new). A pen delivery device that comprises the antibody of claim 7.

32 (new). A pen delivery device that comprises the antibody of claim 8.

33 (new). The antibody of claim 18 wherein the light chain variable region is linked to a kappa light chain constant domain.

34 (new). The antibody of claim 19 wherein the light chain variable region is linked to a kappa light chain constant domain.

35 (new). The antibody of claim 20 wherein the light chain variable region is linked to a kappa light chain constant domain.

Traducción de la Notificación de Concesión	Solicitud No. 15/807,426	Solicitante(s) Gromada et al.	
	Examinador SHULAMITH H SHAFER	Unidad de Arte 16747	Estado AIA (Primer Inventor en Presentar) Sí

-- La FECHA DE ENVIO de esta comunicación aparece en la hoja de cubierta con la dirección de correspondencia--

Todas las reivindicaciones son concedidas, TRÁMITE SOBRE EL FONDO ESTÁ (O PERMANECE) CERRADO en esta solicitud. Si no se incluye acá (o fue enviada previamente), una Notificación de Concesión (PTOL-85) u otra comunicación adecuada será enviada en su debido momento. **ESTA NOTIFICACION DE CONCESION NO ES UNA CONCESION DE DERECHOS DE PATENTE.** Esta solicitud está sujeta a retiro de emisión a la iniciativa de la Oficina o a petición del solicitante. Ver 37 CFR 1.313 y MPEP 1308.

1. ☒ Esta comunicación responde a 2/28/19.
☐ Una declaración bajo **37 CFR 1.130(b)** se presentó el ____.

2. ☐ Se hizo una elección por el solicitante en respuesta a un requerimiento de restricción definido durante la entrevista el ____; el requerimiento de restricción y la elección se han incorporado en esta acción.

3. ☒ Las reivindicaciones concedidas son 4-8, 11 y 18-35. Como resultado de las reivindicaciones aceptadas, usted puede ser elegible del beneficio del programa de **Autopista de Trámite de Patente** en una oficina de propiedad intelectual participante para la correspondiente solicitud. Para más información, por favor ver http://www.uspto.gov/patents/init_events/pph/index.jsp o enviar una pregunta a PPHfeedback@uspto.gov.

4. ☐ Se reconoce una reivindicación de prioridad extranjera bajo 35 USC sección 119(a)-(d) o (f).
Copias certificadas:
a) ☐ Todas b) ☐ Algunas c) ☐ Ninguna de las:
1. ☐ Copias certificadas de los documentos de prioridad se han recibido.
2. ☐ Copias certificadas de los documentos de prioridad se han recibido en la Solicitud No. ____.
3. ☐ Copias de las copias certificadas de los documentos de prioridad se han recibido en esta solicitud de fase nacional de la Oficina Internacional (Regla PCT 17.2 (a)).
* Copias certificadas no recibidas: ____.

El Solicitante tiene TRES MESES A PARTIR DE LA “FECHA DE ENVIO” de esta comunicación para presentar una respuesta que cumpla con los requerimientos indicados anteriormente. Falla en cumplir a tiempo resultará en el ABANDONO de esta solicitud.
ESTE PERIODO DE TRES MESES NO ES EXTENSIBLE

5. ☐ Se deben presentar FIGURAS CORREGIDAS (como “hojas de reemplazo”).
☐ Incluyendo cambios requeridos por la Enmienda/Comentario del Examinador adjunto o en la Acción Oficial de Papel No./Fecha de Envío ____.

Los indicios de identificación tal como el número de solicitud (ver 37 CFR 1.84(c)) se deben escribir en las figuras en el frente (no atrás) de cada hoja. Las hojas de reemplazo deben estar etiquetadas como tal en el encabezado de acuerdo con 37 CFR 1.121(d).

6. ☐ Se debe presentar DEPOSITO DE y/o INFORMACIÓN acerca del depósito de MATERIAL BIOLOGICO. Note el comentario del Examinador adjunto con relación al REQUERIMIENTO PARA EL DEPOSITO DE MATERIAL BIOLOGICO.

Adjunto(s)

1. ☐ Notificación de Referencias Citadas (PTO-892)	5. ☒ Enmienda/Comentario del Examinador
2. ☒ Declaraciones de Divulgación de Información (PTO/SB/08), Papel No./Fecha Envío <u>2/28/19</u>	6. ☐ Declaración del Examinador de Razones para Concesión.
3. ☐ Comentario del Examinador con Relación a Requerimiento para Depósito de Material Biológico	7. ☐ Otro ____.
4. ☒ Resumen de Entrevista (PTO-413), Papel No./Fecha Envío ____.	

/ SHULAMITH H SHAFER / Examinador Principal, Unidad de Arte 1647	
---	--

Acción Detallada

Aviso de estado previo a AIA o AIA

La presente solicitud, presentada a partir del 16 de marzo de 2013, está siendo examinada bajo las disposiciones de la Ley de Invenciones de Norteamericana (AIA por sus siglas en inglés - *America Invents Act*) para el primer inventor en presentar.

Estado de la solicitud, enmiendas y / o reivindicaciones:

Para esta solicitud se presentó una solicitud de continuación de examen bajo la regla 37 CFR 1.114, incluida la tarifa establecida en la regla 37 CFR 1.17(e), después del rechazo final. Dado que esta solicitud es elegible para la continuación de examen bajo la regla 37 CFR 1.114, y que se pagó la tarifa establecida en la regla 37 CFR 1.17(e) oportunamente, la finalidad de la acción anterior de la Oficina ha sido retirada de conformidad con la regla 37 CFR 1.114. La solicitud del solicitante presentada el 28 de febrero de 2019 ha sido ingresada.

Las reivindicaciones 4-8, 11 y 18-35 están pendientes y bajo consideración en la presente solicitud.

Declaración de divulgación de información:

Se han considerado las declaraciones de divulgación de información (IDS) presentadas el 28 de febrero de 2019. Se adjunta la copia firmada.

Conclusión:

Las reivindicaciones 4-8, 11 y 18-35 están permitidas por los motivos establecidos en el Aviso de asignación del 3 de diciembre de 2018.

Cualquier consulta relacionada con esta comunicación o comunicaciones anteriores del examinador debe dirigirse a SHULAMITH H SHAFER cuyo número de teléfono es (571) 272-3332. Normalmente se puede contactar con el examinador de lunes a viernes de 8 a.m. a 5 p.m.

Las entrevistas con los examinadores están disponibles por teléfono, en persona y videoconferencias utilizando una herramienta de colaboración basada en la web suministrada por USPTO. Para programar una entrevista, se recomienda al solicitante que utilice la Solicitud de entrevista automatizada (AIR) de la USPTO en <http://www.uspto.gov/interviewpractice>.

Si los intentos de comunicarse por teléfono con el examinador no tienen éxito, puede comunicarse con el supervisor del examinador, JOANNE HAMA, llamando al 571-272-2911. El número de teléfono de fax de la organización donde se asigna esta solicitud o procedimiento es 571-273-8300.

La información sobre el estado de una solicitud se puede obtener del sistema de recuperación de información de solicitud de patente (PAIR). La información de estado para las solicitudes publicadas se puede obtener de la base de datos Private

PAIR o Public PAIR. La información de estado para solicitudes no publicadas está disponible solo a través de Private PAIR. Para obtener más información sobre el sistema PAIR, consulte <http://pair-direct.uspto.gov>. Si tiene preguntas sobre el acceso al sistema Private PAIR, comuníquese con el Electronic Business Center (EBC) al 866-217-9197 (sin cargo). Si desea asistencia de un Representante de Servicio al Cliente de USPTO o acceso al sistema de información automatizado, llame al 800-786-9199 (EN EE. UU. O CANADÁ) o al 571-272-1000.

/SHULAMITH H SHAFER/

Examinador principal, Unidad de Arte 1647

Modificaciones a las reivindicaciones:

Este listado de reivindicaciones reemplazará todas las versiones anteriores y listados de reivindicaciones en la solicitud.

Lo reclamado es:

1-3 (canceladas).

4 (presentada anteriormente). Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une al receptor de leptina humana (LEPR), en el que el anticuerpo o fragmento de unión a antígeno del mismo comprende: (a) las regiones determinantes de complementariedad (CDR) de una región variable de cadena pesada (HCVR) que comprende una secuencia de aminoácidos establecida en una SEQ ID NO seleccionada del grupo que consiste en SEQ ID NO: 2, SEQ ID NO: 42 y SEQ ID NO: 58 y (b) los CDRs de una región variable de cadena ligera (LCVR) que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

5 (actualmente modificada). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 4, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 14, y una LCDR3 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 16; y

una región variable de cadena pesada que comprende:

(i)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6;[[,]] y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8;

(ii)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 44;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:46;[[,]] y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48;

o

(iii)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:62; [[,]] y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.

6 (presentada anteriormente). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 5, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 2 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

7 (presentada anteriormente). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 5, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 42 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

8 (presentada anteriormente). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 5, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 58 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

9-10 (cancelado).

11 (actualmente modificada). Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno del mismo según la reivindicación 4 [[1]], y un vehículo o diluyente farmacéuticamente aceptable.

12-17 (cancelado).

18 (presentada anteriormente). El anticuerpo según la reivindicación 6, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

19 (presentada anteriormente). El anticuerpo según la reivindicación 7, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

20 (presentada anteriormente). El anticuerpo según la reivindicación 8, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

21 (presentada anteriormente). Una composición farmacéutica que comprende el anticuerpo según la reivindicación 18, y un vehículo o diluyente farmacéuticamente aceptable.

22 (presentada anteriormente). Una composición farmacéutica que comprende el anticuerpo según la reivindicación 19, y un vehículo o diluyente farmacéuticamente aceptable.

23 (presentada anteriormente). Una composición farmacéutica que comprende el anticuerpo según la reivindicación 20, y un vehículo o diluyente farmacéuticamente aceptable.

24 (nueva). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 4, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12;

una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14;

y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6;

y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8.

25 (nueva). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 4, en donde

el anticuerpo o fragmento de unión a antígeno comprende una región variable de la cadena ligera que comprende: una LCDR1 que comprende la secuencia de aminoácidos expuesta en la SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16;

y

una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 44; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 46; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48.

26 (nueva). El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación 4, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16;

y

una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 62; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.

27 (nueva). Un autoinyector que comprende el anticuerpo según la reivindicación 6.

28 (nueva). Un autoinyector que comprende el anticuerpo según la reivindicación 7.

29 (nueva). Un autoinyector que comprende el anticuerpo según la reivindicación 8.

30 (nueva). Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación 6.

31 (nueva). Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación 7.

32 (nueva). Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación 8.

33 (nueva). El anticuerpo según la reivindicación 18 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.

34 (nueva). El anticuerpo según la reivindicación 19 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.

35 (nueva). El anticuerpo según la reivindicación 20 en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.



US010550192B2

(12) **United States Patent**
Gromada et al.

(10) **Patent No.:** **US 10,550,192 B2**

(45) **Date of Patent:** **Feb. 4, 2020**

(54) **ANTIGEN-BINDING PROTEINS THAT
ANTAGONIZE LEPTIN RECEPTOR**

FOREIGN PATENT DOCUMENTS

(71) Applicant: **Regeneron Pharmaceuticals, Inc.,**
Tarrytown, NY (US)

(72) Inventors: **Jesper Gromada**, Scarsdale, NY (US);
Panayiotis Stevis, West Orange, NJ
(US); **Judith Altarejos**, Armonk, NY
(US)

(73) Assignee: **REGENERON
PHARMACEUTICALS, INC.,**
Tarrytown, NY (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 15 days.

AU	2004201496	C1	8/2018
EP	981365	B1	12/2004
EP	885299	B1	10/2005
EP	0730606	B1	11/2005
EP	1619250	B1	11/2009
EP	1019432	B1	1/2012
WO	1996/08510		3/1996
WO	1997/019952		6/1997
WO	1997/025425		7/1997
WO	1997/26272		7/1997
WO	1997/26370		7/1997
WO	1997/26523		7/1997
WO	1997/27286		7/1997
WO	1997/41263		11/1997
WO	1998/48831		11/1998
WO	2006/053883		5/2006
WO	2014/043361	A1	3/2014
WO	2015/124588		8/2015
WO	2017/066204	A1	4/2017

(21) Appl. No.: **15/807,426**

(22) Filed: **Nov. 8, 2017**

(65) **Prior Publication Data**

US 2018/0127508 A1 May 10, 2018

Related U.S. Application Data

(60) Provisional application No. 62/419,062, filed on Nov.
8, 2016.

(51) **Int. Cl.**

C07K 16/00 (2006.01)

C07K 16/28 (2006.01)

A61K 39/395 (2006.01)

A61K 39/00 (2006.01)

A61K 45/06 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 16/2869** (2013.01); **A61K 39/3955**
(2013.01); **A61K 45/06** (2013.01); **A61K**
2039/505 (2013.01); **C07K 2317/56** (2013.01);
C07K 2317/565 (2013.01); **C07K 2317/76**
(2013.01); **C07K 2317/92** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,005,080	A	12/1999	Snodgrass et al.
6,380,363	B1	4/2002	Tartaglia et al.
6,977,240	B1	12/2005	Tartaglia et al.
7,524,937	B2	4/2009	Carter et al.
7,575,878	B2	8/2009	Tavernier et al.
7,863,240	B2	1/2011	Ilan et al.
8,697,396	B2	4/2014	Dall'acqua et al.
8,969,291	B2	3/2015	Ilan et al.
10,023,644	B2	7/2018	Gromada et al.
2014/0134162	A1	5/2014	Stavnhagen et al.
2014/0171623	A1	6/2014	Dall'acqua et al.
2014/0243504	A1	8/2014	Davis et al.
2018/0037648	A1	2/2018	Ilan et al.
2019/0002569	A1	1/2019	Belaid-Choucair et al.

OTHER PUBLICATIONS

Al-Lazikani et al., (1997) "Standard Conformations for the Canonical Structures of Immunoglobulins", J. Mol. Biol. 273:927-948.

Altschul et al. (1990) "Basic Local Alignment Search Tool", J. Mol. Biol. 215:403-410.

Altschul et al. (1997) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-402.

Carpenter et al. (2012) "Structure of the Human Obesity Receptor Leptin-Binding Domain Reveals the Mechanism of Leptin Antagonism by a Monoclonal Antibody", Structure 20(3):487-497.

Chagnon et al. (2000) Journal of Clinical Endocrinology & Metabolism 85(1):29-34.

(Continued)

Primary Examiner — Shulamith H Shafer

(74) *Attorney, Agent, or Firm* — FisherBroyles, LLP;
Cara L. Crowley-Weber; Thomas Triolo

(57)

ABSTRACT

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and antagonize LEPR signaling. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence or absence of leptin. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that exhibit partial agonism of LEPR signaling. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of various conditions, including but not limited to congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by elevated leptin signaling.


24 Claims, 3 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**OTHER PUBLICATIONS**

- Ehring (1999) "Hydrogen Exchange/Electrospray Ionization Mass Spectrometry Studies of Structural Features of Proteins and Protein/Protein Interactions" *Analytical Biochemistry* 267(2):252-259.
- Engen and Smith (2001) *The Basics of Ion Chromatography*, Anal. Chem. 73:256A-265A.
- Fazeli et al. (2006) "Identification of a monoclonal antibody against the leptin receptor that acts as an antagonist and blocks human monocyte and T cell activation", *J. Immunol. Methods* 312:190-200.
- Friedman and Halaas (1998) "Leptin and the regulation of body weight in mammals" *Nature* 395(6704):763-70N.
- Friedman (2014) "Leptin at 20: an overview", *J. Endocrinol.* 223(1):T1-8.
- Gonnet et al. (1992) "Exhaustive Matching of the Entire Protein Sequence Database", *Science* 256: 1443-1445.
- Goodson (1984) *Medical Applications of Controlled Release*, vol. 2, pp. 115-138.
- Junghans et al. (1990) "Anti-Tac-H, a Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders", *Cancer Res.* 50:1495-1502.
- Kazane et al., (2012) "Synthesis of Bispecific Antibodies using Genetically Encoded Unnatural Amino Acids", *J. Am. Chem. Soc.*, 134:9918-9921 [Epub: Dec. 4, 2012].
- Klein et al. (2012) "Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies", *mAbs* 4:6, 653-663.
- Kufer et al. (2004) "A revival of bispecific antibodies", *Trends Biotechnol.* 22:239-244.
- Langer (1990) "New Methods of Drug Delivery", *Science* 249:1527-1533.
- Marcic et al. (2000) "Replacement of the Transmembrane Anchor in Angiotensin I-converting Enzyme (ACE) with a Glycosylphosphatidylinositol Tail Affects Activation of the B2 Bradykinin Receptor by ACE Inhibitors", *J. Biol. Chem.* 275(21):16110-8.
- Mak, et al. (2014) "Exploiting the therapeutic potential of leptin signaling in cachexia", *Current Opinion in Supportive and Palliative Care* 8(4):352-357.
- Martin et al., (1989) "Modeling antibody hypervariable loops: A combined algorithm", *Proc. Natl. Acad. Sci. USA* 86:9268-9272.
- McMurphy et al., (2014) "The Anti-Tumor Activity of a Neutralizing Nanobody Targeting Leptin Receptor in a Mouse Model of Melanoma", *PLOS One* (2014) 9(2):e89895.
- Molek, et al. (2014) "Screening of sythetic phage display scFv libraries yields competitive ligands of human leptin receptor", *Biochemical and Biophysical Research Communications* 452(3):479-483.
- Mordenti et al. (1991) "Interspecies Scaling of Clearance and Volume of Distribution Data for Five Therapeutic Proteins", *Pharmaceut. Res.* 8:1351.
- Pearson (1994) "Using the FASTA Program to Search Protein and DNA Sequence Databases", *Methods Mol. Biol.* 24: 307-331.
- Powell et al. (1998) "Compendium of excipients for parenteral formulations" *PDA* (1998) *J. Pharm. Sci. Technol.* 52:238-311.
- Reddy et al., (2000) "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4", *J. Immunol.* 164:1925-1933.
- Sefton (1987) "Implantable Pumps", *CRC Crit. Ref. Biomed. Eng.* 14:201-240.
- Sweeney (2002) "Leptin signalling", *Cell Signal* 14(8):655-663.
- Tartaglia (1997) "The Leptin Receptor", *J. Biol. Chem* 272(10):6093-6096.
- Taylor et al. (1992) "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins", *Nucl. Acids Res.* 20:6287-6295.
- Tomer (2000) "Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis", *Protein Science* 9:487-496.
- Tutt et al. (1991) "Trispecific F(ab')₃ Derivatives that use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells", *J. Immunol.* 147:60-69.
- Wu et al. (1987) "Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System", *J. Biol. Chem.* 262:4429-4432.
- International Search Report and Written Opinion for PCT/US2017/060690 dated Jan. 10, 2018, 17pages.
- U.S. Appl. No. 16/222,800, filed Dec. 12, 2018.
- Tartaglia et al., (1995) "Identification and Expression Cloning of a Leptin Receptor, OB-R", *Cell*, 83(7):1263-1271.





* $P < 0.05$ Isotype Control vs H4H17322P2

@ $P < 0.05$ Isotype Control vs H4H18457P2

$P < 0.05$ Isotype Control vs H4H18464P2

FIGURE 1

**FIGURE 2**

**FIGURE 3**

1

ANTIGEN-BINDING PROTEINS THAT ANTAGONIZE LEPTIN RECEPTOR

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 34 U.S.C. § 119(e) of U.S. Provisional Application No. 62/419,062, filed Nov. 8, 2016, which is herein specifically incorporated by reference in its entirety.

SEQUENCE LISTING

An official copy of the sequence listing is submitted concurrently with the specification electronically via EFS-Web as an ASCII formatted sequence listing with a file name of 2017_11_08_10271US01_SEQ_LIST_ST25.TXT, a creation date of Nov. 8, 2017, and a size of about 87.4 kilobytes. The sequence listing contained in this ASCII formatted document is part of the specification and is herein incorporated by reference in its entirety.

BACKGROUND

Leptin is a polypeptide hormone predominantly expressed by adipose tissue and is involved in the regulation of metabolism, energy balance and food intake. Leptin activity is mediated by interaction with, and signaling through, the leptin receptor. Leptin receptor, (also known as “LEPR,” “WSX,” “OB receptor,” “OB-R,” and “CD295”) is a single-pass transmembrane receptor of the class I cytokine receptor family with a large (818 amino acid) extracellular domain. Elevated expression of leptin, the Ob-R leptin receptor or both can contribute to multiple disorders including, but not limited to, anorexia or other psychiatric eating disorders, chronic kidney disease cachexia, other cachexias such as congestive heart failure cachexia, pulmonary cachexia, radiation cachexia, and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, depression, nonalcoholic fatty liver disease, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma and breast cancer.

Proposed therapeutic approaches for addressing high leptin signaling include use of leptin receptor peptide antagonists and antagonist mutants such as soluble leptin receptor variants, competitive LEPR antagonists such as antibody 9F8 (Fazeli et al. (2006) J Immunological Methods 312, 190-200) or nanobodies targeting leptin receptor (McMurphy et al., PLOS One (2014) 9(2):e89895), fibronectin III domains, orexigenic substances (e.g., ghrelin and NPY), blockade of leptin’s downstream mediators (e.g., melanocortin receptor 4) and/or lifestyle changes. Such approaches, however, have generally shown limited efficacy. Thus, a need exists in the art for alternative approaches to treating leptin resistance and other conditions associated with elevated serum leptin levels, and/or excessive LEPR signaling.

BRIEF SUMMARY

The present invention provides antibodies and antigen-binding fragments thereof that bind human leptin receptor (LEPR). The antibodies of the present invention are antagonist antibodies; i.e., binding of the anti-LEPR antibodies of the invention to LEPR result in blockade or down-regulation

2

of leptin receptor signaling in cells. Accordingly, in various embodiments, the antagonist antibodies of the present invention exhibit weak partial agonist activity. Instead, the antibodies of the present invention are useful, e.g., for down-regulating the biological activity of leptin in a subject. The antibodies and antigen-binding fragments of the present invention are therefore useful in the therapeutic treatment of diseases and disorders associated with elevated leptin signaling.

The antibodies of the invention can be full-length (for example, an IgG1 or IgG4 antibody) or may comprise only an antigen-binding portion (for example, a Fab, F(ab')₂ or scFv fragment), and may be modified to affect functionality, e.g., to eliminate residual effector functions (Reddy et al., 2000, *J. Immunol.* 164:1925-1933).

Exemplary LEPR antagonist antibodies of the present invention are listed in Tables 1 and 2 herein. Table 1 sets forth the amino acid sequence identifiers of the heavy chain variable regions (HCVRs), light chain variable regions (LCVRs), heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3), and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) of the exemplary LEPR antagonist antibodies. Table 2 sets forth the nucleic acid sequence identifiers of the HCVRs, LCVRs, HCDR1, HCDR2 HCDR3, LCDR1, LCDR2 and LCDR3 of the exemplary LEPR antagonist antibodies.

The present invention provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising an HCVR and an LCVR amino acid sequence pair (HCVR/LCVR) comprising any of the HCVR amino acid sequences listed in Table 1 paired with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCVR/LCVR amino acid sequence pair contained within any of the exemplary anti-LEPR antibodies listed in Table 1. In certain embodiments, the HCVR/LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2/10, 18/10, 26/10, 34/10, 42/10, 50/10, 58/10, 66/10, and 74/82.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1 or a substantially

similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 1 or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising an HCDR3 and an LCDR3 amino acid sequence pair (HCDR3/LCDR3) comprising any of the HCDR3 amino acid sequences listed in Table 1 paired with any of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antibodies, or antigen-binding fragments thereof, comprising an HCDR3/LCDR3 amino acid sequence pair contained within any of the exemplary anti-LEPR antibodies listed in Table 1. In certain embodiments, the HCDR3/LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 8/16, 24/16, 32/16, 40/16, 48/16, 56/16, 64/16, 72/16, 80/16 and 80/88.

The present invention also provides antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising a set of six CDRs (i.e., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) contained within any of the exemplary anti-LEPR antibodies listed in Table 1. In certain embodiments, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 amino acid sequences set is selected from the group consisting of SEQ ID NOs: 4, 6, 8, 12, 14, 16; 20, 22, 24, 12, 14, 16; 28, 30, 32, 12, 14, 16; 36, 38, 40, 12, 14, 16; 52, 54, 56, 12, 14, 16; 60, 62, 64, 12, 14, 16; 68, 70, 72, 12, 14, 16; and 76, 78, 80, 84, 86, 88.

In a related embodiment, the present invention provides antibodies, or antigen-binding fragments thereof that specifically bind LEPR, comprising a set of six CDRs (i.e., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3) contained within an HCVR/LCVR amino acid sequence pair as defined by any of the exemplary anti-LEPR antibodies listed in Table 1. For example, the present invention includes antibodies or antigen-binding fragments thereof that specifically bind LEPR, comprising the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 amino acid sequences set contained within an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID

NOs: 2/10, 18/10, 26/10, 34/10, 42/10, 50/10, 58/10, 66/10, and 74/82. Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specified HCVR and/or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, e.g., the Kabat definition, the Chothia definition, and the AbM definition. In general terms, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of the structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, e.g., Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., *J. Mol. Biol.* 273:927-948 (1997); and Martin et al., *Proc. Natl. Acad. Sci. USA* 86:9268-9272 (1989). Public databases are also available for identifying CDR sequences within an antibody.

The present invention also provides nucleic acid molecules encoding anti-LEPR antibodies or portions thereof. For example, the present invention provides nucleic acid molecules encoding any of the HCVR amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the HCDR1 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the LCDR1 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in

5

Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 1; in certain embodiments the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto.

The present invention also provides nucleic acid molecules encoding an HCVR, wherein the HCVR comprises a set of three CDRs (i.e., HCDR1, HCDR2, HCDR3), wherein the HCDR1, HCDR2, HCDR3 amino acid sequence set is as defined by any of the exemplary anti-LEPR antibodies listed in Table 1.

The present invention also provides nucleic acid molecules encoding an LCVR, wherein the LCVR comprises a set of three CDRs (i.e., LCDR1, LCDR2, LCDR3), wherein the LCDR1, LCDR2, LCDR3 amino acid sequence set is as defined by any of the exemplary anti-LEPR antibodies listed in Table 1.

The present invention also provides nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and wherein the LCVR comprises an amino acid sequence of any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98% or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and LCVR, wherein the HCVR and LCVR are both derived from the same anti-LEPR antibody listed in Table 1.

The present invention also provides recombinant expression vectors capable of expressing a polypeptide comprising a heavy or light chain variable region of an anti-LEPR antibody. For example, the present invention includes recombinant expression vectors comprising any of the nucleic acid molecules mentioned above, i.e., nucleic acid molecules encoding any of the HCVR, LCVR, and/or CDR sequences as set forth in Table 1. Also included within the scope of the present invention are host cells into which such vectors have been introduced, as well as methods of producing the antibodies or portions thereof by culturing the host cells under conditions permitting production of the antibodies or antibody fragments, and recovering the antibodies and antibody fragments so produced.

In another aspect, the invention provides a pharmaceutical composition comprising a recombinant human antibody or fragment thereof which specifically binds LEPR and a

6

pharmaceutically acceptable carrier. In a related aspect, the invention features a composition which is a combination of an anti-LEPR antibody and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that is advantageously combined with an anti-LEPR antibody.

In yet another aspect, the invention provides therapeutic methods for down-regulating or abolishing LEPR signaling using an anti-LEPR antibody or antigen-binding portion of an antibody of the invention. The therapeutic methods according to this aspect of the invention comprise administering a therapeutically effective amount of a pharmaceutical composition comprising an antibody or antigen-binding fragment of an antibody of the invention to a subject in need thereof. The disorder treated is any disease or condition which is improved, ameliorated, inhibited or prevented by down-regulating or abolishing LEPR signaling, or by blocking the activity of leptin.

Other embodiments will become apparent from a review of the ensuing detailed description.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the percent change in food intake of mice treated with 30 mg/kg of anti-LEPR antibodies H4H17322P2, H4H18457P2, or H4H18464, or with an isotope control antibody.

FIG. 2 shows the average percent change in body weight of mice treated with 30 mg/kg of anti-LEPR antibodies H4H17322P2, H4H18457P2, or H4H18464, or with an isotope control antibody.

FIG. 3 shows the average fat mass of mice treated with 30 mg/kg of anti-LEPR antibodies H4H17322P2, H4H18457P2, or H4H18464, or with an isotope control antibody.

DETAILED DESCRIPTION

Before the present invention is described, it is to be understood that this invention is not limited to particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. As used herein, the term "about," when used in reference to a particular recited numerical value, means that the value may vary from the recited value by no more than 1%. For example, as used herein, the expression "about 100" includes 99 and 101 and all values in between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All patents, applications and non-patent publications mentioned in this specification are incorporated herein by reference in their entireties.

Definitions

The expression "leptin receptor," "LEPR," and the like, as used herein, refers to the human leptin receptor, comprising the amino acid sequence as set forth in SEQ ID NO: 89 (see

also UniProtKB/Swiss-Prot Accession No. P48357). Alternative names for LEPR used in the scientific literature include "OB receptor," "OB-R," and "CD295." LEPR is also referred to as "WSX" (see, e.g., U.S. Pat. No. 7,524, 937). The expression "LEPR" includes both monomeric and multimeric (e.g., dimeric) LEPR molecules. As used herein, the expression "monomeric human LEPR" means a LEPR protein or portion thereof that does not contain or possess any multimerizing domains and that exists under normal conditions as a single LEPR molecule without a direct physical connection to another LEPR molecule. An exemplary monomeric LEPR molecule is the molecule referred to herein as "hLEPR.mmh" comprising the amino acid sequence of SEQ ID NO:90 (see, e.g., Example 3, herein). As used herein, the expression "dimeric human LEPR" means a construct comprising two LEPR molecules connected to one another through a linker, covalent bond, non-covalent bond, or through a multimerizing domain such as an antibody Fc domain. An exemplary dimeric LEPR molecule is the molecule referred to herein as "hLEPR.mFc" comprising the amino acid sequence of SEQ ID NO:91 (see, e.g., Example 3, herein), or the molecule referred to herein as "hLEPR.hFc" comprising the amino acid sequence of SEQ ID NO:92. As used herein, expressions such "anti-LEPR antibody," "antibody that specifically binds LEPR," "LEPR-specific binding protein," and the like, unless specifically indicated otherwise, refer to molecules that bind full length human LEPR, monomeric human LEPR, dimeric human LEPR, or other constructs that comprise or consist of the LEPR extracellular domain.

All references to proteins, polypeptides and protein fragments herein are intended to refer to the human version of the respective protein, polypeptide or protein fragment unless explicitly specified as being from a non-human species. Thus, the expression "LEPR" means human LEPR unless specified as being from a non-human species, e.g., "mouse LEPR," "monkey LEPR," etc.

As used herein, the expression "cell surface-expressed LEPR" means one or more LEPR protein(s), or the extracellular domain thereof, that is/are expressed on the surface of a cell in vitro or in vivo, such that at least a portion of a LEPR protein is exposed to the extracellular side of the cell membrane and is accessible to an antigen-binding portion of an antibody. A "cell surface-expressed LEPR" can comprise or consist of a LEPR protein expressed on the surface of a cell which normally (e.g., in the native or wild-type state) expresses LEPR protein. Alternatively, "cell surface-expressed LEPR" can comprise or consist of LEPR protein expressed on the surface of a cell that normally does not express human LEPR on its surface but has been artificially engineered to express LEPR on its surface.

As used herein, the expressions such as "anti-LEPR antibody," or "antibody that binds human leptin receptor," include both monovalent antibodies with a single specificity, as well as bispecific antibodies comprising a first arm that binds LEPR and a second arm that binds a second (target) antigen, wherein the anti-LEPR arm comprises any of the HCVR/LCVR or CDR sequences as set forth in Table 1 herein.

The term "antibody", as used herein, means any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that specifically binds to or interacts with a particular antigen (e.g., LEPR). The term "antibody" includes immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM). Each heavy

chain comprises a heavy chain variable region (abbreviated herein as HCVR or V_H) and a heavy chain constant region. The heavy chain constant region comprises three domains, C_H1 , C_H2 and C_H3 . Each light chain comprises a light chain variable region (abbreviated herein as LCVR or V_L) and a light chain constant region. The light chain constant region comprises one domain (C_L1). The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of the anti-LEPR antibody (or antigen-binding portion thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

The term "antibody", as used herein, also includes antigen-binding fragments of full antibody molecules. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex. Antigen-binding fragments of an antibody may be derived, e.g., from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g., commercial sources, DNA libraries (including, e.g., phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.

Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')₂ fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (e.g., an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment," as used herein.

An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a V_H domain associated with a V_L domain, the V_H and V_L domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain V_H - V_H , V_H - V_L

or V_L - V_L dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V_H or V_L domain.

In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) V_H - C_H1 ; (ii) V_H - C_H2 ; (iii) V_H - C_H3 ; (iv) V_H - C_H1 - C_H2 ; (v) V_H - C_H1 - C_H2 - C_H3 ; (vi) V_H - C_H2 - C_H3 ; (vii) V_H - C_L ; (viii) V_L - C_H1 ; (ix) V_L - C_H2 ; (x) V_L - C_H3 ; (xi) V_L - C_H1 - C_H2 ; (xii) V_L - C_H1 - C_H2 - C_H3 ; (xiii) V_L - C_H2 - C_H3 ; and (xiv) V_L - C_L . In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids, which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present invention may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V_H or V_L domain (e.g., by disulfide bond(s)).

As with full antibody molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). A multispecific antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present invention using routine techniques available in the art.

In certain embodiments of the invention, the anti-LEPR antibodies of the invention are human antibodies. The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

The antibodies of the invention may, in some embodiments, be recombinant human antibodies. The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant, combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor et al. (1992) *Nucl. Acids Res.* 20:6287-6295) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA

sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when an animal transgenic for human Ig sequences is used, in vivo somatic mutagenesis) and thus the amino acid sequences of the V_H and V_L regions of the recombinant antibodies are sequences that, while derived from and related to human germline V_H and V_L sequences, may not naturally exist within the human antibody germline repertoire in vivo.

The present invention encompasses antibodies having one or more mutations in the hinge, C_H2 or C_H3 region, which may be desirable, for example, in production, to improve the yield of the desired antibody form.

The antibodies of the invention may be isolated antibodies. An "isolated antibody," as used herein, means an antibody that has been identified and separated and/or recovered from at least one component of its natural environment. For example, an antibody that has been separated or removed from at least one component of an organism, or from a tissue or cell in which the antibody naturally exists or is naturally produced, is an "isolated antibody" for purposes of the present invention. An isolated antibody also includes an antibody in situ within a recombinant cell. Isolated antibodies are antibodies that have been subjected to at least one purification or isolation step. According to certain embodiments, an isolated antibody may be substantially free of other cellular material and/or chemicals.

The present invention includes variants of the anti-LEPR antibodies disclosed herein comprising one or more amino acid substitutions, insertions and/or deletions in the framework and/or CDR regions of the heavy and light chain variable domains as compared to the corresponding germline sequences from which the antibodies were derived. Such mutations can be readily ascertained by comparing the amino acid sequences disclosed herein to germline sequences available from, for example, public antibody sequence databases. The present invention includes antibodies, and antigen-binding fragments thereof, which are derived from any of the amino acid sequences disclosed herein, wherein one or more amino acids within one or more framework and/or CDR regions are mutated to the corresponding residue(s) of the germline sequence from which the antibody was derived, or to the corresponding residue(s) of another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are referred to herein collectively as "germline mutations"). A person of ordinary skill in the art, starting with the heavy and light chain variable region sequences disclosed herein, can easily produce numerous antibodies and antigen-binding fragments which comprise one or more individual germline mutations or combinations thereof. In certain embodiments, all of the framework and/or CDR residues within the V_H and/or V_L domains are mutated back to the residues found in the original germline sequence from which the antibody was derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only the mutated residues found within the first 8 amino acids of FR1 or within the last 8 amino acids of FR4, or only the mutated residues found within CDR1, CDR2 or CDR3. In other embodiments, one or more of the framework and/or CDR residue(s) are mutated to the corresponding residue(s) of a different germline sequence (i.e., a germline sequence that is different from the germline sequence from which the antibody was originally derived). Furthermore, the antibody

ies of the present invention may contain any combination of two or more germline mutations within the framework and/or CDR regions, e.g., wherein certain individual residues are mutated to the corresponding residue of a particular germline sequence while certain other residues that differ from the original germline sequence are maintained or are mutated to the corresponding residue of a different germline sequence. Once obtained, antibodies and antigen-binding fragments that contain one or more germline mutations can be easily tested for one or more desired property such as, improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antibodies and antigen-binding fragments obtained in this general manner are encompassed within the present invention.

The present invention also includes anti-LEPR antibodies comprising variants of any of the HCVR, LCVR, and/or CDR amino acid sequences disclosed herein having one or more conservative substitutions. For example, the present invention includes anti-LEPR antibodies having HCVR, LCVR, and/or CDR amino acid sequences with, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc. conservative amino acid substitutions relative to any of the HCVR, LCVR, and/or CDR amino acid sequences set forth in Table 1 herein. In certain embodiments, the present invention provides anti-LEPR antibodies comprising variant HCVR, LCVR and/or CDR amino acid sequences relative to the sequences set forth in Table 1 herein (e.g., comprising conservative amino acid substitutions), wherein such variant antibodies nonetheless exhibit one or more functions and/or properties of the exemplary anti-LEPR antibodies disclosed herein.

The term "epitope" refers to an antigenic determinant that interacts with a specific antigen binding site in the variable region of an antibody molecule known as a paratope. A single antigen may have more than one epitope. Thus, different antibodies may bind to different areas on an antigen and may have different biological effects. Epitopes may be either conformational or linear. A conformational epitope is produced by spatially juxtaposed amino acids from different segments of the linear polypeptide chain. A linear epitope is one produced by adjacent amino acid residues in a polypeptide chain. In certain circumstance, an epitope may include moieties of saccharides, phosphoryl groups, or sulfonyl groups on the antigen.

The present invention includes anti-LEPR antibodies and antigen-binding fragments thereof that comprise amino acid sequences that are substantially similar or substantially identical to one or more variable domain or CDR amino acid sequences as found in any of the exemplary anti-LEPR antibodies disclosed herein.

As applied to polypeptides, the term "substantial similarity" or "substantially similar" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 95% sequence identity, even more preferably at least 98% or 99% sequence identity. Preferably, residue positions which are not identical differ by conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent

sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson (1994) *Methods Mol. Biol.* 24: 307-331, herein incorporated by reference. Examples of groups of amino acids that have side chains with similar chemical properties include (1) aliphatic side chains: glycine, alanine, valine, leucine and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartate and glutamate, and (7) sulfur-containing side chains are cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamate-aspartate, and asparagine-glutamine. Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet et al. (1992) *Science* 256: 1443-1445, herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG software contains programs such as Gap and Bestfit which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. See, e.g., GCG Version 6.1. Polypeptide sequences also can be compared using FASTA using default or recommended parameters, a program in GCG Version 6.1. FASTA (e.g., FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson (2000) *supra*). Another preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially BLASTP or TBLASTN, using default parameters. See, e.g., Altschul et al. (1990) *J. Mol. Biol.* 215:403-410 and Altschul et al. (1997) *Nucleic Acids Res.* 25:3389-402, each herein incorporated by reference.

Anti-LEPR Antibodies Comprising Fc Variants

According to certain embodiments of the present invention, anti-LEPR antibodies are provided comprising an Fc domain comprising one or more mutations which enhance or diminish antibody binding to the FcRn receptor, e.g., at acidic pH as compared to neutral pH. For example, the present invention includes anti-LEPR antibodies comprising a mutation in the C_H2 or a C_H3 region of the Fc domain, wherein the mutation(s) increases the affinity of the Fc domain to FcRn in an acidic environment (e.g., in an endosome where pH ranges from about 5.5 to about 6.0). Such mutations may result in an increase in serum half-life of the antibody when administered to an animal. Non-limiting examples of such Fc modifications include, e.g., a modification at position 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L/Y/F/W or T), 254 (e.g., S or T), and 256 (e.g., S/R/Q/E/D or T); or a modification at position 428 and/or 433 (e.g., H/L/R/S/P/Q or K) and/or 434 (e.g., H/F or Y); or a modification at position 250 and/or 428; or a

modification at position 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modification comprises a 428L (e.g., M428L) and 434S (e.g., N434S) modification; a 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modification; a 433K (e.g., H433K) and a 434 (e.g., 434Y) modification; a 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modification; a 250Q and 428L modification (e.g., T250Q and M428L); and a 307 and/or 308 modification (e.g., 308F or 308P).

For example, the present invention includes anti-LEPR antibodies comprising an Fc domain comprising one or more pairs or groups of mutations selected from the group consisting of: 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); and 433K and 434F (e.g., H433K and N434F). All possible combinations of the foregoing Fc domain mutations, and other mutations within the antibody variable domains disclosed herein, are contemplated within the scope of the present invention.

The anti-LEPR antibodies of the present invention may comprise a modified Fc domain having reduced effector function. As used herein, a “modified Fc domain having reduced effector function” means any Fc portion of an immunoglobulin that has been modified, mutated, truncated, etc., relative to a wild-type, naturally occurring Fc domain such that a molecule comprising the modified Fc exhibits a reduction in the severity or extent of at least one effect selected from the group consisting of cell killing (e.g., ADCC and/or CDC), complement activation, phagocytosis and opsonization, relative to a comparator molecule comprising the wild-type, naturally occurring version of the Fc portion. In certain embodiments, a “modified Fc domain having reduced effector function” is an Fc domain with reduced or attenuated binding to an Fc receptor (e.g., FcγR).

In certain embodiments of the present invention, the modified Fc domain is a variant IgG1 Fc or a variant IgG4 Fc comprising a substitution in the hinge region. For example, a modified Fc for use in the context of the present invention may comprise a variant IgG1 Fc wherein at least one amino acid of the IgG1 Fc hinge region is replaced with the corresponding amino acid from the IgG2 Fc hinge region. Alternatively, a modified Fc for use in the context of the present invention may comprise a variant IgG4 Fc wherein at least one amino acid of the IgG4 Fc hinge region is replaced with the corresponding amino acid from the IgG2 Fc hinge region. Non-limiting, exemplary modified Fc regions that can be used in the context of the present invention are set forth in US Patent Application Publication No. 2014/0243504, the disclosure of which is hereby incorporated by reference in its entirety, as well as any functionally equivalent variants of the modified Fc regions set forth therein.

Other modified Fc domains and Fc modifications that can be used in the context of the present invention include any of the modifications as set forth in US 2014/0171623; U.S. Pat. No. 8,697,396; US 2014/0134162; WO 2014/043361, the disclosures of which are hereby incorporated by reference in their entireties. Methods of constructing antibodies or other antigen-binding fusion proteins comprising a modified Fc domain as described herein are known in the art. Biological Characteristics of the Antibodies

The present invention includes antibodies and antigen-binding fragments thereof that bind human LEPR and antagonize LEPR signaling. Such antibodies may be referred to herein as “antagonist antibodies.” In the context of the present invention, an “antagonist of LEPR signaling” means an antibody or fragment thereof that binds to LEPR

and inhibits an intracellular effect that normally results from the interaction of leptin with LEPR in cells that express LEPR. In various embodiments, the antagonist antibodies of the invention inhibit the function of LEPR agonists, and/or the function of LEPR partial agonists. In certain embodiments, “antagonizing LEPR signaling” means inhibition of leptin-stimulated transcriptional activation of STAT3, which can be detected using any method that can measure or identify, directly or indirectly, STAT3 activity, e.g., using a labeled version of STAT3 expressed in a reporter cell line. For example, the present invention includes antagonist antibodies and antigen-binding fragments thereof that down-regulate LEPR signaling in a cell-based reporter assay as described in Example 6, or a substantially similar assay. The present invention also includes antagonist antibodies and antigen-binding fragments thereof that demonstrate complete inhibition of leptin induced LEPR signaling with IC₅₀ values ranging from 723 pM to 1.8 nM in the assay of Example 6, or a substantially similar assay. Cell-based binding assays that detect antibody binding to cells expressing LEPR such as the assay described in Example 5 herein, demonstrated binding to HEK293/hLEPR-GPI cells with binding ratios of 824- to 3187-fold without Leptin and of 398- to 3106-fold in the presence of 1 μM Leptin. Antibodies of the invention were found to bind LEPR even in the presence of excess leptin at 1 μM, indicating that the LEPR antibodies of the invention bind to sites on hLEPR that do not overlap with Leptin binding sites. The invention also includes anti-LEPR antibodies that antagonize leptin signaling but also promote partial LEPR signaling in the absence of leptin; such antibodies are also referred to herein as “partial agonists” or “antibodies that exhibit agonism of LEPR signaling.”

In certain exemplary embodiments of the present invention, anti-LEPR antibodies are provided that bind human dimeric LEPR (hLEPR.hFc, SEQ ID NO:92) in the presence or absence of leptin, with none of the antibodies of the invention demonstrating greater than 40% blockade of the LEPR:leptin interaction, e.g., using an assay format as defined in Example 4 herein, or a substantially similar assay.

The present invention includes antibodies and antigen-binding fragments thereof that bind monomeric human LEPR with high affinity. For example, the present invention includes anti-LEPR antibodies that bind monomeric human LEPR (e.g., hLEPR.mmh, SEQ ID NO:90) with a K_D of less than about 10 nM as measured by surface plasmon resonance at 25° C., or less than about 25 nM as measured by surface plasmon resonance at 37° C., e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay. According to certain embodiments, anti-LEPR antibodies are provided that bind monomeric human LEPR at 25° C. with a K_D of less than about 12 nM, less than about 11 nM, less than about 10 nM, less than about 9 nM, less than about 8 nM, less than about 7 nM, less than about 6 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM or less than about 100 pM as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay.

The present invention also includes antibodies and antigen-binding fragments thereof that bind monomeric human LEPR (e.g., hLEPR.mmh, SEQ ID NO:90) with a dissociative half-life (t_{1/2}) of greater than about 5 minutes as measured by surface plasmon resonance at 25° C. or greater

than about 1 minute as measured by surface plasmon resonance at 37° C., e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay. According to certain embodiments, anti-LEPR antibodies are provided that bind monomeric human LEPR at 25° C. with a $t_{1/2}$ of greater than about 5 minutes, greater than about 10 minutes, greater than about 20 minutes, greater than about 40 minutes, greater than about 50 minutes or longer, as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay.

The present invention also includes antibodies and antigen-binding fragments thereof that bind dimeric human LEPR (e.g., hLEPR.mFc, SEQ ID NO:91) with high affinity. For example, the present invention includes anti-LEPR antibodies that bind dimeric human LEPR (e.g., hLEPR.mFc, SEQ ID NO:91) with a K_D of less than about 4 nM as measured by surface plasmon resonance at 25° C. or 37° C., e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay. According to certain embodiments, anti-LEPR antibodies are provided that bind dimeric human LEPR at 25° C. with a K_D of less than about 15 nM, less than about 10 nM, less than about 9.0 nM, less than about 8.0 nM, less than about 7.0 nM, less than about 6.0 nM, less than about 5.0 nM, less than about 4.0 nM, less than about 3.0 nM, less than about 2.0 nM, less than about 1.0 nM, less than about 900 pM, less than about 800 pM, less than about 700 pM, less than about 600 pM, less than about 500 pM, less than about 400 pM, less than about 300 pM, less than about 200 pM, or less than about 100 pM, as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay.

The present invention also includes antibodies and antigen-binding fragments thereof that bind dimeric human LEPR (e.g., hLEPR.mFc, SEQ ID NO:91) with a dissociative half-life ($t_{1/2}$) of greater than about 10 minutes as measured by surface plasmon resonance at 25° C. or 37° C., e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay. According to certain embodiments, anti-LEPR antibodies are provided that bind dimeric human LEPR at 25° C. with a $t_{1/2}$ of greater than about 15 minutes, about 20 minutes, greater than about 30 minutes, greater than about 40 minutes, greater than 50 minutes, greater than about 60 minutes, greater than about 70 minutes, greater than 80 minutes, greater than 90 minutes, greater than 100 minutes, or longer, as measured by surface plasmon resonance, e.g., using an assay format as defined in Example 3 herein, or a substantially similar assay.

The present invention also includes antibodies and antigen-binding fragments thereof that bind LEPR in complex with human leptin ("LEPR in complex with human leptin" may also be represented by the expression "leptin:LEPR"). For example the present invention includes antibodies and antigen-binding fragments thereof that are capable of binding to a pre-formed complex comprising hLEPR and human leptin. That is, according to certain embodiments, the interaction between anti-LEPR antibodies and LEPR is not inhibited by the presence of leptin in complex with LEPR; likewise, the interaction between leptin and LEPR, according to this aspect of the invention, is not inhibited by the presence of an anti-LEPR antibody. An exemplary assay format for determining whether an antibody or antigen-binding fragment thereof binds to LEPR in complex with human leptin is set forth in Example 4 herein.

The present invention also includes antibodies and antigen-binding fragments thereof that bind cell surface-ex-

pressed LEPR in the presence and/or absence of human leptin. Cell surface-expressed LEPR means LEPR or a portion thereof (e.g., an extracellular portion of LEPR) expressed on the surface of a cell, either naturally or in an engineered cell line, such that an antibody or antigen-binding fragment thereof is capable of binding to the LEPR molecule. In certain embodiments, cell surface-expressed LEPR includes recombinant complexes comprising an extracellular domain of LEPR connected to a cell via a tag or anchor (e.g., a GPI anchor as illustrated in Example 6 herein). According to this aspect of the invention, antibodies are provided which are capable of binding cell surface-expressed LEPR in the absence of leptin, and are also capable of binding cell surface-expressed LEPR in the presence of leptin (i.e., under circumstances wherein leptin is capable of binding to cell surface-expressed LEPR). That is, according to certain embodiments, the interaction between anti-LEPR antibodies and cell surface-expressed LEPR is not inhibited by the presence of leptin in complex with cell surface-expressed LEPR. Antibodies according to this aspect of the invention are capable of forming a three-member complex on the surface of a cell comprising the antibody, cell surface-expressed LEPR and leptin. An exemplary assay format for determining whether an antibody or antigen-binding fragment thereof is capable of binding cell surface-expressed LEPR in the presence and absence of human leptin is set forth in Example 5 herein.

The antibodies of the present invention may possess one or more of the aforementioned biological characteristics, or any combination thereof. The foregoing list of biological characteristics of the antibodies of the invention is not intended to be exhaustive. Other biological characteristics of the antibodies of the present invention will be evident to a person of ordinary skill in the art from a review of the present disclosure including the working Examples herein. Epitope Mapping and Related Technologies

The epitope to which the antibodies of the present invention bind may consist of a single contiguous sequence of 3 or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more) amino acids of a LEPR protein. Alternatively, the epitope may consist of a plurality of non-contiguous amino acids (or amino acid sequences) of LEPR. In some embodiments, the epitope is located on or near the leptin-binding domain of LEPR. In other embodiments, the epitope is located at a region distinct from the leptin-binding domain of LEPR, e.g., at a location on the surface of LEPR at which an antibody, when bound to such an epitope, does not interfere with leptin binding to LEPR.

Various techniques known to persons of ordinary skill in the art can be used to identify the amino acids within an epitope recognized by a particular antibody. Exemplary techniques include, e.g., alanine scanning mutational analysis, peptide blot analysis, and peptide cleavage analysis. In addition, methods such as epitope excision, epitope extraction and chemical modification of antigens can be employed (Tomer (2000) *Protein Science* 9:487-496). Another method that can be used to identify the amino acids within a polypeptide with which an antibody interacts is hydrogen/deuterium exchange detected by mass spectrometry. In general terms, the hydrogen/deuterium exchange method involves deuterium-labeling the protein of interest, followed by binding the antibody to the deuterium-labeled protein. Next, the protein/antibody complex is transferred to water to allow hydrogen-deuterium exchange to occur at all residues except for the residues protected by the antibody (which remain deuterium-labeled). After dissociation of the antibody, the target protein is subjected to protease cleavage and

mass spectrometry analysis, thereby revealing the deuterium-labeled residues which correspond to the specific amino acids with which the antibody interacts. See, e.g., Ehring (1999) *Analytical Biochemistry* 267(2):252-259; Engen and Smith (2001) *Anal. Chem.* 73:256A-265A. X-ray crystallography analysis of an antibody in complex with its antigen may also be used to identify the amino acids within a polypeptide with which an antibody interacts.

The present invention further includes anti-LEPR antibodies that bind to the same epitope as any of the specific exemplary antibodies described herein (e.g. antibodies comprising any of the amino acid sequences as set forth in Table 1 herein). Likewise, the present invention also includes anti-LEPR antibodies that compete for binding to LEPR with any of the specific exemplary antibodies described herein (e.g. antibodies comprising any of the amino acid sequences as set forth in Table 1 herein).

One can determine whether an antibody binds to the same epitope as, or competes for binding with, a reference anti-LEPR antibody by using routine methods known in the art and exemplified herein. For example, to determine if a test antibody binds to the same epitope as a reference anti-LEPR antibody of the invention, the reference antibody is allowed to bind to a LEPR protein. Next, the ability of a test antibody to bind to the LEPR molecule is assessed. If the test antibody is able to bind to LEPR following saturation binding with the reference anti-LEPR antibody, it can be concluded that the test antibody binds to a different epitope than the reference anti-LEPR antibody. On the other hand, if the test antibody is not able to bind to the LEPR molecule following saturation binding with the reference anti-LEPR antibody, then the test antibody may bind to the same epitope as the epitope bound by the reference anti-LEPR antibody of the invention. Additional routine experimentation (e.g., peptide mutation and binding analyses) can then be carried out to confirm whether the observed lack of binding of the test antibody is in fact due to binding to the same epitope as the reference antibody or if steric blocking (or another phenomenon) is responsible for the lack of observed binding. Experiments of this sort can be performed using ELISA, RIA, Biacore, flow cytometry or any other quantitative or qualitative antibody-binding assay available in the art. In accordance with certain embodiments of the present invention, two antibodies bind to the same (or overlapping) epitope if, e.g., a 1-, 5-, 10-, 20- or 100-fold excess of one antibody inhibits binding of the other by at least 50% but preferably 75%, 90% or even 99% as measured in a competitive binding assay (see, e.g., Junghans et al. (1990) *Cancer Res.* 50:1495-1502). Alternatively, two antibodies are deemed to bind to the same epitope if essentially all amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other. Two antibodies are deemed to have "overlapping epitopes" if only a subset of the amino acid mutations that reduce or eliminate binding of one antibody reduce or eliminate binding of the other.

To determine if an antibody competes for binding (or cross-competes for binding) with a reference anti-LEPR antibody, the above-described binding methodology is performed in two orientations: In a first orientation, the reference antibody is allowed to bind to a LEPR protein under saturating conditions followed by assessment of binding of the test antibody to the LEPR molecule. In a second orientation, the test antibody is allowed to bind to a LEPR molecule under saturating conditions followed by assessment of binding of the reference antibody to the LEPR molecule. If, in both orientations, only the first (saturating) antibody is capable of binding to the LEPR molecule, then

it is concluded that the test antibody and the reference antibody compete for binding to LEPR. As will be appreciated by a person of ordinary skill in the art, an antibody that competes for binding with a reference antibody may not necessarily bind to the same epitope as the reference antibody, but may sterically block binding of the reference antibody by binding an overlapping or adjacent epitope.

Preparation of Human Antibodies

The anti-LEPR antibodies of the present invention can be fully human antibodies. Methods for generating monoclonal antibodies, including fully human monoclonal antibodies are known in the art. Any such known methods can be used in the context of the present invention to make human antibodies that specifically bind to human LEPR.

Using VELOCIMMUNETTM technology, for example, or any other similar known method for generating fully human monoclonal antibodies, high affinity chimeric antibodies to LEPR are initially isolated having a human variable region and a mouse constant region. As in the experimental section below, the antibodies are characterized and selected for desirable characteristics, including affinity, ligand blocking activity, selectivity, epitope, etc. If necessary, mouse constant regions are replaced with a desired human constant region, for example wild-type or modified IgG1 or IgG4, to generate a fully human anti-LEPR antibody. While the constant region selected may vary according to specific use, high affinity antigen-binding and target specificity characteristics reside in the variable region. In certain instances, fully human anti-LEPR antibodies are isolated directly from antigen-positive B cells.

Bioequivalents

The anti-LEPR antibodies and antibody fragments of the present invention encompass proteins having amino acid sequences that vary from those of the described antibodies but that retain the ability to bind human LEPR. Such variant antibodies and antibody fragments comprise one or more additions, deletions, or substitutions of amino acids when compared to parent sequence, but exhibit biological activity that is essentially equivalent to that of the described antibodies. Likewise, the anti-LEPR antibody-encoding DNA sequences of the present invention encompass sequences that comprise one or more additions, deletions, or substitutions of nucleotides when compared to the disclosed sequence, but that encode an anti-LEPR antibody or antibody fragment that is essentially bioequivalent to an anti-LEPR antibody or antibody fragment of the invention. Examples of such variant amino acid and DNA sequences are discussed above.

Two antigen-binding proteins, or antibodies, are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical alternatives whose rate and extent of absorption do not show a significant difference when administered at the same molar dose under similar experimental conditions, either single dose or multiple dose. Some antibodies will be considered equivalents or pharmaceutical alternatives if they are equivalent in the extent of their absorption but not in their rate of absorption and yet may be considered bioequivalent because such differences in the rate of absorption are intentional and are reflected in the labeling, are not essential to the attainment of effective body drug concentrations on, e.g., chronic use, and are considered medically insignificant for the particular drug product studied.

In one embodiment, two antigen-binding proteins are bioequivalent if there are no clinically meaningful differences in their safety, purity, and potency.

In one embodiment, two antigen-binding proteins are bioequivalent if a patient can be switched one or more times between the reference product and the biological product without an expected increase in the risk of adverse effects, including a clinically significant change in immunogenicity, or diminished effectiveness, as compared to continued therapy without such switching.

In one embodiment, two antigen-binding proteins are bioequivalent if they both act by a common mechanism or mechanisms of action for the condition or conditions of use, to the extent that such mechanisms are known.

Bioequivalence may be demonstrated by in vivo and in vitro methods. Bioequivalence measures include, e.g., (a) an in vivo test in humans or other mammals, in which the concentration of the antibody or its metabolites is measured in blood, plasma, serum, or other biological fluid as a function of time; (b) an in vitro test that has been correlated with and is reasonably predictive of human in vivo bioavailability data; (c) an in vivo test in humans or other mammals in which the appropriate acute pharmacological effect of the antibody (or its target) is measured as a function of time; and (d) in a well-controlled clinical trial that establishes safety, efficacy, or bioavailability or bioequivalence of an antibody.

Bioequivalent variants of anti-LEPR antibodies of the invention may be constructed by, for example, making various substitutions of residues or sequences or deleting terminal or internal residues or sequences not needed for biological activity. For example, cysteine residues not essential for biological activity can be deleted or replaced with other amino acids to prevent formation of unnecessary or incorrect intramolecular disulfide bridges upon renaturation. In other contexts, bioequivalent antibodies may include anti-LEPR antibody variants comprising amino acid changes which modify the glycosylation characteristics of the antibodies, e.g., mutations which eliminate or remove glycosylation.

Species Selectivity and Species Cross-Reactivity

The present invention, according to certain embodiments, provides anti-LEPR antibodies that bind to human LEPR but not to LEPR from other species. The present invention also includes anti-LEPR antibodies that bind to human LEPR and to LEPR from one or more non-human species.

For example, the anti-LEPR antibodies of the invention may bind to human LEPR and may bind or not bind, as the case may be, to one or more of mouse, rat, guinea pig, hamster, gerbil, pig, cat, dog, rabbit, goat, sheep, cow, horse, camel, cynomolgous, marmoset, rhesus or chimpanzee LEPR. According to certain exemplary embodiments of the present invention, anti-LEPR antibodies are provided which specifically bind human LEPR and cynomolgus monkey (e.g., *Macaca fascicularis*) LEPR. Other anti-LEPR antibodies of the invention bind human LEPR but do not bind, or bind only weakly, to cynomolgus monkey LEPR.

Multispecific Antibodies

The antibodies of the present invention may be monospecific or multispecific (e.g., bispecific). Multispecific antibodies may be specific for different epitopes of one target polypeptide or may contain antigen-binding domains specific for more than one target polypeptide. See, e.g., Tutt et al. (1991) *J. Immunol.* 147:60-69; Kufer et al. (2004) *Trends Biotechnol.* 22:238-244. The anti-LEPR antibodies of the present invention can be linked to or co-expressed with another functional molecule, e.g., another peptide or protein. For example, an antibody or fragment thereof can be functionally linked (e.g., by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody or antibody

fragment to produce a bi-specific or a multispecific antibody with a second binding specificity.

The present invention includes bispecific antibodies wherein one arm of an immunoglobulin binds human LEPR, and the other arm of the immunoglobulin is specific for a second antigen. The LEPR-binding arm can comprise any of the HCVR/LCVR or CDR amino acid sequences as set forth in Table 1 herein.

An exemplary bispecific antibody format that can be used in the context of the present invention involves the use of a first immunoglobulin (Ig) C_H3 domain and a second Ig C_H3 domain, wherein the first and second Ig C_H3 domains differ from one another by at least one amino acid, and wherein at least one amino acid difference reduces binding of the bispecific antibody to Protein A as compared to a bi-specific antibody lacking the amino acid difference. In one embodiment, the first Ig C_H3 domain binds Protein A and the second Ig C_H3 domain contains a mutation that reduces or abolishes Protein A binding such as an H95R modification (by IMGT exon numbering; H435R by EU numbering). The second C_H3 may further comprise a Y96F modification (by IMGT; Y436F by EU). Further modifications that may be found within the second C_H3 include: D16E, L18M, N44S, K52N, V57M, and V821 (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU) in the case of IgG1 antibodies; N44S, K52N, and V821 (IMGT; N384S, K392N, and V422I by EU) in the case of IgG2 antibodies; and Q15R, N44S, K52N, V57M, R69K, E79Q, and V821 (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU) in the case of IgG4 antibodies. Variations on the bispecific antibody format described above are contemplated within the scope of the present invention.

Other exemplary bispecific formats that can be used in the context of the present invention include, without limitation, e.g., scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knobs-into-holes, common light chain (e.g., common light chain with knobs-into-holes, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1/IgG2, dual acting Fab (DAF)-IgG, and Mab² bispecific formats (see, e.g., Klein et al. (2012) mAbs 4:6, 1-11, and references cited therein, for a review of the foregoing formats). Bispecific antibodies can also be constructed using peptide/nucleic acid conjugation, e.g., wherein unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates which then self-assemble into multimeric complexes with defined composition, valency and geometry. (See, e.g., Kazane et al., *J. Am. Chem. Soc.* [Epub: Dec. 4, 2012]).

Therapeutic Formulation and Administration

The invention provides pharmaceutical compositions comprising the anti-LEPR antibodies or antigen-binding fragments thereof of the present invention. The pharmaceutical compositions of the invention are formulated with suitable carriers, excipients, and other agents that provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTINTM, Life Technologies, Carlsbad, Calif.), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al.

"Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52:238-311.

The dose of antibody administered to a patient may vary depending upon the age and the size of the patient, target disease, conditions, route of administration, and the like. The preferred dose is typically calculated according to body weight or body surface area. In an adult patient, it may be advantageous to intravenously administer the antibody of the present invention normally at a single dose of about 0.01 to about 20 mg/kg body weight, more preferably about 0.02 to about 7, about 0.03 to about 5, or about 0.05 to about 3 mg/kg body weight. Depending on the severity of the condition, the frequency and the duration of the treatment can be adjusted. Effective dosages and schedules for administering anti-LEPR antibodies may be determined empirically; for example, patient progress can be monitored by periodic assessment, and the dose adjusted accordingly. Moreover, interspecies scaling of dosages can be performed using well-known methods in the art (e.g., Mordenti et al. (1991) *Pharmaceut. Res.* 8:1351).

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu et al. (1987) *J. Biol. Chem.* 262:4429-4432). Methods of introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local.

A pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, with respect to subcutaneous delivery, a pen delivery device readily has applications in delivering a pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. A reusable pen delivery device generally utilizes a replaceable cartridge that contains a pharmaceutical composition. Once all of the pharmaceutical composition within the cartridge has been administered and the cartridge is empty, the empty cartridge can readily be discarded and replaced with a new cartridge that contains the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device comes prefilled with the pharmaceutical composition held in a reservoir within the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.

Numerous reusable pen and autoinjector delivery devices have applications in the subcutaneous delivery of a pharmaceutical composition of the present invention. Examples include, but are not limited to AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), DISETRONIC™ pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25™ pen, HUMALOG™ pen, HUMALIN 70/30™ pen (Eli Lilly and Co., Indianapolis, Ind.), NOVOPEN™ I, II and III (Novo Nordisk, Copenhagen, Denmark), NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), BD™ pen (Becton Dickinson, Franklin Lakes, N.J.), OPTIPEN™, OPTIPEN PRO™, OPTIPEN STARLET™, and OPTICLIK™ (sanofi-aventis, Frankfurt,

Germany), to name only a few. Examples of disposable pen delivery devices having applications in subcutaneous delivery of a pharmaceutical composition of the present invention include, but are not limited to the SOLOSTAR™ pen (sanofi-aventis), the FLEXPEN™ (Novo Nordisk), and the KWIKPEN™ (Eli Lilly), the SURECLICK™ Autoinjector (Amgen, Thousand Oaks, Calif.), the PENLET™ (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L. P.), and the HUMIRA™ Pen (Abbott Labs, Abbott Park Ill.), to name only a few.

In certain situations, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra; Sefton (1987) *CRC Crit. Ref. Biomed. Eng.* 14:201). In another embodiment, polymeric materials can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.) (1974) CRC Pres., Boca Raton, Fla. In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, thus requiring only a fraction of the systemic dose (see, e.g., Goodson (1984) in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138). Other controlled release systems are discussed in the review by Langer (1990) *Science* 249:1527-1533.

The injectable preparations may include dosage forms for intravenous, subcutaneous, intracutaneous and intramuscular injections, drip infusions, etc. These injectable preparations may be prepared by methods publicly known. For example, the injectable preparations may be prepared, e.g., by dissolving, suspending or emulsifying the antibody or its salt described above in a sterile aqueous medium or an oily medium conventionally used for injections. As the aqueous medium for injections, there are, for example, physiological saline, an isotonic solution containing glucose and other auxiliary agents, etc., which may be used in combination with an appropriate solubilizing agent such as an alcohol (e.g., ethanol), a polyalcohol (e.g., propylene glycol, polyethylene glycol), a nonionic surfactant [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As the oily medium, there are employed, e.g., sesame oil, soybean oil, etc., which may be used in combination with a solubilizing agent such as benzyl benzoate, benzyl alcohol, etc. The injection thus prepared is preferably filled in an appropriate ampoule.

Advantageously, the pharmaceutical compositions for oral or parenteral use described above are prepared into dosage forms in a unit dose suited to fit a dose of the active ingredients. Such dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc. The amount of the aforesaid antibody contained is generally about 5 to about 500 mg per dosage form in a unit dose; especially in the form of injection, it is preferred that the aforesaid antibody is contained in about 5 to about 100 mg and in about 10 to about 250 mg for the other dosage forms.

Therapeutic Uses of the Antibodies

The present invention includes methods comprising administering to a subject in need thereof a therapeutic composition comprising an antagonist anti-LEPR antibody (e.g., an anti-LEPR antibody comprising any of the HCVR/LCVR or CDR sequences as set forth in Table 1 herein). The therapeutic composition can comprise any of the anti-LEPR antibodies disclosed herein, or antigen-binding fragments thereof, and a pharmaceutically acceptable carrier or diluent.

The antibodies of the invention are useful, inter alia, for the treatment, prevention and/or amelioration of any disease or disorder associated with or mediated by elevated leptin levels (hyperleptinemia) and/or elevated expression of

OB-R leptin receptor that results in excess LEPR signaling. In various embodiments, the disease or disorder is selected, but not limited to, anorexia or other psychiatric eating disorders, chronic kidney disease cachexia, other cachexias such as congestive heart failure cachexia, pulmonary cachexia, radiation cachexia, and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, depression, neurodegenerative disorders, cancer such as hepatocellular carcinoma, melanoma and breast cancer.

The present invention also includes anti-LEPR antibodies and antigen-binding fragments thereof that are useful for antagonizing LEPR signaling in cells, tissues and organs expressing normal or high leptin levels. As used herein, a LEPR mutant that exhibits enhanced signaling in the presence of leptin (as compared to wild-type LEPR) is referred to as a "signaling enhanced LEPR mutant." An exemplary signaling-enhanced LEPR mutation is LEPR-Q223R (Chagnon et al. (2009) *Journal of Clinical Endocrinology & Metabolism* 85(1):29-34). Thus, the present invention includes anti-LEPR antibodies and antigen-binding fragments thereof that are useful for the treatment, prevention and/or amelioration of diseases and disorders caused by or associated with enhanced signaling LEPR mutants.

In the context of the methods of treatment described herein, the anti-LEPR antibodies may be administered as a monotherapy (i.e., as the only therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).

Combination Therapies and Formulations

The present invention includes compositions and therapeutic formulations comprising any of the anti-LEPR antibodies described herein in combination with one or more additional therapeutically active components, and methods of treatment comprising administering such combinations to subjects in need thereof.

The anti-LEPR antagonist antibodies of the present invention may be co-formulated with and/or administered in combination with one or more additional therapeutically active component(s), such as, e.g., pharmaceutical products prescribed for the treatment of congestive heart failure cachexia, pulmonary cachexia and cancer cachexia, autoimmune disorders such as inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, cardiovascular diseases, elevated blood pressure, neurodegenerative disorders, depression, cancer such as hepatocellular carcinoma, melanoma, breast cancer, and other diseases and disorders associated with or caused by decreased leptin signaling. Examples of such additional therapeutically active components include, but are not limited to, e.g., angiotensin-converting enzyme inhibitors (e.g., ACE, ACE-I, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramapril, trandolapril), angiotensin receptor blockers (e.g., ARB), smooth muscle relaxants (e.g., hydralazine), long-acting nitrates (e.g., isosorbide dinitrate with or without, e.g., ACE-I and ARBs), diuretics (e.g., loop diuretics, thiazide-like diuretics and potassium-sparing diuretics), iron-deficient anemia treatments (e.g., parenteral iron), long- or short-acting bronchodilators (e.g., β_2 agonists such as arformoterol, buphenine, clenbuterol, dopexamine, epinephrine, fenoterol, formoterol, isoetarine, isoprenaline, isoproterenol, levosalbutamol, orciprenaline, pirbuterol, procaterol, ritodrine, salbutamol, albuterol, terbutaline, tiotropium), anticholinergics (e.g., hyoscyamine, atropine, phenobarbital, scopolamine, dicyclomine, phenobarbital, mepenzolate and combinations such as atropine, hyoscy-

mine, phenobarbital and scopolamine), corticosteroids (e.g., hydrocortisone, hydrocortisone-17-valerate, hydrocortisone-17-butyrate, prednisone, prednisolone, triamcinolone acetate, triamcinolone alcohol, betamethasone, dexamethasone, fluocortolone, flunisolide, budesonide), long-term antibiotics (e.g., macrolides such as erythromycin, azithromycin, and methylxanthines such as theophylline) non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, naproxen, oxaprozin, piroxicam, salicylate, sulindac, tolmetin, etc.), 5-aminosalicylic acids (5-ASA) (e.g., mesalazine), immunosuppressants (e.g., prednisone, TNF inhibitors, azathioprine, methotrexate, 6-mercaptopurine), relapsing-remitting multiple sclerosis therapies (e.g., interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, teriflumide, dimethyl fumarate, alemtuzumab, daclizumab, CD20 monoclonal antibodies such as rituximab, ocrelizumab and ofatumumab), topical agents for psoriasis treatment (e.g., topical agents such as para-aminobenzoic acid, coconut oil, coal tar, dithranol, corticosteroids such as desoximetasone, fluocinonide, vitamin D₃ and other vitamin D analogues, psoralen, and systemic agents such as methotrexate, ciclosporin, hydroxycarbamide, fumarates such as dimethyl fumarate and retinoids), TNF- α antagonists (e.g., infliximab, adalimumab, golimumab and certolizumab pegol), psoriasis treatments that target T-cells (e.g., efalizumab and alefacept), treatments for hypertension and cardiovascular disease (e.g., aspirin, statins such as atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and combinations such as simvastatin+ezetimibe, lovastatin+niacin, and atorvastatin+amlodipine), therapies for neurodegenerative disorders (e.g., dimebon, and proline-rich peptide (PRP)-1), anti-depressants (e.g., sertraline, citalopram, fluoxetine, escitalopram, trazodone, venlafaxine, bupropion, duloxetine, paroxetine, amitriptyline, venlafacine, desvenlafaxine, and nortriptyline), and anti-cancer therapies (e.g., sorafenib, JX-594, interleukin-2, ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda), vemurafenib (Zelboraf), dabrafenib (Tafinlar), Trametinib (Mekinist), anthracyclines such as doxorubicin (Adriamycin®), epirubicin (Ellence®), taxanes such as paclitaxel (Taxol®) and docetaxel (Taxotere®), 5-fluorouracil (5-FU), cyclophosphamide (Cytoxan®), carboplatin (Paraplatin®) or a combination thereof).

Administration Regimens

According to certain embodiments of the present invention, multiple doses of an anti-LEPR antagonist antibody (or a pharmaceutical composition comprising a combination of an anti-LEPR antagonist antibody and any of the additional therapeutically active agents mentioned herein) may be administered to a subject over a defined time course. The methods according to this aspect of the invention comprise sequentially administering to a subject multiple doses of an anti-LEPR antibody of the invention. As used herein, "sequentially administering" means that each dose of anti-LEPR antibody is administered to the subject at a different point in time, e.g., on different days separated by a predetermined interval (e.g., hours, days, weeks or months). The present invention includes methods which comprise sequentially administering to the patient a single initial dose of an anti-LEPR antibody, followed by one or more secondary doses of the anti-LEPR antibody, and optionally followed by one or more tertiary doses of the anti-LEPR antibody.

The terms "initial dose," "secondary doses," and "tertiary doses," refer to the temporal sequence of administration of the anti-LEPR antibody of the invention. Thus, the "initial

25

dose" is the dose which is administered at the beginning of the treatment regimen (also referred to as the "baseline dose," "loading dose," "starting dose," and the like); the "secondary doses" are the doses which are administered after the initial dose; and the "tertiary doses" are the doses which are administered after the secondary doses. The initial, secondary, and tertiary doses may all contain the same amount of anti-LEPR antibody, but generally may differ from one another in terms of frequency of administration. In certain embodiments, however, the amount of anti-LEPR antibody contained in the initial, secondary and/or tertiary doses varies from one another (e.g., adjusted up or down as appropriate) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the beginning of the treatment regimen as "loading doses" followed by subsequent doses that are administered on a less frequent basis (e.g., "maintenance doses").

Diagnostic and Analytic Uses of the Antibodies

The anti-LEPR antibodies of the present invention may also be used to detect and/or measure LEPR, or LEPR-expressing cells in a sample, e.g., for diagnostic purposes. For example, an anti-LEPR antibody, or fragment thereof, may be used to diagnose a condition or disease characterized by aberrant expression (e.g., over-expression, under-expression, lack of expression, etc.) of LEPR. Exemplary diagnostic assays for LEPR may comprise, e.g., contacting a sample, obtained from a patient, with an anti-LEPR antibody of the invention, wherein the anti-LEPR antibody is labeled with a detectable label or reporter molecule. Alternatively, an unlabeled anti-LEPR antibody can be used in diagnostic applications in combination with a secondary antibody which is itself detectably labeled. The detectable label or reporter molecule can be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I ; a fluorescent or chemiluminescent moiety such as fluorescein isothiocyanate, or rhodamine; or an enzyme such as alkaline phosphatase, beta-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure LEPR in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).

Samples that can be used in LEPR diagnostic assays according to the present invention include any tissue or fluid sample obtainable from a patient which contains detectable quantities of LEPR protein, or fragments thereof, under normal or pathological conditions. Generally, levels of

26

LEPR in a particular sample obtained from a healthy patient (e.g., a patient not afflicted with a disease or condition associated with abnormal LEPR levels or activity) will be measured to initially establish a baseline, or standard, level of LEPR. This baseline level of LEPR can then be compared against the levels of LEPR measured in samples obtained from individuals suspected of having a LEPR related disease or condition.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

Example 1. Generation of Antigen-Binding Proteins that Specifically Bind the Leptin Receptor (LEPR)

Anti-LEPR antibodies were obtained by immunizing a VELOCIMMUNE® mouse (i.e., an engineered mouse comprising DNA encoding human immunoglobulin heavy and kappa light chain variable regions) with an immunogen comprising the extracellular domain of LEPR. The antibody immune response was monitored by a LEPR-specific immunoassay. Using previously described techniques, fully human anti-LEPR antibodies were isolated and purified.

Certain biological properties of the exemplary anti-LEPR antibodies generated in accordance with the methods of this Example are described in detail in the Examples set forth below.

Example 2. Heavy and Light Chain Variable Region Amino Acid and Nucleic Acid Sequences

Table 1 sets forth the amino acid sequence identifiers of the heavy and light chain variable regions and CDRs of selected anti-LEPR antibodies of the invention. The corresponding nucleic acid sequence identifiers are set forth in Table 2.

TABLE 1

Amino Acid Sequence Identifiers								
Antibody Designation	SEQ ID NOs:							
	HCVR	HCDR1	HCDR2	HCDR3	LCVR	LCDR1	LCDR2	LCDR3
H4H17322P2	2	4	6	8	10	12	14	16
H4H18437P2	18	20	22	24	10	12	14	16
H4H18439P2	26	28	30	32	10	12	14	16
H4H18440P2	34	36	38	40	10	12	14	16
H4H18457P2	42	44	46	48	10	12	14	16
H4H18462P2	50	52	54	56	10	12	14	16
H4H18464P2	58	60	62	64	10	12	14	16
H4H18466P2	66	68	70	72	10	12	14	16
H4H18508P2	74	76	78	80	82	84	86	88

TABLE 2

Nucleic Acid Sequence Identifiers								
Antibody	SEQ ID NOS:							
Designation	HCVR	HCDR1	HCDR2	HCDR3	LCVR	LCDR1	LCDR2	LCDR3
H4H17322P2	1	3	5	7	9	11	13	15
H4H18437P2	17	19	21	23	9	11	13	15
H4H18439P2	25	27	29	31	9	11	13	15
H4H18440P2	33	35	37	39	9	11	13	15
H4H18457P2	41	43	45	47	9	11	13	15
H4H18462P2	49	51	53	55	9	11	13	15
H4H18464P2	57	59	61	63	9	11	13	15
H4H18466P2	65	67	69	71	9	11	13	15
H4H18508P2	73	75	77	79	81	83	85	87

Antibodies are typically referred to herein according to the following nomenclature: Fc prefix (e.g. “H4H,” “H1M,” “H2M,” etc.), followed by a numerical identifier (e.g. “17322,” “18457,” etc.), followed by a “P” or “N” suffix. Thus, according to this nomenclature, an antibody may be referred to herein as, e.g., “H4H17322P2,” “H4H18457P2,” etc. The Fc prefixes on the antibody designations used herein (H4H, H1M and H2M) indicate the particular Fc region isotype of the antibody. For example, an “H4H” antibody has a human IgG4 Fc, whereas an “H1M” antibody has a mouse IgG1 Fc, (all variable regions are fully human as denoted by the first ‘H’ in the antibody designation). As will be appreciated by a person of ordinary skill in the art, an antibody having a particular Fc isotype can be converted to an antibody with a different Fc isotype (e.g., an antibody with a mouse IgG1 Fc can be converted to an antibody with a human IgG4, etc.), but in any event, the variable domains (including the CDRs)—which are indicated by the numerical identifiers shown in Tables 1 and 2—will remain the same, and the binding properties are expected to be identical or substantially similar regardless of the nature of the Fc domain.

Comparator Antibody.

The Comparator antibody used in the following Examples refers to Fab 9F8 described in Fazeli et al. (2006) *J Immunol Methods* 312:190-200 and Carpenter et al. (2012) *Structure* 20(3):487-97.

Example 3. Surface Plasmon Resonance Derived Binding Affinities and Kinetic Constants of Human Monoclonal Anti-LEPR Antibodies

Equilibrium dissociation constants (K_D values) for antigen binding to purified anti-LEPR monoclonal antibodies of the invention were determined using a real-time surface plasmon resonance biosensor using a Biacore 4000 instrument. All binding studies were performed in running buffer containing 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% v/v Surfactant Tween-20, pH 7.4 (HBS-ET running buffer) at 25° C. and 37° C. The Biacore sensor surface was first derivatized by amine coupling with a monoclonal mouse anti-human Fc antibody (GE,

BR-1008-39) to the capture anti-LEPR monoclonal antibodies. The LEPR reagents tested for binding to the anti-LEPR monoclonal antibodies included recombinant human LEPR extracellular domain expressed with a C-terminal myc-myc-hexahistidine tag (hLEPR.MMH; SEQ ID NO:90), recombinant cynomolgus monkey LEPR extracellular domain expressed with a C-terminal myc-myc-hexahistidine tag (mLEPR.MMH; SEQ ID NO:93), recombinant mouse LEPR extracellular domain expressed with a C-terminal myc-myc-hexahistidine tag (mLEPR.MMH; SEQ ID NO:94), recombinant rat LEPR extracellular domain expressed with a C-terminal myc-myc-hexahistidine tag (rLEPR.MMH; SEQ ID NO:95), and recombinant human LEPR extracellular domain expressed with a C-terminal mouse IgG2a Fc tag (hLEPR.mFc; SEQ ID NO:91). LEPR constructs that include MMH tags are monomeric LEPR constructs, and LEPR constructs including an mFc tag are dimeric LEPR constructs. Different concentrations of LEPR reagents were first prepared in HBS-ET running buffer at final concentrations ranging from 100 nM to 3.7 nM in 3-fold serial dilutions and were then injected over the anti-LEPR monoclonal antibody captured surface for 4 minutes at a flow rate of 30 μ L/minute. The dissociation of monoclonal antibody bound LEPR reagent was monitored for 10 minutes in HBS-ET running buffer. Kinetic association (k_a) and dissociation (k_d) rate constants were determined by fitting the real-time binding sensorgrams to a 1:1 binding model with mass transport limitation using Scrubber 2.0c curve-fitting software. Binding dissociation equilibrium constants (K_D) and dissociative half-lives ($t_{1/2}$) were calculated from the kinetic rate constants as:

$$K_D(M) = \frac{k_d}{k_a}, \text{ and } t_{1/2} \text{ (min)} = \frac{\ln(2)}{60 * k_d}$$

Binding kinetics parameters for hLEPR-MMH, mLEPR-MMH, hLEPR.mFc, mLEPR-MMH or rLEPR-MMH binding to different anti-LEPR monoclonal antibodies of the invention at 25° C. and 37° C. are shown in Tables 3 through 13.

TABLE 3

Binding kinetics parameters of anti-LEPR antibodies binding to hLEPR-MMH at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM hLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	178 ± 1.2	66	4.38E+04	2.24E-04	5.11E-09	52
H4H18437P2	171 ± 0.5	56	5.74E+04	3.75E-03	6.53E-08	3.1
H4H18439P2	156 ± 0.7	21	1.07E+04	1.13E-03	1.06E-07	10
H4H18440P2	170 ± 0.5	71	4.23E+04	4.97E-04	1.18E-08	23
H4H18457P2	166 ± 0.9	119	2.55E+05	2.52E-03	9.89E-09	5
H4H18462P2	175 ± 0.6	34	6.79E+04	7.65E-03	1.13E-07	1.5
H4H18464P2	160 ± 0.4	60	1.24E+05	1.13E-03	9.09E-09	10
H4H18466P2	161 ± 0.5	24	2.64E+04	5.11E-03	1.94E-07	2.3
H4H18508P2	180 ± 1.5	127	1.76E+05	1.67E-03	9.53E-09	7
Comparator Antibody	380 ± 8.2	26	4.48E+04	7.46E-05	1.66E-09	155
Isotype Control Antibody	171 ± 0.4	4	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

TABLE 4

Binding kinetics parameters of anti-LEPR antibodies binding to hLEPR-MMH at 37° C.						
mAb Captured	mAb Capture Level (RU)	100 nM hLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	225 ± 3	99	6.95E+04	8.12E-04	1.17E-08	14
H4H18437P2	213 ± 3	55	1.14E+05	8.84E-03	7.76E-08	1.3
H4H18439P2	180 ± 1.5	19	2.32E+04	4.69E-03	2.02E-07	2.5
H4H18440P2	207 ± 1.2	95	6.34E+04	1.73E-03	2.73E-08	7
H4H18457P2	198 ± 1.6	108	3.45E+05	8.55E-03	2.48E-08	1.4
H4H18462P2	204 ± 2.1	31	4.58E+04	1.14E-02	2.48E-07	1.0
H4H18464P2	185 ± 1.2	68	1.54E+05	3.15E-03	2.05E-08	3.7
H4H18466P2	184 ± 1.3	26	4.55E+04	6.74E-03	1.48E-07	1.7
H4H18508P2	204 ± 1.4	117	2.69E+05	6.88E-03	2.55E-08	1.7
Comparator Antibody	315 ± 7.6	37	5.39E+04	4.81E-04	8.92E-09	24
Isotype Control Antibody	193 ± 1.5	6	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

As shown in Table 3, at 25° C., all of the anti-LEPR monoclonal antibodies of the invention bound to hLEPR-MMH with K_D values ranging from 5.11 nM to 194 nM. As

shown in Table 4, at 37° C., all of the anti-LEPR monoclonal antibodies of the invention bound to hLEPR-MMH with K_D values ranging from 11.7 nM to 248 nM.

TABLE 5

Binding kinetics parameters of anti-LEPR antibodies binding to mLEPR-MMH at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM mLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	177 ± 0.5	102	7.02E+04	2.92E-04	4.16E-09	40
H4H18437P2	171 ± 0.3	70	6.87E+04	4.05E-03	5.89E-08	2.9
H4H18439P2	155 ± 0.5	22	1.57E+04	1.52E-03	9.63E-08	8
H4H18440P2	170 ± 0.9	67	4.95E+04	2.68E-03	5.41E-08	4.3
H4H18457P2	165 ± 0.4	133	2.73E+05	3.31E-03	1.22E-08	3.5
H4H18462P2	174 ± 0.4	42	7.42E+04	1.33E-02	1.79E-07	0.9
H4H18464P2	159 ± 0.4	15	3.82E+04	2.31E-03	6.04E-08	5.0
H4H18466P2	161 ± 0.5	30	4.50E+04	6.69E-03	1.48E-07	1.7
H4H18508P2	178 ± 0.4	145	2.04E+05	1.63E-03	8.00E-09	7
Comparator Antibody	359 ± 4.8	1	NB*	NB*	NB*	NB*
Isotype Control Antibody	171 ± 0.4	0	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

TABLE 6

Binding kinetics parameters of anti-LEPR antibodies binding to mLEPR-MMH at 37° C.						
mAb Captured	mAb Capture Level (RU)	100 nM mLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	218 ± 1.7	142	1.43E+05	1.10E-03	7.72E-09	10
H4H18437P2	207 ± 1.4	58	8.69E+04	1.27E-02	1.47E-07	0.9
H4H18439P2	178 ± 1.4	14	4.69E+04	7.92E-03	1.69E-07	1.5
H4H18440P2	204 ± 1	66	7.15E+04	7.24E-03	1.01E-07	1.6
H4H18457P2	195 ± 1.4	117	3.47E+05	1.04E-02	3.00E-08	1.1
H4H18462P2	199 ± 1.1	28	1.29E+05	3.37E-02	2.61E-07	0.3
H4H18464P2	183 ± 0.6	13	3.92E+04	8.41E-03	2.15E-07	1.4
H4H18466P2	181 ± 0.9	27	8.43E+04	1.38E-02	1.64E-07	0.8
H4H18508P2	200 ± 1	125	2.85E+05	7.89E-03	2.77E-08	1.5
Comparator Antibody	298 ± 3.2	-1	NB*	NB*	NB*	NB*
Isotype Control Antibody	190 ± 1	1	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

As shown in Table 5, at 25° C., all of the anti-LEPR monoclonal antibodies of the invention bound to mLEPR-MMH with K_D values ranging from 4.16 nM to 179 nM. As

shown in Table 6, at 37° C., all of the anti-LEPR monoclonal antibodies of the invention bound to mLEPR-MMH with K_D values ranging from 7.72 nM to 261 nM.

TABLE 7

Binding kinetics parameters of anti-LEPR antibodies binding to hLEPR-mFc at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM hLEPR-mFc Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	176 ± 0.4	74	6.45E+04	1.14E-04	1.77E-09	102
H4H18437P2	169 ± 1.1	70	1.02E+05	5.36E-04	5.27E-09	22
H4H18439P2	155 ± 0.2	53	4.87E+04	1.80E-04	3.69E-09	64
H4H18440P2	169 ± 0.5	140	1.54E+05	6.82E-05	4.43E-10	169
H4H18457P2	165 ± 0.8	149	4.91E+05	4.23E-04	8.63E-10	27
H4H18462P2	173 ± 0.5	68	9.08E+04	2.96E-04	3.26E-09	39
H4H18464P2	159 ± 0.4	84	2.11E+05	1.88E-04	8.91E-10	61
H4H18466P2	160 ± 0.2	37	3.97E+04	4.72E-04	1.19E-08	24
H4H18508P2	178 ± 0.4	138	2.21E+05	2.99E-04	1.35E-09	39
Comparator Antibody	344 ± 4.9	36	1.56E+05	1.45E-05	9.28E-11	798
Isotype Control Antibody	170 ± 0.7	-2	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

TABLE 8

Binding kinetics parameters of anti-LEPR antibodies binding to hLEPR-mFc at 37° C.						
mAb Captured	mAb Capture Level (RU)	100 nM hLEPR-mFc Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	214 ± 1.8	105	1.33E+05	4.40E-04	3.31E-09	26
H4H18437P2	202 ± 1.1	88	1.29E+05	5.56E-04	4.30E-09	21
H4H18439P2	176 ± 0.7	67	6.09E+04	9.23E-04	1.51E-08	13
H4H18440P2	200 ± 1.4	181	2.12E+05	1.12E-04	5.27E-10	103
H4H18457P2	193 ± 1	166	5.56E+05	7.04E-04	1.27E-09	16
H4H18462P2	196 ± 0.9	84	1.28E+05	5.43E-04	4.26E-09	21
H4H18464P2	182 ± 0.4	105	4.04E+05	5.17E-04	1.28E-09	22
H4H18466P2	179 ± 1	52	5.87E+04	5.20E-04	8.86E-09	22
H4H18508P2	198 ± 1	146	4.71E+05	1.02E-03	2.16E-09	11
Comparator Antibody	288 ± 2.5	50	1.50E+05	7.74E-05	5.14E-10	149
Isotype Control Antibody	188 ± 0.8	1	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

As shown in Table 7, at 25° C., all of the anti-LEPR monoclonal antibodies of the invention bound to hLEPR-mFc with K_D values ranging from 443 pM to 11.9 nM. As

shown in Table 8, at 37° C., all of the anti-LEPR monoclonal antibodies of the invention bound to hLEPR-mFc with K_D values ranging from 527 pM to 15.1 nM.

TABLE 9

Binding kinetics parameters of anti-LEPR monoclonal antibodies binding to mLEPR-MMH at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM mLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	176	0	NB*	NB*	NB*	NB*
H4H18437P2	169	6	1.58E+04	4.18E-03	2.64E-07	2.8
H4H18439P2	155	-2	NB*	NB*	NB*	NB*
H4H18440P2	169	-3	NB*	NB*	NB*	NB*
H4H18457P2	164	1	NB*	NB*	NB*	NB*
H4H18462P2	173	2	NB*	NB*	NB*	NB*
H4H18464P2	159	-1	NB*	NB*	NB*	NB*
H4H18466P2	160	1	NB*	NB*	NB*	NB*
H4H18508P2	177	25	2.78E+05	6.07E-02	2.18E-07	0.19
Comparator Antibody	334 ± 2.5	2	NB*	NB*	NB*	NB*
Isotype Control Antibody	169	-2	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

TABLE 10

Binding kinetics parameters of anti-LEPR antibodies binding to mLEPR-MMH at 37° C.						
mAb Captured	mAb Capture Level (RU)	100 nM mLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	212	-1	NB*	NB*	NB*	NB*
H4H18437P2	201	6	1.15E+04	1.33E-02	1.16E-06	0.9
H4H18439P2	175	-1	NB*	NB*	NB*	NB*
H4H18440P2	200	-1	NB*	NB*	NB*	NB*
H4H18457P2	191	-1	NB*	NB*	NB*	NB*
H4H18462P2	194	3	IC*	IC*	IC*	IC*
H4H18464P2	181	1	NB*	NB*	NB*	NB*
H4H18466P2	178	3	NB*	NB*	NB*	NB*
H4H18508P2	196	17	5.12E+05	1.05E-01	2.05E-07	0.11
Comparator Antibody	283 ± 1.1	0	NB*	NB*	NB*	NB*
Isotype Control Antibody	187	0	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

*IC indicates that observed binding was inclusive and was unable to fit the real time binding data under the current experimental conditions.

As shown in Table 9, at 25° C., two out of 9 of the anti-LEPR monoclonal antibodies of the invention bound to mLEPR-MMH with K_D values of 218 nM and 264 nM. As shown in Table 10, at 37° C., two out of 9 of the anti-LEPR monoclonal antibodies of the invention bound to mLEPR-MMH with K_D values of 205 nM and 1.16 μ M.

TABLE 11

Binding kinetics parameters of anti-LEPR antibodies binding to rLEPR-MMH at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM rLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (Ms)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	176 ± 0.9	10	IC*	IC*	IC*	IC*
H4H18437P2	169 ± 0.2	13	4.21E+04	1.38E-02	3.28E-07	0.8
H4H18439P2	155 ± 0.2	-1	NB*	NB*	NB*	NB*
H4H18440P2	169 ± 0.4	-2	NB*	NB*	NB*	NB*
H4H18457P2	164 ± 0.5	18	2.83E+04	2.06E-02	7.30E-07	0.6
H4H18462P2	173 ± 0.2	5	3.21E+04	1.08E-02	3.36E-07	1.1
H4H18464P2	159 ± 0	-1	NB*	NB*	NB*	NB*
H4H18466P2	160 ± 0.6	5	2.10E+04	1.98E-02	9.43E-07	0.6
H4H18508P2	177 ± 0.1	22	1.39E+05	4.76E-02	3.41E-07	0.24

TABLE 11-continued

Binding kinetics parameters of anti-LEPR antibodies binding to rLEPR-MMH at 25° C.						
mAb Captured	mAb Capture Level (RU)	100 nM rLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (Ms)	K_D (M)	$t_{1/2}$ (min)
Comparator Antibody	328 ± 1.6	1	NB*	NB*	NB*	NB*
Isotype Control Antibody	170 ± 0.2	-1	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

*IC indicates that observed binding was inclusive and was unable to fit the real time binding data under the current experimental conditions.

TABLE 12

Binding kinetics parameters of anti-LEPR antibodies binding to rLEPR-MMH at 37° C.						
mAb Captured	mAb Capture Level (RU)	100 nM rLEPR-MMH Bound (RU)	k_a (1/Ms)	k_d (1/s)	K_D (M)	$t_{1/2}$ (min)
H4H17322P2	212 ± 0.3	9	9.32E+04	3.28E-02	3.52E-07	0.4
H4H18437P2	200 ± 0	10	3.07E+04	1.93E-02	6.29E-07	0.6
H4H18439P2	175 ± 0.8	0	NB*	NB*	NB*	NB*
H4H18440P2	200 ± 0.1	0	NB*	NB*	NB*	NB*
H4H18457P2	192 ± 0.3	16	3.02E+04	1.75E-02	5.80E-07	0.7
H4H18462P2	194 ± 0.9	5	IC*	IC*	IC*	IC*
H4H18464P2	181 ± 0.1	1	NB*	NB*	NB*	NB*
H4H18466P2	177 ± 0.7	6	3.26E+04	2.52E-02	7.71E-07	0.5
H4H18508P2	196 ± 1.6	17	2.71E+05	4.57E-02	1.68E-07	0.25
Comparator Antibody	279 ± 0.4	-1	NB*	NB*	NB*	NB*
Isotype Control Antibody	186 ± 0.1	0	NB*	NB*	NB*	NB*

*NB indicates that no binding was observed under the current experimental conditions.

*IC indicates that observed binding was inclusive and was unable to fit the real time binding data under the current experimental conditions.

As shown in Table 11, at 25° C., five out of 9 of the anti-LEPR monoclonal antibodies of the invention bound to rLEPR-MMH with K_D values ranging from 328 nM to 943 nM. As shown in Table 12, at 37° C., five out of 9 of the anti-LEPR monoclonal antibodies of the invention bound to rLEPR-MMH with K_D values ranging from 168 nM to 771 nM.

Example 4. Anti-LEPR Antibodies of the Invention do not Block hLEPR-hFc Binding to hLeptin

The ability of anti-LEPR monoclonal antibodies of the invention to block binding of dimeric human LEPR to its natural ligand, human Leptin, was measured using a competition sandwich ELISA.

For the ELISA, human Leptin (hLeptin; R&D Systems, #398-LP-01M) was coated at a concentration of 5 µg/mL in PBS on a 96-well microtiter plate overnight at 4° C. Non-specific binding sites were subsequently blocked using a 0.5% (w/v) solution of BSA in PBS. A constant amount of 10 nM of extracellular domain portion of LEPR protein that was expressed with a C-terminal human Fc tag (hLEPR.hFc; SEQ ID NO:92) was titrated with anti-LEPR antibodies, hLeptin protein, or an isotype control antibody ranging from 8.5 pM to 500 nM in serial dilution. These antibody-protein or protein-protein complexes were then incubated for 1.5 hour at room temperature (RT). Complexes were subsequently transferred to microtiter plates coated with hLeptin and incubated for 2 hours at RT, the wells were washed, and plate-bound hLEPR-hFc was detected with an anti-human IgG polyclonal antibody conjugated with horseradish peroxidase (Jackson ImmunoResearch Inc, #109-035-098). Samples were developed with a TMB solution (BD Biosciences, #555214; substrate A and B mixed at 1:1 ratio as per manufacturer's instructions) to produce a colorimetric reaction and then neutralized with 1M sulfuric acid before measuring absorbance at 450 nm on a Victor X5 plate reader.

Data analysis was performed using a sigmoidal dose-response model within Prism™ software (GraphPad). Percent blockade at maximum concentration of the antibody tested was calculated as an indicator of the ability of the antibodies to block the binding of 10 nM of hLEPR-hFc to human Leptin on the plate. In the calculation, binding signal of 10 nM of hLEPR-hFc without the presence of the antibody was referenced as 100% binding or 0% blocking; and the baseline signal of buffer alone without the presence of hLEPR-hFc was referenced as 0% binding or 100% blocking. The blocking data at 500 nM antibody concentration is summarized in Table 13.

TABLE 13

ELISA blocking of hLEPR-hFc binding to hLeptin by anti-LEPR antibodies	
Antibody	500 nM Ab Blocking of 10 nM hLEPR-hFc Binding to hLeptin (% blockade)
H4H18440P2	3
H4H18466P2	2
H4H18457P2	4
H4H18437P2	9
H4H18464P2	-5
H4H17322P2	13
H4H18439P2	-1
H4H18462P2	14
H4H18508P2	40
Controls	
Isotype control antibody	-3
Human Leptin	99
Comparator Antibody	99
Mouse IgG2a Isotype control	32

As shown in Table 13, none of the anti-LEPR antibodies of the invention demonstrated >40% blockade of the binding of hLEPR-hFc to the hLeptin coated surface. However, the Comparator Antibody and the hLeptin, as the positive control, were able to block 99% of the hLEPR-hFc binding to the hLeptin coated surface. The isotype control antibody demonstrated no measurable blocking at concentrations up to 500 nM.

Example 5. Cell Binding by FACS Analysis with HEK293/Myx2-hLEPR(Ecto)-GPI Anchored Cells

Leptin receptor, LEPR, is a single-pass transmembrane receptor of the class I cytokine receptor family with a large, 818 amino acid long extracellular domain (Tartaglia (1997) *J. Biol. Chem* 7:272(10):6093-6). LEPR can bind to Leptin, a protein predominantly expressed by adipose tissue that is involved in regulation of food intake and metabolism (Friedman (2014) *J Endocrinol* 223(1):T1-8). Different isoforms of LEPR exist yielding soluble or membrane-bound forms of the receptor and the membrane-bound forms differ in the length of their intracellular domain. The isoform with the longest intracellular domain is highly expressed in the hypothalamus, an important site of Leptin action in relation to obesity (Friedman and Halaas (1998) *Nature* 395(6704):763-70). LEPR is localized predominantly within the cell bodies and to a lesser extent on the cell surface. LEPR undergoes ligand-induced internalization adding an additional level of regulation of Leptin signaling (Sweeney (2002) *Cell Signal* 14(8):655-63).

In order to assess cell binding by anti-LEPR antibodies of the invention, a HEK293 cell line was generated to stably express the extracellular domain of human LEPR (hLEPR; amino acids 22-839 of accession # P48357, Isoform B) with an N-terminal myc-myc tag and C-terminal peptide sequence from human carboxypeptidase M that guides the addition of glycosylphosphatidylinositol (GPI) (Marcic et al. (2000) *J Biol Chem*. 275(21):16110-8) such that the protein can be GPI-anchored to the membrane. Since the hLEPR in the cell line does not possess an intracellular domain, it is not internalized upon ligand binding, greatly increasing the amount of LEPR available for antibody and/or ligand binding. The cell line was selected in DMEM containing 10% FBS, NEAA, penicillin/streptomycin, and 500 µg/mL of G418, then sorted for high expression of the receptor using an anti-Myc antibody. The resulting stable cell line, referred to as HEK293/hLEPR-GPI, was maintained in DMEM containing 10% FBS, NEAA, and penicillin/streptomycin.

For the FACS analysis, HEK293 parental cells and HEK293/hLEPR-GPI cells were dissociated and plated onto 96-well v-bottom plates at 5×10^5 cells/well in PBS containing 2% FBS (FACS buffer). In order to test whether the anti-hLEPR antibodies binding to cells is affected by the presence of Leptin, FACS buffer with or without 1 µM human Leptin (R&D Systems, #398-LP) was incubated with the cells for 30 minutes at 4° C., followed by the addition of anti-LEPR antibodies or control antibodies at 10 nM in FACS buffer. The cells were subsequently incubated for 30 minutes at 4° C., followed by washing and then incubation with 16 µg/mL of Alexa Fluor®-647 conjugated secondary antibody (Jackson ImmunoResearch Laboratories Inc., #109-547-003) for 30 minutes at 4° C. Cells were subsequently fixed using BD CytoFix™ (Becton Dickinson, #554655), filtered, and analyzed on a HyperCyt Flow Cytometer (Beckman Coulter). Unstained and secondary antibody alone controls were also tested for all cell lines. The results were analyzed using ForeCyt (IntelliCyt) and FlowJo version 10 softwares to determine the geometric means of fluorescence for viable cells. The geometric mean of fluorescence for each sample was then normalized to the

geometric mean of unstained cells to obtain relative binding per condition referred to as “binding ratios”, and these binding ratios were recorded in Table 14 for each antibody tested.

As shown in Table 14, the 9 anti-LEPR antibodies of the invention tested at 10 nM demonstrated binding to HEK293/hLEPR-GPI cells with binding ratios ranging from 824-fold to 3187-fold without Leptin and 398-fold to 3590-fold in the presence of 1 µM Leptin. Based on the similarity of these binding ratios, the ability of the anti-LEPR antibodies of the invention to bind to LEPR expressed on cells does not appear to be significantly affected by the presence of excess Leptin at 1 µM, suggesting that the binding sites of the anti-LEPR antibodies on LEPR do not overlap with Leptin binding sites on LEPR. The anti-LEPR antibodies of the invention did not demonstrate any significant binding to the HEK293 parental cells with binding ratios with and without 1 µM Leptin ranging from 1- to 9-fold. Binding of the comparator to cells expressing GPI-anchored LEPR was significantly reduced in the presence of Leptin. The isotype control antibody and secondary antibody alone samples also did not demonstrate significant binding to either cell line with or without Leptin, with binding ratios ranging from 1- to 6-fold.

TABLE 14

Binding of 10 nM anti-LEPR antibodies to HEK293/hLEPR-GPI and HEK293 parental cells +/- 1 µM Human Leptin

Antibody	Binding Ratio: Normalized to Unstained Sample of Each Cell Line			
	No added Leptin		1 µM Leptin	
	HEK293 parental	HEK293/ hLEPR-GPI	HEK293 parental	HEK293/ hLEPR-GPI
H4H17322P2	3	1307	6	1317
H4H18457P2	2	3187	3	3106
H4H18464P2	5	2318	7	3590
H4H18437P2	1	1314	2	1441
H4H18439P2	4	1533	6	2477
H4H18440P2	3	1640	7	2557
H4H18462P2	2	1173	3	759
H4H18466P2	1	824	2	398
H4H18508P2	1	1311	2	1873
Comparator	6	2349	3	112
Antibody				
Human IgG isotype control antibody	1	6	2	4
Anti-human IgG secondary antibody alone	1	3	2	3
Mouse IgG isotype control antibody	2	2	3	3
Anti-mouse IgG secondary antibody alone	2	2	2	2
Unstained	1	1	1	1

Example 6: Anti-LEPR Antibodies of the Invention Demonstrated Complete Inhibition of Leptin Signaling in the Presence of hLeptin

A bioassay was developed to detect the transcriptional activation of STAT3 via LEPR activation using a reporter cell line that stably expresses full-length human LEPR (hLEPR; amino acids 1 through 1165 of accession number NP_002294.2) along with a luciferase reporter (STAT3-Luc; Qiagen, # CLS-6028L) in an IMR-32 cell line, a human neuroblastoma cell line. The resulting stable cell line, referred to as IMR-32/STAT3-Luc/hLEPR, was isolated and

39

maintained in MEM-Earl medium supplemented with 10% FBS, NEAA, 1 ug/mL Puromycin, 100 ug/mL of Hygromycin B and Penicillin/Streptomycin/L-Glutamine (Complete Medium).

The resulting bioassay was used to measure the effect of anti-LEPR antibodies of the invention on LEPR signaling in the presence or absence of Leptin. For the bioassay, IMR-32/STAT3-Luc/hLEPR cells were plated at a density of 20,000 cells/100 ul/well for 96 well format in the complete medium and then the following day the medium was replaced with the appropriate volume of Opti-MEM supplemented with 1% BSA and 0.1% FBS (Assay Buffer) for 30 minutes. To measure the effect of the antibodies of the invention in the absence of Leptin, the anti-LEPR antibodies or an isotype control antibody were half-log serially diluted to final concentrations ranging from 100 nM to 300 fM in Assay Buffer and were then added to the cells and subsequently incubated overnight at 37° C. in 5% CO₂. To measure the effect of the antibodies of the invention in the presence of Leptin, a fixed concentration of human Leptin (hLeptin; R&D Systems, #398-LP) at 200 pM in Assay Buffer was added to the cells, immediately followed by the addition of anti-LEPR antibodies or isotype control antibody that were half-log serially diluted to final concentrations ranging from 100 nM to 300 fM. The samples were then incubated overnight at 37° C. in 5% CO₂. OneGlo reagent (Promega, # E6051) was then added to the samples and luciferase activity was measured on a Envision Multilable Plate Reader (Perkin Elmer) in Luminescent mode. The relative light units (RLU) values were obtained and the results were analyzed using nonlinear regression with GraphPad Prism software (GraphPad). The maximum RLU value obtained from the hLeptin dose response was defined as 100% activation in the IMR-32/STAT3-Luc/hLEPR assay.

As shown in Table 15, in the absence of hLeptin, the anti-LEPR antibodies tested demonstrated weak stimulation of the IMR-32/STAT3-Luc/hLEPR cells with maximal activation of 4% to 8%, respectively, that of maximum activation obtained from the hLeptin dose response. One antibody with weak stimulation had an EC₅₀ value of 1.27 nM, while another of the antibodies, H4H18440P2, did not have a measurable EC₅₀ value. In the presence of 200 pM of hLeptin, three of the anti-LEPR antibodies that were tested demonstrated complete inhibition of Leptin in the IMR-32/STAT3-Luc/hLEPR cells with IC₅₀ values ranging from 723 pM (antibody H4H18457P2) to 1.83 nM (antibody H4H17322P2) or 2.9 nM (antibody H4H18464P2). Six of the anti-LEPR antibodies tested did not demonstrate any measurable inhibition in the presence of 200 pM of human Leptin. The isotype control antibody did not demonstrate any measurable stimulation of the IMR-32/STAT3-Luc/hLEPR cells in any of the assays.

TABLE 15

Activation and Inhibition of hLEPR by anti-LEPR antibodies				
Antibody	IMR-32/LEPR without human Leptin		IMR-32/LEPR with 200 pM human Leptin	
	EC ₅₀ (M)	% activation	IC ₅₀ (M)	% inhibition
H4H18457P2	N/A	N/A	7.23E-10	100
H4H17322P2	1.27E-09	8	1.83E-09	100
H4H18464P2	1.30E-10	6	2.9E-09	100
H4H18437P2	N/A*	N/A*	N/A*	N/A*

40

TABLE 15-continued

Activation and Inhibition of hLEPR by anti-LEPR antibodies				
Antibody	IMR-32/LEPR without human Leptin		IMR-32/LEPR with 200 pM human Leptin	
	EC ₅₀ (M)	% activation	IC ₅₀ (M)	% inhibition
H4H18439P2	N/A*	N/A*	N/A*	N/A*
H4H18440P2	IC*	4	N/A*	N/A*
H4H18462P2	N/A*	N/A*	N/A*	N/A*
H4H18466P2	N/A*	N/A*	N/A*	N/A*
H4H18508P2	N/A*	N/A*	N/A*	N/A*
Comparator Antibody	N/A*	N/A*	1.03E-09	100

*N/A denotes no measurable inhibition and/or activation in the assay

*IC denotes an inconclusive result in that a calculated EC₅₀ value could not be determined.

Example 7. Octet Cross-Competition Between Different Anti-LEPR Monoclonal Antibodies

Binding competition between a panel of different anti-LEPR monoclonal antibodies was determined using a real time, label-free bio-layer interferometry assay on the Octet HTX biosensor platform (Pall ForteBio Corp.). The entire experiment was performed at 25° C. in buffer containing 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% v/v Surfactant Tween-20, 1 mg/mL BSA, pH7.4 (HBS-EBT) with the plate shaking at the speed of 1000 rpm.

To assess whether two antibodies were able to compete with one another for binding to recombinant human LEPR expressed with a C-terminal myc-myc-hexahistidine tag (hLEPR.MMH; SEQ ID:90), about 0.25 nm of hLEPR-MMH was first captured onto anti-penta-His antibody coated Octet biosensor tips (ForteBio Inc, #18-5122) by submerging the biosensor tips for 5 minutes in wells containing 20 µg/mL of hLEPR-MMH. The antigen captured biosensor tips were then saturated with a first anti-LEPR monoclonal antibody (subsequently referred to as mAb-1) by dipping into wells containing 50 µg/mL solution of mAb-1 for 210 seconds. The biosensor tips were then subsequently dipped into wells containing a 50 µg/mL solution of a second anti-LEPR monoclonal antibody (subsequently referred to as mAb-2) for 150 seconds. The biosensor tips were washed in HBS-EBT buffer in between every step of the experiment. The real-time binding response was monitored during the entire course of the experiment and the binding response at the end of every step was recorded. The response of mAb-2 binding to hLEPR-MMH pre-complexed with mAb-1 was compared and competitive/non-competitive behavior of different anti-LEPR monoclonal antibodies was determined as shown in Table 16.

TABLE 16

Cross-competition between anti-LEPR monoclonal antibodies	
First antibody (mAb-1) binding to captured hLEPR-MMH	Second antibody (mAb-2) shown to compete with mAb-1
H4H18439P2	H4H18440P2
H4H18440P2	H4H18439P2
H4H18457P2	H4H18462P2
	H4H18437P2
	H4H18466P2
	H4H18508P2

TABLE 16-continued

Cross-competition between anti-LEPR monoclonal antibodies	
First antibody (mAb-1) binding to captured hLEPR-MMH	Second antibody (mAb-2) shown to compete with mAb-1
H4H18462P2	H4H18457P2 H4H18437P2 H4H18466P2
H4H18437P2	H4H18457P2 H4H18462P2 H4H18466P2
H4H18466P2	H4H18457P2 H4H18462P2 H4H18437P2
H4H17322P2	None
H4H18464P2	None

As shown in Table 16, antibodies H4H18439P2 and H4H18440P2 compete with one another for binding to their respective epitopes. LEPR antibodies H4H18457P2, H4H18462P2, H4H18437P2, H4H18466P2 and H4H18508P2 compete with one another for binding to their respective epitopes. Antibodies H4H17322P2 and H4H18464P2 do not compete for binding to the respective epitopes of H4H18439P2, H4H18440P2, H4H18457P2, H4H18462P2, H4H18437P2, and H4H18466P2.

Example 8: In Vivo Efficacy Testing of LEPR Antagonist Antibodies in Humanized LEPR Mice

The effects of three specific antagonist anti-LEPR antibodies of the invention, H4H17322P2, H4H18457P2 and H4H18464P2, on food intake, body weight and adiposity were determined in singly-housed genetically engineered LEPR^{HuHu} mice that express a leptin receptor which is composed of the human LEPR ectodomain sequence in place of the murine LEPR ectodomain sequence.

Baseline daily food intake was measured between 5 days and 1 day prior to treatment (days -5 and -1). Four days prior to treatment and 6 days post treatment (days -4 and -6) body composition, including adiposity, was quantified by μ CT. At day 0, thirty-two 12- to 13-week old male LEPR^{HuHu} mice were randomized to four groups of 8 mice based on body weight from 1-day pretreatment (day -1). At day 0, each group received via subcutaneous injection either a single dose of isotype control antibody at 30 mg/kg, H4H17322P2 at 30 mg/kg, H4H18457P2 at 30 mg/kg, or H4H18464P2 at 30 mg/kg. The isotype control antibody does not bind any known mouse protein. Food intake and body weight were measured for the duration of the study for each animal. FIG. 1 summarizes the percent change in food intake from the average baseline daily food intake for each treatment group at each time point. The percent change in body weight from day 0 was calculated for each animal at each time point. FIG. 2 summarizes the average percent change in body weight for animals in each treatment group. FIG. 3 summarizes the average fat mass for animals in each antibody treatment group quantified by μ CT 6 days prior to and 6 days following antibody treatment. All results are expressed as mean $\pm$ SEM.

As shown in FIGS. 1 and 2, mice treated with the anti-LEPR antagonist antibodies demonstrated increases in percent change in food intake and percent change in body weight. These increases were not observed with the isotype control antibody treatment. As shown in FIG. 1, mice treated with H4H17322P2 at 30 mg/kg exhibited significant increases in food intake starting at one day after treatment (day 1) and at the subsequent time points compared to mice injected with isotype control antibody. Mice treated with H4H18457P2 at 30 mg/kg exhibited a significant increase in

food intake starting at day 2 and at the subsequent time points compared to mice injected with isotype control antibody. Mice treated with H4H18464P2 at 30 mg/kg exhibited a significant increase in food intake starting at day 2 and at the subsequent time points, but not day 4 compared to mice injected with isotype control antibody. As shown in FIG. 2, mice treated with H4H17322P2 at 30 mg/kg exhibited a significant increase in percent body weight change starting four days after treatment (day 4) and at the subsequent time points compared to mice injected with isotype control antibody. Mice treated with H4H18457P2 at 30 mg/kg exhibited a significant increase in percent body weight change starting at day 3 and at the subsequent time points compared to mice injected with isotype control antibody. Mice treated with H4H18464P2 at 30 mg/kg exhibited a significant increase in percent body weight change starting at day 4 and at subsequent time points compared to mice injected with isotype control antibody. As depicted in FIG. 3, there were no differences in fat mass between the groups prior to treatment (day -4). Mice treated with H4H17322P2, H4H18457P2 and H4H18464P2 antibody at 30 mg/kg demonstrated a significant increase in fat mass 6 days after treatment (day 6) as compared to isotype control antibody. In conclusion, treatment with LEPR antagonist antibody, but not an isotype control antibody, increased food intake, body weight and adiposity in mice.

Example 9: Determination of Epitopes of Human LEPR to which the Anti-LEPR Antibodies of the Invention Bind

To determine the epitope of human LEPR on which anti-LEPR antibodies of the invention bind, a Luminex FLEXMAP (FM3DD, LuminexCorp) flow cytometry based analysis was utilized to characterize the interaction of anti-LEPR antibodies with recombinant human LEPR protein domains. For the assay, approximately 3 million carboxylated Microplex® microspheres (Luminex, Cat# LC1000A), were washed, vortexed and sonicated in 0.1 M NaPO₄, pH 6.2 (activation buffer) then centrifuged to remove the supernatant. The microspheres were resuspended in 120 μ L of activation buffer and the carboxylate groups (—COOH) were activated by addition of 15 μ L of 50 mg/mL of N-hydroxysuccinimide (NHS, Thermo Scientific, Cat#24500) followed by addition of 15 μ L of 50 mg/mL of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC, ThermoScientific, Cat#22980) at 25° C. After 10 minutes, the pH of the reaction was reduced to 5.0 with the addition of 600 μ L of 50 mM MES, pH 5 (coupling buffer), and the microspheres were vortexed, and centrifuged to remove supernatant. The activated beads were immediately mixed with 500 μ L of 20 μ g/mL monoclonal anti-myc antibodies with either a mouse IgG or a human IgG, in coupling buffer and incubated for two hours at 25° C. The coupling reaction was quenched by addition of 50 μ L of 1M Tris-HCl, pH 8.0 and the microspheres were rapidly vortexed, centrifuged, and washed four times with 1 mL of DPBS, to remove uncoupled proteins and other reaction components.

The transiently expressed LEPR proteins, included human LEPR extracellular domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR-MMH, SEQ ID NO: 89), human LEPR CRH1 (D1) expressed with a C-terminal myc-myc hexahistidine tag (human LEPR CRH1 (D1)-MMH, amino acids 1-208 of SEQ ID NO: 89 with a myc-myc hexahistidine tag, amino acids 209-236), human LEPR CRH1 (D1,D2) domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR CRH1 (D1,D2)-MMH, amino acids 1-318 of SEQ ID NO: 89 with a myc-myc hexahistidine tag, amino acids 319-346), human LEPR CRH1-Ig (D1,D2,D3) domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR CRH1 (D1,D2,D3)-MMH, amino acids 1-278 of SEQ ID NO: 89

43

with a myc-myc hexahistidine tag, amino acids 279-306), human LEPR CRH1-Ig (D2,D3) domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR CRH1-Ig (D2,D3)-MMH, amino acids 1-198 of SEQ ID NO: 89 with a myc-myc hexahistidine tag, amino acids 199-226), human LEPR Ig (D3) domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR Ig (D3)-MMH, amino acids 1-88 of SEQ ID NO: 89 with a myc-myc hexahistidine tag, amino acids 89-116), human LEPR CRH2 domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR CRH2-MMH, amino acids 1-207 of SEQ ID NO: 89 with a myc-myc-hexahistidine tag, amino acids 208-235), human LEPR FNIII domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR FNIII-MMH, amino acids 1-204 of SEQ ID NO: 89 with a myc-myc hexahistidine tag, amino acids 205-232), and human LEPR Ig-CRH2-FNIII domain expressed with a C-terminal myc-myc hexahistidine tag (human LEPR Ig-CRH2-FNIII-MMH, amino acids 1-510 of SEQ ID NO: 89 with a myc-myc-hexahistidine tag, amino acids 511-538), were suspended in serum free CHO-S-SFM II Medium (Thermo Fisher, Cat #31033020) and were then clarified by centrifugation. Aliquots of microspheres with immobilized anti-myc monoclonal antibodies, prepared as described above, were added individually to 1 mL of each of these protein supernatants. The microspheres were gently mixed, incubated for two hours at 25° C., washed twice with 1 mL of DBPS, centrifuged to remove the supernatant and finally resuspended in 1 mL of DPBS buffer. Forty eight L of anti-myc IgG coupled microspheres from individual reactions with full length human LEPR and with each of the human LEPR domain proteins were withdrawn and mixed together in 3.6 mL of PBS+20 mg/mL BSA+ 0.05% sodium azide (blocking buffer).

44

From this mixed pool, 75 μ L of microspheres were plated per well on a 96 well filter plate (Millipore, Cat. No: MSBVN1250) and mixed with 25 μ L of individual anti-human LEPR monoclonal antibodies (0.5 or 5 μ g/mL), incubated for two hours at 25° C. and then washed twice with 200 μ L of DPBS with 0.05% Tween 20 (washing buffer). To detect and quantify the amounts of bound anti-LEPR antibody levels to individual microspheres, either 100 μ L of 2.5 μ g/mL R-Phycoerythrin conjugated goat F(ab')₂ anti-human kappa (Southern Biotech, Cat#2063-09) in blocking buffer or 100 μ L of 1.25 μ g/mL R-Phycoerythrin AffiniPure F(ab')₂ in blocking buffer or 100 μ L of 1.25 μ g/mL R-Phycoerythrin AffiniPure F(ab')₂ Fragment Goat Anti-Mouse IgG, F(ab')₂ Fragment Specific (Jackson ImmunoResearch, Cat. No: 115-116-072) in blocking buffer, was added and incubated for 30 minutes at 25° C. After 30 minutes, the samples were washed twice with 200 μ L of washing buffer and resuspended in 150 μ L of wash buffer. The Median Fluorescence intensity (MFI) of the microspheres was measured in a Luminex Analyzer.

The results of the Luminex based analysis are tabulated in Table 17. Luminex MFI signal intensities indicate that the nine anti-LEPR antibodies of the invention bound to the complete human LEPR extracellular domain. Anti-LEPR antibodies H4H18439P2 and H4H18440P2, bound to epitopes within the CRH1 D2 domain of human LEPR. Anti-LEPR antibody H4H17322P2 and COMP3551, bound to epitopes within the CRH2 domain of human LEPR. Anti-LEPR antibodies, H4H18437P2, H4H18457P2, H4H18508P2, H4H18466P2 and H4H18462P2, bound to epitopes within the FNIII domain of human LEPR. Anti-LEPR antibody, H4H18464P2 bound to epitopes within the Ig(D3) domain of human LEPR.

TABLE 17

Luminex MFI signal of anti-LEPR antibodies binding to myc tag captured full-length extracellular domain of human LEPR and isolated human LEPR domains.										
Antibody	CRH1 (D1)	CRH1 (D1, D2)	CRH1-Ig (D1, D2, D3)	CRH1-Ig (D2, D3)	Ig (D3)	CRH2	FNIII	Ig-CRH2-FNIII	Full Length extracellular domain	Probable Binding site
H4H17322P2	14	50	31	58	26	19745	23	15097	8932	CRH2
H4H18437P2	21	82	34	43	26	25	1593	15625	8644	FNIII
H4H18457P2	13	53	31	43	18	18	1187	13235	7500	FNIII
H4H18508P2	10	274	217	372	24	18	741	13007	5865	FNIII
H4H18466P2	15	56	209	76	26	17	457	11270	5070	FNIII
H4H18439P2	11	21179	8021	10026	18	16	13	43	5472	CRH1 D2
H4H18440P2	8	19337	8245	9165	14	17	10	32	7035	CRH1 D2
H4H18464P2	13	59	5557	3742	27	24	23	15119	9385	Ig(D3)
H4H18462P2	5381	5731	3961	47	21	24	581	14858	5852	FNIII
H4H18462P2*	615	665	461	25	10	8	229	11153	3610	FNIII
Comparator Antibody	-14	19	-57	27	10	9404	73	7112	3908	CRH2

*Antibody tested at 0.5 μ g/mL instead of 5 μ g/mL.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 95

<210> SEQ ID NO 1

<211> LENGTH: 378

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 1

```

cagctgcagc tgcaggagtc gggcccagga ctggtgaagc ctcgggagac cctgtccctc    60
acctgcactg tctctggtgc ctctatcagc agtagtcggt tctacggggg ctggatccgc    120
cagccccagc ggaaggtctt ggagtggtatt ggggatattc attatagtgg gaatacctac    180
tacaaccctg ccctocagag tcgagtcacc atatccgtag acacgtccaa gaatcagttc    240
tccctgaagc tgagctctgt gaccgccgca gacacggctg tgtattactg tgcgagacac    300
cttatgatta cgtttggggg acttatcgtc gagggttttg atatttgggg ccaagggaca    360
atggtcacccg tctcttca                                     378
  
```

<210> SEQ ID NO 2
 <211> LENGTH: 126
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 2

```

Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1           5           10           15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ala Ser Ile Ser Ser Ser
          20           25           30
Arg Phe Tyr Gly Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
          35           40           45
Trp Ile Gly Asp Ile Tyr Tyr Ser Gly Asn Thr Tyr Tyr Asn Pro Ser
          50           55           60
Leu Gln Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
65           70           75           80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
          85           90           95
Cys Ala Arg His Leu Met Ile Thr Phe Gly Gly Leu Ile Val Glu Gly
          100          105          110
Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
          115          120          125
  
```

<210> SEQ ID NO 3
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 3

```

ggtgccctcta tcagcagtag tcgtttctac    30
  
```

<210> SEQ ID NO 4
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 4

```

Gly Ala Ser Ile Ser Ser Ser Arg Phe Tyr
1           5           10
  
```

-continued

<210> SEQ ID NO 5
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 5

atctattata gtggaatac c 21

<210> SEQ ID NO 6
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 6

Ile Tyr Tyr Ser Gly Asn Thr
 1 5

<210> SEQ ID NO 7
 <211> LENGTH: 54
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 7

gcgagacacc ttatgattac gtttggggga cttatcgctg agggttttga tatt 54

<210> SEQ ID NO 8
 <211> LENGTH: 18
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 8

Ala Arg His Leu Met Ile Thr Phe Gly Gly Leu Ile Val Glu Gly Phe
 1 5 10 15

Asp Ile

<210> SEQ ID NO 9
 <211> LENGTH: 324
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 9

gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc 60

atcacttgcc gggcaagtca gaggattagc agctatttaa attggtatca gcagaaacca 120

gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg ggtcccgta 180

aggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag tctgcaacct 240

gaagattttg caacttacta ctgtcaacag agttacagta cccctccgat caccttcggc 300

caagggacac gactggagat taaa 324

<210> SEQ ID NO 10
 <211> LENGTH: 108
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence

-continued

```

<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 10

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1           5           10           15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
           20           25           30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
           35           40           45

Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
           50           55           60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65           70           75           80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Pro
           85           90           95

Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
           100           105

```

```

<210> SEQ ID NO 11
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

```

```

<400> SEQUENCE: 11

```

```

cagagcatta gcagctat

```

18

```

<210> SEQ ID NO 12
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

```

```

<400> SEQUENCE: 12

```

```

Gln Ser Ile Ser Ser Tyr
1           5

```

```

<210> SEQ ID NO 13
<211> LENGTH: 9
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

```

```

<400> SEQUENCE: 13

```

```

gctgcatcc

```

9

```

<210> SEQ ID NO 14
<211> LENGTH: 3
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

```

```

<400> SEQUENCE: 14

```

```

Ala Ala Ser
1

```

```

<210> SEQ ID NO 15
<211> LENGTH: 30

```

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 15

caacagagtt acagtacccc tccgatcacc

30

<210> SEQ ID NO 16
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 16

Gln Gln Ser Tyr Ser Thr Pro Pro Ile Thr
 1 5 10

<210> SEQ ID NO 17
 <211> LENGTH: 366
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 17

cagggtgcagc tgggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60
 tcctgtgcag cctctggatt cactttcagt agctatggca tccactgggt ccgccaggct 120
 ccaggcaagg ggctggagtg ggtggcagtt atatcatatg atggaaataa taaatactat 180
 gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat 240
 ctgcaaatga acagcctgag agctgaggac acggctgtat attactgtgc gaaagatcta 300
 tttttggagt ggttatttca cggtatgggc gtctggggcc aagggaccac ggtcaccgtc 360
 tcctca 366

<210> SEQ ID NO 18
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 18

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Val Ile Ser Tyr Asp Gly Asn Asn Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Lys Asp Leu Phe Leu Glu Trp Leu Phe His Gly Met Gly Val Trp
 100 105 110
 Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

-continued

<210> SEQ ID NO 19
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 19

ggattcactt tcagtagcta tggc

24

<210> SEQ ID NO 20
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 20

Gly Phe Thr Phe Ser Ser Tyr Gly
1 5

<210> SEQ ID NO 21
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 21

atatcatatg atggaaataa taaa

24

<210> SEQ ID NO 22
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 22

Ile Ser Tyr Asp Gly Asn Asn Lys
1 5

<210> SEQ ID NO 23
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 23

gcgaaagatc tatttttggg gtggttatgt cacggtatgg gcgtc

45

<210> SEQ ID NO 24
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 24

Ala Lys Asp Leu Phe Leu Glu Trp Leu Phe His Gly Met Gly Val
1 5 10 15

<210> SEQ ID NO 25
<211> LENGTH: 372

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 25

```
cagctgcagc tgcaggagtc gggcccagga ctagtgaagc cttcgagac cctgtccctc   60
acctgcattg tctctggtgg cgacatcacc agtagtagtt attactggaa ctggatccgc   120
cagcccccag ggaagggtt ggagtggtt gggaatatct attatagtg aagcaccaac   180
tacaaccctg ccctcaagag tcgagtcacc atatccatag acacgtccaa gagccagttc   240
tccctgaagc tgaggtctgt gaccgccgca gacacggctg tttattactg tgcgagatta   300
ttacgatatt ttgactggtc aaaaggatac ctgactact ggggccaggg aacctggtc   360
accgtctcct ca                                     372
```

<210> SEQ ID NO 26
 <211> LENGTH: 124
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 26

```
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1           5           10          15
Thr Leu Ser Leu Thr Cys Ile Val Ser Gly Gly Asp Ile Thr Ser Ser
20          25          30
Ser Tyr Tyr Trp Asn Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu
35          40          45
Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser
50          55          60
Leu Lys Ser Arg Val Thr Ile Ser Ile Asp Thr Ser Lys Ser Gln Phe
65          70          75          80
Ser Leu Lys Leu Arg Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85          90          95
Cys Ala Arg Leu Leu Arg Tyr Phe Asp Trp Ser Lys Gly Tyr Leu Asp
100         105         110
Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115         120
```

<210> SEQ ID NO 27
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 27

```
ggtggcgaca tcaccagtag tagttattac   30
```

<210> SEQ ID NO 28
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 28

```
Gly Gly Asp Ile Thr Ser Ser Ser Tyr Tyr
1           5           10
```

-continued

<210> SEQ ID NO 29
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 29

atctattata gtggaagcac c

21

<210> SEQ ID NO 30
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 30

Ile Tyr Tyr Ser Gly Ser Thr
 1 5

<210> SEQ ID NO 31
 <211> LENGTH: 48
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 31

gcgagattat tacgatattt tgactggtca aaaggatacc ttgactac

48

<210> SEQ ID NO 32
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 32

Ala Arg Leu Leu Arg Tyr Phe Asp Trp Ser Lys Gly Tyr Leu Asp Tyr
 1 5 10 15

<210> SEQ ID NO 33
 <211> LENGTH: 369
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 33

cagggtgcagc tgggtgagtc tgggggaggc atggtcaagc ctggagggtc cctgagactc 60

tcctgtgcag cctctggatt caccttcagt gactactata tgagctggat ccgccaggct 120

ccagggaagg gtctggagtg gatttcacac attagtatta ctggtagcac catatactac 180

gcgactctg tgaagggccg attcaccatc tccagggaca acgccaagaa ttcactgtat 240

ttggaaatga acgactgag agacgaggac acggccgtat attactgtac gagagatgag 300

ccggatatgt tactagtaag gtacgggtatg gacgtctggg gccaaaggac cacggtcacc 360

gtctcctca 369

<210> SEQ ID NO 34
 <211> LENGTH: 123
 <212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 34

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Met Val Lys Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr
 20 25 30
 Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Ser His Ile Ser Ile Thr Gly Ser Thr Ile Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80
 Leu Glu Met Asn Arg Leu Arg Asp Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Thr Arg Asp Glu Pro Asp Ile Val Leu Val Arg Tyr Gly Met Asp Val
 100 105 110
 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 115 120

<210> SEQ ID NO 35
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 35

ggattcacct tcaagtgaacta ctat

24

<210> SEQ ID NO 36
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 36

Gly Phe Thr Phe Ser Asp Tyr Tyr
 1 5

<210> SEQ ID NO 37
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 37

attagtatta ctggtagcac cata

24

<210> SEQ ID NO 38
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 38

Ile Ser Ile Thr Gly Ser Thr Ile
 1 5

-continued

<210> SEQ ID NO 39
 <211> LENGTH: 48
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 39

acgagagatg agccggatat tgtactagta aggtacggta tggacgtc 48

<210> SEQ ID NO 40
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 40

Thr Arg Asp Glu Pro Asp Ile Val Leu Val Arg Tyr Gly Met Asp Val
 1 5 10 15

<210> SEQ ID NO 41
 <211> LENGTH: 351
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 41

gagggtgcagc tgggtggagtc tgggggaagt gtggtacggc ctggggaatc cctgagactc 60
 tcctgtgcag cctctggatt cacattgat gattatggca tgagctgggt ccgccaagct 120
 ccaggggaagg ggtctggagt ggtctctggt attagtggga atggtggcat cacagtttat 180
 gcagactctg tgaagggccg attcaccgtc tccagagaca acgccaagaa ctccctgtat 240
 ctgcaaatga acagtctgag agccgaggac acggccctct atcactgtgc gagagcccgt 300
 tatggtggcg ccgactactg gggccaggga accctgggtca ccgtctcctc a 351

<210> SEQ ID NO 42
 <211> LENGTH: 117
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 42

Glu Val Gln Leu Val Glu Ser Gly Gly Ser Val Val Arg Pro Gly Glu
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr
 20 25 30

Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

Ser Gly Ile Ser Trp Asn Gly Gly Ile Thr Val Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
 65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr His Cys
 85 90 95

Ala Arg Ala Arg Tyr Gly Gly Ala Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110

-continued

Val Thr Val Ser Ser
115

<210> SEQ ID NO 43
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 43

ggattcacat ttgatgatta tggc

24

<210> SEQ ID NO 44
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 44

Gly Phe Thr Phe Asp Asp Tyr Gly
1 5

<210> SEQ ID NO 45
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 45

attagttgga atggtggcat caca

24

<210> SEQ ID NO 46
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 46

Ile Ser Trp Asn Gly Gly Ile Thr
1 5

<210> SEQ ID NO 47
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 47

gcgagagccc gttatggtgg cgccgactac

30

<210> SEQ ID NO 48
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 48

Ala Arg Ala Arg Tyr Gly Gly Ala Asp Tyr
1 5 10

-continued

<210> SEQ ID NO 49
 <211> LENGTH: 366
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 49

gagggtgcagc tgggtggagtc tgggggagac ttggtacagc ctgggcggtc cctgagactc	60
tcctgtgcag cctctggatt cacotttagc agttttgccca tgagctgggt ccgccaggct	120
ccaggaggagg gactggagtg ggtctcaagt ctcaagtata gtggtgataa cacatactac	180
gcagactccg tgaaggggccg gttcaccatc tccagagaca attccaaaaa tacgttgtat	240
ctgcaaatga acaacctgag agccgaggac acggccggtt attactgtgc gaaagatctc	300
ttttcggggg gggtattcca tggttttgat gtctggggcc aagggacaat ggtcaccgtc	360
tcttca	366

<210> SEQ ID NO 50
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 50

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Arg	
1 5 10 15	
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe	
20 25 30	
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Trp Val	
35 40 45	
Ser Ser Leu Ser Asp Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val	
50 55 60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70 75 80	
Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
Ala Lys Asp Leu Phe Ser Gly Trp Leu Phe His Gly Phe Asp Val Trp	
100 105 110	
Gly Gln Gly Thr Met Val Thr Val Ser Ser	
115 120	

<210> SEQ ID NO 51
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 51

ggattcacct ttagcagttt tgcc	24
----------------------------	----

<210> SEQ ID NO 52
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 52

-continued

Gly Phe Thr Phe Ser Ser Phe Ala
1 5

<210> SEQ ID NO 53
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 53

ctcagtgata gtggtgataa caca

24

<210> SEQ ID NO 54
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 54

Leu Ser Asp Ser Gly Asp Asn Thr
1 5

<210> SEQ ID NO 55
<211> LENGTH: 45
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 55

gcgaaagatc tcttttcggg gtggttatcc catggttttg atgtc

45

<210> SEQ ID NO 56
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 56

Ala Lys Asp Leu Phe Ser Gly Trp Leu Phe His Gly Phe Asp Val
1 5 10 15

<210> SEQ ID NO 57
<211> LENGTH: 351
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 57

cagggttcagc tgggtgcagtc tggacctgaa gtgaaaaaac ctggggcctc agtgaaggtc

60

tcttgtaagg gttctgggta caccttttcc tggatggaa tcagctggat ccgacaggcc

120

cctggacacg gccttgaatg gatgggatgg atcagcgctt ccagtggtaa tacaagattt

180

gcacagaagg tccagggcag actcaccatg accacagaca catcgacgag tacagcctac

240

atggagctga ggagcctgag atctgacgac acggccgctt attactgtgc gagaacgggg

300

actcggccct ttgactattg gggccaggga accctggtea ccgtctcctc a

351

<210> SEQ ID NO 58
<211> LENGTH: 117
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 58

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
 1 5 10 15
 Ser Val Lys Val Ser Cys Lys Gly Ser Gly Tyr Thr Phe Ser Trp Tyr
 20 25 30
 Gly Ile Ser Trp Ile Arg Gln Ala Pro Gly His Gly Leu Glu Trp Met
 35 40 45
 Gly Trp Ile Ser Ala Ser Ser Gly Asn Thr Arg Phe Ala Gln Lys Val
 50 55 60
 Gln Gly Arg Leu Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
 65 70 75 80
 Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Thr Gly Thr Arg Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ser
 115

<210> SEQ ID NO 59
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 59

ggttacacct tttctcggtgta tgga

24

<210> SEQ ID NO 60
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 60

Gly Tyr Thr Phe Ser Trp Tyr Gly
 1 5

<210> SEQ ID NO 61
 <211> LENGTH: 24
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 61

atcagcgctt ccagtggtaa taca

24

<210> SEQ ID NO 62
 <211> LENGTH: 8
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 62

Ile Ser Ala Ser Ser Gly Asn Thr
 1 5

-continued

<210> SEQ ID NO 63
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 63

gcgagaacgg ggactcggcc ctttgactat

30

<210> SEQ ID NO 64
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 64

Ala Arg Thr Gly Thr Arg Pro Phe Asp Tyr
 1 5 10

<210> SEQ ID NO 65
 <211> LENGTH: 366
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 65

gagggtgcagc tgggtggagtc tggggggaggc ttggtccagc cggggggggtc cctgagactc 60
 tcctgtacag cctctggatt caccttcagt agctatggtc tgcactgggt ccgccagggt 120
 ccagggaagg gactggaata tgtttcaagt attaatcata atgggggtag taaatattat 180
 gcagactctg tgaagggcag attcaccatc tccagagaca attcgaagaa cacgctgttt 240
 cttcaaatgg gcagcctgaa aactgaggac atggctgttt attactgtgc gagagatctc 300
 tttttggagt gggtattcca tggttttgat atctggggcc aagggaacaat ggtcaccgtc 360
 tcttca 366

<210> SEQ ID NO 66
 <211> LENGTH: 122
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 66

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30
 Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Val
 35 40 45
 Ser Ser Ile Asn His Asn Gly Gly Ser Lys Tyr Tyr Ala Asp Ser Val
 50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Phe
 65 70 75 80
 Leu Gln Met Gly Ser Leu Lys Thr Glu Asp Met Ala Val Tyr Tyr Cys
 85 90 95
 Ala Arg Asp Leu Phe Leu Glu Trp Leu Phe His Gly Phe Asp Ile Trp

-continued

<210> SEQ ID NO 73
 <211> LENGTH: 357
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 73

```
cagggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc    60
acctgttctg tctctggtgg ctccataaac actggttctt acttctggac ttggatccgc    120
cagcaccacag gggagggcct ggagtggatt gggtagatct attacaatgg agacacctac    180
tacaatccgt ccctcaagag tcgagttacc ttatcactag acacgtctaa gaaccagttc    240
tccctgaagc tgaactctct gactgccggg gacacggcgg tttattactg tgcgagaagt    300
gactggaact ccctttttga ccactggggc caggggaccc tggtcaccgt ctctca    357
```

<210> SEQ ID NO 74
 <211> LENGTH: 119
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 74

```
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1              5              10              15
Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Asn Thr Gly
20            25            30
Ser Tyr Phe Trp Thr Trp Ile Arg Gln His Pro Gly Glu Gly Leu Glu
35            40            45
Trp Ile Gly Tyr Ile Tyr Tyr Asn Gly Asp Thr Tyr Tyr Asn Pro Ser
50            55            60
Leu Lys Ser Arg Val Thr Leu Ser Leu Asp Thr Ser Lys Asn Gln Phe
65            70            75            80
Ser Leu Lys Leu Asn Ser Leu Thr Ala Gly Asp Thr Ala Val Tyr Tyr
85            90            95
Cys Ala Arg Ser Asp Trp Asn Ser Leu Phe Asp His Trp Gly Gln Gly
100           105           110
Thr Leu Val Thr Val Ser Ser
115
```

<210> SEQ ID NO 75
 <211> LENGTH: 30
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 75

```
ggtggctcca taaacactgg ttcttacttc    30
```

<210> SEQ ID NO 76
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 76

-continued

Gly Gly Ser Ile Asn Thr Gly Ser Tyr Phe
1 5 10

<210> SEQ ID NO 77
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 77

atctattaca atggagacac c 21

<210> SEQ ID NO 78
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 78

Ile Tyr Tyr Asn Gly Asp Thr
1 5

<210> SEQ ID NO 79
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 79

gcgagaagtg actggaactc cctttttgac cac 33

<210> SEQ ID NO 80
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 80

Ala Arg Ser Asp Trp Asn Ser Leu Phe Asp His
1 5 10

<210> SEQ ID NO 81
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 81

gaaattgtgt tgacgcagtc tccaggcacc ctgtctttgt ctccagggga aagagccacc 60

ctctcctgca gggccagtc gagtgtagc agcagctact tagcctggta ccagcagaaa 120

cctggccagg ctcccaggct cctcatctat ggtgcatcca gcagggccac tggcatccca 180

gacaggttca gtggcagtggt gtctgggaca gacttcactc tcaccatcag cagactggag 240

cctgaagatt ttgcagtgtat ttactgtcag cagtatggta gctcaccttg gacgttcggc 300

caagggaacca aggtggaaat caaa 324

<210> SEQ ID NO 82
<211> LENGTH: 108
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 82

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15
 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30
 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
 50 55 60
 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
 85 90 95
 Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105

<210> SEQ ID NO 83
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 83

cagagtgtta gcagcagcta c

21

<210> SEQ ID NO 84
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 84

Gln Ser Val Ser Ser Ser Tyr
 1 5

<210> SEQ ID NO 85
 <211> LENGTH: 9
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 85

ggtgcatcc

9

<210> SEQ ID NO 86
 <211> LENGTH: 3
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 86

Gly Ala Ser
 1

<210> SEQ ID NO 87

-continued

<211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 87

cagcagtatg gtagctcacc ttggacg

27

<210> SEQ ID NO 88
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic

<400> SEQUENCE: 88

Gln Gln Tyr Gly Ser Ser Pro Trp Thr
 1 5

<210> SEQ ID NO 89
 <211> LENGTH: 1165
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: hLEPR P48357

<400> SEQUENCE: 89

Met Ile Cys Gln Lys Phe Cys Val Val Leu Leu His Trp Glu Phe Ile
 1 5 10 15

Tyr Val Ile Thr Ala Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg
 20 25 30

Phe Lys Leu Ser Cys Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu
 35 40 45

Leu Pro Ala Gly Leu Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr
 50 55 60

Glu Thr Ala Val Glu Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser
 65 70 75 80

Asn Leu Ser Lys Thr Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp
 85 90 95

Arg Asn Cys Ser Leu Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val
 100 105 110

Ser Thr Val Asn Ser Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn
 115 120 125

Ile Gln Cys Trp Leu Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val
 130 135 140

Glu Ser Leu Phe Lys Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val His
 145 150 155 160

Leu Leu Tyr Val Leu Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro
 165 170 175

Gln Lys Gly Ser Phe Gln Met Val His Cys Asn Cys Ser Val His Glu
 180 185 190

Cys Cys Glu Cys Leu Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr
 195 200 205

Leu Leu Met Cys Leu Lys Ile Thr Ser Gly Gly Val Ile Phe Gln Ser
 210 215 220

Pro Leu Met Ser Val Gln Pro Ile Asn Met Val Lys Pro Asp Pro Pro
 225 230 235 240

Leu Gly Leu His Met Glu Ile Thr Asp Asp Gly Asn Leu Lys Ile Ser

-continued

			245					250					255				
Trp	Ser	Ser	Pro	Pro	Leu	Val	Pro	Phe	Pro	Leu	Gln	Tyr	Gln	Val	Lys		
			260					265					270				
Tyr	Ser	Glu	Asn	Ser	Thr	Thr	Val	Ile	Arg	Glu	Ala	Asp	Lys	Ile	Val		
		275					280					285					
Ser	Ala	Thr	Ser	Leu	Leu	Val	Asp	Ser	Ile	Leu	Pro	Gly	Ser	Ser	Tyr		
	290					295					300						
Glu	Val	Gln	Val	Arg	Gly	Lys	Arg	Leu	Asp	Gly	Pro	Gly	Ile	Trp	Ser		
305					310					315					320		
Asp	Trp	Ser	Thr	Pro	Arg	Val	Phe	Thr	Thr	Gln	Asp	Val	Ile	Tyr	Phe		
				325					330					335			
Pro	Pro	Lys	Ile	Leu	Thr	Ser	Val	Gly	Ser	Asn	Val	Ser	Phe	His	Cys		
		340						345					350				
Ile	Tyr	Lys	Lys	Glu	Asn	Lys	Ile	Val	Pro	Ser	Lys	Glu	Ile	Val	Trp		
	355					360						365					
Trp	Met	Asn	Leu	Ala	Glu	Lys	Ile	Pro	Gln	Ser	Gln	Tyr	Asp	Val	Val		
370						375					380						
Ser	Asp	His	Val	Ser	Lys	Val	Thr	Phe	Phe	Asn	Leu	Asn	Glu	Thr	Lys		
385					390					395					400		
Pro	Arg	Gly	Lys	Phe	Thr	Tyr	Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	His		
				405					410					415			
Glu	Cys	His	His	Arg	Tyr	Ala	Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile		
			420					425					430				
Asn	Ile	Ser	Cys	Glu	Thr	Asp	Gly	Tyr	Leu	Thr	Lys	Met	Thr	Cys	Arg		
	435						440					445					
Trp	Ser	Thr	Ser	Thr	Ile	Gln	Ser	Leu	Ala	Glu	Ser	Thr	Leu	Gln	Leu		
450						455						460					
Arg	Tyr	His	Arg	Ser	Ser	Leu	Tyr	Cys	Ser	Asp	Ile	Pro	Ser	Ile	His		
465					470					475					480		
Pro	Ile	Ser	Glu	Pro	Lys	Asp	Cys	Tyr	Leu	Gln	Ser	Asp	Gly	Phe	Tyr		
				485					490					495			
Glu	Cys	Ile	Phe	Gln	Pro	Ile	Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp		
			500					505					510				
Ile	Arg	Ile	Asn	His	Ser	Leu	Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys		
	515						520					525					
Val	Leu	Pro	Asp	Ser	Val	Val	Lys	Pro	Leu	Pro	Pro	Ser	Ser	Val	Lys		
	530						535				540						
Ala	Glu	Ile	Thr	Ile	Asn	Ile	Gly	Leu	Leu	Lys	Ile	Ser	Trp	Glu	Lys		
545					550					555					560		
Pro	Val	Phe	Pro	Glu	Asn	Asn	Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu		
				565					570					575			
Ser	Gly	Lys	Glu	Val	Gln	Trp	Lys	Met	Tyr	Glu	Val	Tyr	Asp	Ala	Lys		
		580						585					590				
Ser	Lys	Ser	Val	Ser	Leu	Pro	Val	Pro	Asp	Leu	Cys	Ala	Val	Tyr	Ala		
		595					600					605					
Val	Gln	Val	Arg	Cys	Lys	Arg	Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn		
	610					615					620						
Trp	Ser	Asn	Pro	Ala	Tyr	Thr	Val	Val	Met	Asp	Ile	Lys	Val	Pro	Met		
625					630					635				640			
Arg	Gly	Pro	Glu	Phe	Trp	Arg	Ile	Ile	Asn	Gly	Asp	Thr	Met	Lys	Lys		
				645					650					655			
Glu	Lys	Asn	Val	Thr	Leu	Leu	Trp	Lys	Pro	Leu	Met	Lys	Asn	Asp	Ser		
			660					665					670				

-continued

Leu Cys Ser Val Gln Arg Tyr Val Ile Asn His His Thr Ser Cys Asn		
675	680	685
Gly Thr Trp Ser Glu Asp Val Gly Asn His Thr Lys Phe Thr Phe Leu		
690	695	700
Trp Thr Glu Gln Ala His Thr Val Thr Val Leu Ala Ile Asn Ser Ile		
705	710	715
Gly Ala Ser Val Ala Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser		
725	730	735
Lys Val Asn Ile Val Gln Ser Leu Ser Ala Tyr Pro Leu Asn Ser Ser		
740	745	750
Cys Val Ile Val Ser Trp Ile Leu Ser Pro Ser Asp Tyr Lys Leu Met		
755	760	765
Tyr Phe Ile Ile Glu Trp Lys Asn Leu Asn Glu Asp Gly Glu Ile Lys		
770	775	780
Trp Leu Arg Ile Ser Ser Ser Val Lys Lys Tyr Tyr Ile His Asp His		
785	790	795
Phe Ile Pro Ile Glu Lys Tyr Gln Phe Ser Leu Tyr Pro Ile Phe Met		
805	810	815
Glu Gly Val Gly Lys Pro Lys Ile Ile Asn Ser Phe Thr Gln Asp Asp		
820	825	830
Ile Glu Lys His Gln Ser Asp Ala Gly Leu Tyr Val Ile Val Pro Val		
835	840	845
Ile Ile Ser Ser Ser Ile Leu Leu Leu Gly Thr Leu Leu Ile Ser His		
850	855	860
Gln Arg Met Lys Lys Leu Phe Trp Glu Asp Val Pro Asn Pro Lys Asn		
865	870	875
Cys Ser Trp Ala Gln Gly Leu Asn Phe Gln Lys Pro Glu Thr Phe Glu		
885	890	895
His Leu Phe Ile Lys His Thr Ala Ser Val Thr Cys Gly Pro Leu Leu		
900	905	910
Leu Glu Pro Glu Thr Ile Ser Glu Asp Ile Ser Val Asp Thr Ser Trp		
915	920	925
Lys Asn Lys Asp Glu Met Met Pro Thr Thr Val Val Ser Leu Leu Ser		
930	935	940
Thr Thr Asp Leu Glu Lys Gly Ser Val Cys Ile Ser Asp Gln Phe Asn		
945	950	955
Ser Val Asn Phe Ser Glu Ala Glu Gly Thr Glu Val Thr Tyr Glu Asp		
965	970	975
Glu Ser Gln Arg Gln Pro Phe Val Lys Tyr Ala Thr Leu Ile Ser Asn		
980	985	990
Ser Lys Pro Ser Glu Thr Gly Glu Glu Gln Gly Leu Ile Asn Ser Ser		
995	1000	1005
Val Thr Lys Cys Phe Ser Ser Lys Asn Ser Pro Leu Lys Asp Ser		
1010	1015	1020
Phe Ser Asn Ser Ser Trp Glu Ile Glu Ala Gln Ala Phe Phe Ile		
1025	1030	1035
Leu Ser Asp Gln His Pro Asn Ile Ile Ser Pro His Leu Thr Phe		
1040	1045	1050
Ser Glu Gly Leu Asp Glu Leu Leu Lys Leu Glu Gly Asn Phe Pro		
1055	1060	1065
Glu Glu Asn Asn Asp Lys Lys Ser Ile Tyr Tyr Leu Gly Val Thr		
1070	1075	1080

-continued

Ser Ile Lys Lys Arg Glu Ser Gly Val Leu Leu Thr Asp Lys Ser
 1085 1090 1095
 Arg Val Ser Cys Pro Phe Pro Ala Pro Cys Leu Phe Thr Asp Ile
 1100 1105 1110
 Arg Val Leu Gln Asp Ser Cys Ser His Phe Val Glu Asn Asn Ile
 1115 1120 1125
 Asn Leu Gly Thr Ser Ser Lys Lys Thr Phe Ala Ser Tyr Met Pro
 1130 1135 1140
 Gln Phe Gln Thr Cys Ser Thr Gln Thr His Lys Ile Met Glu Asn
 1145 1150 1155
 Lys Met Cys Asp Leu Thr Val
 1160 1165

<210> SEQ ID NO 90
 <211> LENGTH: 846
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: hLEPR-mmh aa 1-818: F22-D839 of P48357 aa
 819-846: myc-myc-hexahistidine tag

<400> SEQUENCE: 90

Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg Phe Lys Leu Ser Cys
 1 5 10 15
 Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu Leu Pro Ala Gly Leu
 20 25 30
 Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr Glu Thr Ala Val Glu
 35 40 45
 Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser Asn Leu Ser Lys Thr
 50 55 60
 Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp Arg Asn Cys Ser Leu
 65 70 75 80
 Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val Ser Thr Val Asn Ser
 85 90 95
 Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn Ile Gln Cys Trp Leu
 100 105 110
 Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val Glu Ser Leu Phe Lys
 115 120 125
 Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val His Leu Leu Tyr Val Leu
 130 135 140
 Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro Gln Lys Gly Ser Phe
 145 150 155 160
 Gln Met Val His Cys Asn Cys Ser Val His Glu Cys Cys Glu Cys Leu
 165 170 175
 Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr Leu Leu Met Cys Leu
 180 185 190
 Lys Ile Thr Ser Gly Gly Val Ile Phe Gln Ser Pro Leu Met Ser Val
 195 200 205
 Gln Pro Ile Asn Met Val Lys Pro Asp Pro Pro Leu Gly Leu His Met
 210 215 220
 Glu Ile Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp Ser Ser Pro Pro
 225 230 235 240
 Leu Val Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr Ser Glu Asn Ser
 245 250 255
 Thr Thr Val Ile Arg Glu Ala Asp Lys Ile Val Ser Ala Thr Ser Leu
 260 265 270

-continued

Leu	Val	Asp	Ser	Ile	Leu	Pro	Gly	Ser	Ser	Tyr	Glu	Val	Gln	Val	Arg
	275						280					285			
Gly	Lys	Arg	Leu	Asp	Gly	Pro	Gly	Ile	Trp	Ser	Asp	Trp	Ser	Thr	Pro
	290					295					300				
Arg	Val	Phe	Thr	Thr	Gln	Asp	Val	Ile	Tyr	Phe	Pro	Pro	Lys	Ile	Leu
305					310					315					320
Thr	Ser	Val	Gly	Ser	Asn	Val	Ser	Phe	His	Cys	Ile	Tyr	Lys	Lys	Glu
				325					330						335
Asn	Lys	Ile	Val	Pro	Ser	Lys	Glu	Ile	Val	Trp	Trp	Met	Asn	Leu	Ala
			340					345					350		
Glu	Lys	Ile	Pro	Gln	Ser	Gln	Tyr	Asp	Val	Val	Ser	Asp	His	Val	Ser
		355					360					365			
Lys	Val	Thr	Phe	Phe	Asn	Leu	Asn	Glu	Thr	Lys	Pro	Arg	Gly	Lys	Phe
	370					375					380				
Thr	Tyr	Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	His	Glu	Cys	His	His	Arg
385					390					395					400
Tyr	Ala	Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile	Asn	Ile	Ser	Cys	Glu
				405					410						415
Thr	Asp	Gly	Tyr	Leu	Thr	Lys	Met	Thr	Cys	Arg	Trp	Ser	Thr	Ser	Thr
			420					425					430		
Ile	Gln	Ser	Leu	Ala	Glu	Ser	Thr	Leu	Gln	Leu	Arg	Tyr	His	Arg	Ser
			435					440				445			
Ser	Leu	Tyr	Cys	Ser	Asp	Ile	Pro	Ser	Ile	His	Pro	Ile	Ser	Glu	Pro
	450					455					460				
Lys	Asp	Cys	Tyr	Leu	Gln	Ser	Asp	Gly	Phe	Tyr	Glu	Cys	Ile	Phe	Gln
465					470					475					480
Pro	Ile	Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp	Ile	Arg	Ile	Asn	His
				485					490						495
Ser	Leu	Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys	Val	Leu	Pro	Asp	Ser
			500					505					510		
Val	Val	Lys	Pro	Leu	Pro	Pro	Ser	Ser	Val	Lys	Ala	Glu	Ile	Thr	Ile
		515					520					525			
Asn	Ile	Gly	Leu	Leu	Lys	Ile	Ser	Trp	Glu	Lys	Pro	Val	Phe	Pro	Glu
	530					535					540				
Asn	Asn	Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu	Ser	Gly	Lys	Glu	Val
545					550					555					560
Gln	Trp	Lys	Met	Tyr	Glu	Val	Tyr	Asp	Ala	Lys	Ser	Lys	Ser	Val	Ser
				565					570						575
Leu	Pro	Val	Pro	Asp	Leu	Cys	Ala	Val	Tyr	Ala	Val	Gln	Val	Arg	Cys
			580					585					590		
Lys	Arg	Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn	Trp	Ser	Asn	Pro	Ala
		595					600					605			
Tyr	Thr	Val	Val	Met	Asp	Ile	Lys	Val	Pro	Met	Arg	Gly	Pro	Glu	Phe
	610					615					620				
Trp	Arg	Ile	Ile	Asn	Gly	Asp	Thr	Met	Lys	Lys	Glu	Lys	Asn	Val	Thr
625					630					635					640
Leu	Leu	Trp	Lys	Pro	Leu	Met	Lys	Asn	Asp	Ser	Leu	Cys	Ser	Val	Gln
				645					650						655
Arg	Tyr	Val	Ile	Asn	His	His	Thr	Ser	Cys	Asn	Gly	Thr	Trp	Ser	Glu
			660					665					670		
Asp	Val	Gly	Asn	His	Thr	Lys	Phe	Thr	Phe	Leu	Trp	Thr	Glu	Gln	Ala
		675					680						685		

-continued

```

His Thr Val Thr Val Leu Ala Ile Asn Ser Ile Gly Ala Ser Val Ala
 690                695                700

Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val Asn Ile Val
 705                710                715                720

Gln Ser Leu Ser Ala Tyr Pro Leu Asn Ser Ser Cys Val Ile Val Ser
                725                730                735

Trp Ile Leu Ser Pro Ser Asp Tyr Lys Leu Met Tyr Phe Ile Ile Glu
 740                745                750

Trp Lys Asn Leu Asn Glu Asp Gly Glu Ile Lys Trp Leu Arg Ile Ser
 755                760                765

Ser Ser Val Lys Lys Tyr Tyr Ile His Asp His Phe Ile Pro Ile Glu
 770                775                780

Lys Tyr Gln Phe Ser Leu Tyr Pro Ile Phe Met Glu Gly Val Gly Lys
 785                790                795                800

Pro Lys Ile Ile Asn Ser Phe Thr Gln Asp Asp Ile Glu Lys His Gln
                805                810                815

Ser Asp Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Gly Glu Gln
                820                825                830

Lys Leu Ile Ser Glu Glu Asp Leu His His His His His His
 835                840                845

<210> SEQ ID NO 91
<211> LENGTH: 1051
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: hLEPR-mFc aa 1-818: F22-D839 of P48357 aa
                        819-1051: mouse IgG2a (E98-K330 of P01863)

<400> SEQUENCE: 91

Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg Phe Lys Leu Ser Cys
 1                5                10                15

Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu Leu Pro Ala Gly Leu
 20                25                30

Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr Glu Thr Ala Val Glu
 35                40                45

Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser Asn Leu Ser Lys Thr
 50                55                60

Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp Arg Asn Cys Ser Leu
 65                70                75                80

Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val Ser Thr Val Asn Ser
                85                90                95

Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn Ile Gln Cys Trp Leu
 100               105               110

Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val Glu Ser Leu Phe Lys
 115               120               125

Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val His Leu Leu Tyr Val Leu
 130               135               140

Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro Gln Lys Gly Ser Phe
 145               150               155               160

Gln Met Val His Cys Asn Cys Ser Val His Glu Cys Cys Glu Cys Leu
 165               170               175

Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr Leu Leu Met Cys Leu
 180               185               190

Lys Ile Thr Ser Gly Gly Val Ile Phe Gln Ser Pro Leu Met Ser Val
 195               200               205

```

-continued

Gln	Pro	Ile	Asn	Met	Val	Lys	Pro	Asp	Pro	Pro	Leu	Gly	Leu	His	Met
210						215					220				
Glu	Ile	Thr	Asp	Asp	Gly	Asn	Leu	Lys	Ile	Ser	Trp	Ser	Ser	Pro	Pro
225					230					235				240	
Leu	Val	Pro	Phe	Pro	Leu	Gln	Tyr	Gln	Val	Lys	Tyr	Ser	Glu	Asn	Ser
				245					250					255	
Thr	Thr	Val	Ile	Arg	Glu	Ala	Asp	Lys	Ile	Val	Ser	Ala	Thr	Ser	Leu
			260					265					270		
Leu	Val	Asp	Ser	Ile	Leu	Pro	Gly	Ser	Ser	Tyr	Glu	Val	Gln	Val	Arg
		275					280				285				
Gly	Lys	Arg	Leu	Asp	Gly	Pro	Gly	Ile	Trp	Ser	Asp	Trp	Ser	Thr	Pro
290					295						300				
Arg	Val	Phe	Thr	Thr	Gln	Asp	Val	Ile	Tyr	Phe	Pro	Pro	Lys	Ile	Leu
305					310					315				320	
Thr	Ser	Val	Gly	Ser	Asn	Val	Ser	Phe	His	Cys	Ile	Tyr	Lys	Lys	Glu
			325					330					335		
Asn	Lys	Ile	Val	Pro	Ser	Lys	Glu	Ile	Val	Trp	Trp	Met	Asn	Leu	Ala
			340					345					350		
Glu	Lys	Ile	Pro	Gln	Ser	Gln	Tyr	Asp	Val	Val	Ser	Asp	His	Val	Ser
		355					360				365				
Lys	Val	Thr	Phe	Phe	Asn	Leu	Asn	Glu	Thr	Lys	Pro	Arg	Gly	Lys	Phe
		370				375					380				
Thr	Tyr	Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	His	Glu	Cys	His	His	Arg
385					390					395				400	
Tyr	Ala	Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile	Asn	Ile	Ser	Cys	Glu
			405					410					415		
Thr	Asp	Gly	Tyr	Leu	Thr	Lys	Met	Thr	Cys	Arg	Trp	Ser	Thr	Ser	Thr
			420					425					430		
Ile	Gln	Ser	Leu	Ala	Glu	Ser	Thr	Leu	Gln	Leu	Arg	Tyr	His	Arg	Ser
		435					440					445			
Ser	Leu	Tyr	Cys	Ser	Asp	Ile	Pro	Ser	Ile	His	Pro	Ile	Ser	Glu	Pro
		450				455					460				
Lys	Asp	Cys	Tyr	Leu	Gln	Ser	Asp	Gly	Phe	Tyr	Glu	Cys	Ile	Phe	Gln
465					470					475				480	
Pro	Ile	Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp	Ile	Arg	Ile	Asn	His
			485					490					495		
Ser	Leu	Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys	Val	Leu	Pro	Asp	Ser
			500					505				510			
Val	Val	Lys	Pro	Leu	Pro	Pro	Ser	Ser	Val	Lys	Ala	Glu	Ile	Thr	Ile
		515					520				525				
Asn	Ile	Gly	Leu	Leu	Lys	Ile	Ser	Trp	Glu	Lys	Pro	Val	Phe	Pro	Glu
		530				535				540					
Asn	Asn	Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu	Ser	Gly	Lys	Glu	Val
545					550					555				560	
Gln	Trp	Lys	Met	Tyr	Glu	Val	Tyr	Asp	Ala	Lys	Ser	Lys	Ser	Val	Ser
			565					570					575		
Leu	Pro	Val	Pro	Asp	Leu	Cys	Ala	Val	Tyr	Ala	Val	Gln	Val	Arg	Cys
			580					585				590			
Lys	Arg	Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn	Trp	Ser	Asn	Pro	Ala
		595					600				605				
Tyr	Thr	Val	Val	Met	Asp	Ile	Lys	Val	Pro	Met	Arg	Gly	Pro	Glu	Phe
610						615					620				

Trp	Arg	Ile	Ile	Asn	Gly	Asp	Thr	Met	Lys	Lys	Glu	Lys	Asn	Val	Thr
625					630					635					640
Leu	Leu	Trp	Lys	Pro	Leu	Met	Lys	Asn	Asp	Ser	Leu	Cys	Ser	Val	Gln
				645					650					655	
Arg	Tyr	Val	Ile	Asn	His	His	Thr	Ser	Cys	Asn	Gly	Thr	Trp	Ser	Glu
			660					665					670		
Asp	Val	Gly	Asn	His	Thr	Lys	Phe	Thr	Phe	Leu	Trp	Thr	Glu	Gln	Ala
		675					680					685			
His	Thr	Val	Thr	Val	Leu	Ala	Ile	Asn	Ser	Ile	Gly	Ala	Ser	Val	Ala
	690					695					700				
Asn	Phe	Asn	Leu	Thr	Phe	Ser	Trp	Pro	Met	Ser	Lys	Val	Asn	Ile	Val
705					710					715					720
Gln	Ser	Leu	Ser	Ala	Tyr	Pro	Leu	Asn	Ser	Ser	Cys	Val	Ile	Val	Ser
				725					730					735	
Trp	Ile	Leu	Ser	Pro	Ser	Asp	Tyr	Lys	Leu	Met	Tyr	Phe	Ile	Ile	Glu
			740					745					750		
Trp	Lys	Asn	Leu	Asn	Glu	Asp	Gly	Glu	Ile	Lys	Trp	Leu	Arg	Ile	Ser
		755					760					765			
Ser	Ser	Val	Lys	Lys	Tyr	Tyr	Ile	His	Asp	His	Phe	Ile	Pro	Ile	Glu
	770					775					780				
Lys	Tyr	Gln	Phe	Ser	Leu	Tyr	Pro	Ile	Phe	Met	Glu	Gly	Val	Gly	Lys
785					790					795					800
Pro	Lys	Ile	Ile	Asn	Ser	Phe	Thr	Gln	Asp	Asp	Ile	Glu	Lys	His	Gln
				805					810					815	
Ser	Asp	Glu	Pro	Arg	Gly	Pro	Thr	Ile	Lys	Pro	Cys	Pro	Pro	Cys	Lys
			820					825					830		
Cys	Pro	Ala	Pro	Asn	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Ile	Phe	Pro
	835						840					845			
Pro	Lys	Ile	Lys	Asp	Val	Leu	Met	Ile	Ser	Leu	Ser	Pro	Ile	Val	Thr
	850					855					860				
Cys	Val	Val	Val	Asp	Val	Ser	Glu	Asp	Asp	Pro	Asp	Val	Gln	Ile	Ser
865					870					875					880
Trp	Phe	Val	Asn	Asn	Val	Glu	Val	His	Thr	Ala	Gln	Thr	Gln	Thr	His
			885						890					895	
Arg	Glu	Asp	Tyr	Asn	Ser	Thr	Leu	Arg	Val	Val	Ser	Ala	Leu	Pro	Ile
			900					905					910		
Gln	His	Gln	Asp	Trp	Met	Ser	Gly	Lys	Glu	Phe	Lys	Cys	Lys	Val	Asn
		915					920					925			
Asn	Lys	Asp	Leu	Pro	Ala	Pro	Ile	Glu	Arg	Thr	Ile	Ser	Lys	Pro	Lys
	930					935					940				
Gly	Ser	Val	Arg	Ala	Pro	Gln	Val	Tyr	Val	Leu	Pro	Pro	Pro	Glu	Glu
945					950					955					960
Glu	Met	Thr	Lys	Lys	Gln	Val	Thr	Leu	Thr	Cys	Met	Val	Thr	Asp	Phe
			965						970					975	
Met	Pro	Glu	Asp	Ile											

-continued

1040	1045	1050
<210> SEQ ID NO 92		
<211> LENGTH: 1045		
<212> TYPE: PRT		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: hLEPR-hFc aa 1-818: F22-D839 of P48357 aa		
819-1045: human IgG1 (D104-K330 of P01857)		
<400> SEQUENCE: 92		
Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg Phe Lys Leu Ser Cys		
1 5 10 15		
Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu Leu Pro Ala Gly Leu		
20 25 30		
Ser Lys Asn Thr Ser Asn Ser Asn Gly His Tyr Glu Thr Ala Val Glu		
35 40 45		
Pro Lys Phe Asn Ser Ser Gly Thr His Phe Ser Asn Leu Ser Lys Thr		
50 55 60		
Thr Phe His Cys Cys Phe Arg Ser Glu Gln Asp Arg Asn Cys Ser Leu		
65 70 75 80		
Cys Ala Asp Asn Ile Glu Gly Lys Thr Phe Val Ser Thr Val Asn Ser		
85 90 95		
Leu Val Phe Gln Gln Ile Asp Ala Asn Trp Asn Ile Gln Cys Trp Leu		
100 105 110		
Lys Gly Asp Leu Lys Leu Phe Ile Cys Tyr Val Glu Ser Leu Phe Lys		
115 120 125		
Asn Leu Phe Arg Asn Tyr Asn Tyr Lys Val His Leu Leu Tyr Val Leu		
130 135 140		
Pro Glu Val Leu Glu Asp Ser Pro Leu Val Pro Gln Lys Gly Ser Phe		
145 150 155 160		
Gln Met Val His Cys Asn Cys Ser Val His Glu Cys Cys Glu Cys Leu		
165 170 175		
Val Pro Val Pro Thr Ala Lys Leu Asn Asp Thr Leu Leu Met Cys Leu		
180 185 190		
Lys Ile Thr Ser Gly Gly Val Ile Phe Gln Ser Pro Leu Met Ser Val		
195 200 205		
Gln Pro Ile Asn Met Val Lys Pro Asp Pro Pro Leu Gly Leu His Met		
210 215 220		
Glu Ile Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp Ser Ser Pro Pro		
225 230 235 240		
Leu Val Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr Ser Glu Asn Ser		
245 250 255		
Thr Thr Val Ile Arg Glu Ala Asp Lys Ile Val Ser Ala Thr Ser Leu		
260 265 270		
Leu Val Asp Ser Ile Leu Pro Gly Ser Ser Tyr Glu Val Gln Val Arg		
275 280 285		
Gly Lys Arg Leu Asp Gly Pro Gly Ile Trp Ser Asp Trp Ser Thr Pro		
290 295 300		
Arg Val Phe Thr Thr Gln Asp Val Ile Tyr Phe Pro Pro Lys Ile Leu		
305 310 315 320		
Thr Ser Val Gly Ser Asn Val Ser Phe His Cys Ile Tyr Lys Lys Glu		
325 330 335		
Asn Lys Ile Val Pro Ser Lys Glu Ile Val Trp Trp Met Asn Leu Ala		
340 345 350		

Glu 355	Lys	Ile	Pro	Gln	Ser	Gln 360	Tyr	Asp	Val	Val	Ser 365	Asp	His	Val	Ser
Lys 370	Val	Thr	Phe	Phe	Asn 375	Leu	Asn	Glu	Thr	Lys 380	Pro	Arg	Gly	Lys	Phe
Thr 385	Tyr	Asp	Ala	Val	Tyr 390	Cys	Cys	Asn	Glu	His 395	Glu	Cys	His	His	Arg 400
Tyr	Ala	Glu	Leu	Tyr 405	Val	Ile	Asp	Val	Asn 410	Ile	Asn	Ile	Ser	Cys 415	Glu
Thr	Asp	Gly	Tyr 420	Leu	Thr	Lys	Met	Thr 425	Cys	Arg	Trp	Ser	Thr 430	Ser	Thr
Ile	Gln	Ser 435	Leu	Ala	Glu	Ser	Thr 440	Leu	Gln	Leu	Arg	Tyr 445	His	Arg	Ser
Ser	Leu	Tyr 450	Cys	Ser	Asp 455	Ile	Pro	Ser	Ile	His	Pro 460	Ile	Ser	Glu	Pro
Lys 465	Asp	Cys	Tyr	Leu	Gln 470	Ser	Asp	Gly	Phe	Tyr 475	Glu	Cys	Ile	Phe	Gln 480
Pro	Ile	Phe	Leu	Leu 485	Ser	Gly	Tyr	Thr	Met	Trp 490	Ile	Arg	Ile	Asn 495	His
Ser	Leu	Gly	Ser	Leu 500	Asp	Ser	Pro	Pro 505	Thr	Cys	Val	Leu	Pro 510	Asp	Ser
Val	Val	Lys 515	Pro	Leu	Pro	Pro	Ser 520	Ser	Val	Lys	Ala	Glu 525	Ile	Thr	Ile
Asn	Ile	Gly 530	Leu	Leu	Lys 535	Ile	Ser	Trp	Glu	Lys	Pro 540	Val	Phe	Pro	Glu
Asn 545	Asn	Leu	Gln	Phe	Gln 550	Ile	Arg	Tyr	Gly	Leu 555	Ser	Gly	Lys	Glu	Val 560
Gln	Trp	Lys	Met	Tyr 565	Glu	Val	Tyr	Asp	Ala 570	Lys	Ser	Lys	Ser	Val 575	Ser
Leu	Pro	Val	Pro	Asp 580	Leu	Cys	Ala	Val 585	Tyr	Ala	Val	Gln	Val 590	Arg	Cys
Lys	Arg	Leu 595	Asp	Gly	Leu	Gly	Tyr 600	Trp	Ser	Asn	Trp	Ser 605	Asn	Pro	Ala
Tyr	Thr	Val 610	Val	Met	Asp 615	Ile	Lys	Val	Pro	Met	Arg 620	Gly	Pro	Glu	Phe
Trp	Arg	Ile 625	Ile	Asn	Gly 630	Asp	Thr	Met	Lys	Lys 635	Glu	Lys	Asn	Val	Thr 640
Leu	Leu	Trp	Lys	Pro 645	Leu	Met	Lys	Asn	Asp 650	Ser	Leu	Cys	Ser	Val 655	Gln
Arg	Tyr	Val 660	Ile	Asn	His	His	Thr	Ser 665	Cys	Asn	Gly	Thr 670	Trp	Ser	Glu
Asp	Val	Gly 675	Asn	His	Thr	Lys	Phe 680	Thr	Phe	Leu	Trp	Thr 685	Glu	Gln	Ala
His	Thr	Val 690	Thr	Val	Leu 695	Ala	Ile	Asn	Ser	Ile	Gly 700	Ala	Ser	Val	Ala
Asn	Phe	Asn 705	Leu	Thr	Phe 710	Ser	Trp	Pro	Met	Ser 715	Lys	Val	Asn	Ile	Val 720
Gln	Ser	Leu	Ser	Ala 725	Tyr	Pro	Leu	Asn	Ser	Ser 730	Cys	Val	Ile	Val 735	Ser
Trp	Ile	Leu	Ser	Pro 740	Ser	Asp	Tyr	Lys 745	Leu	Met	Tyr	Phe 750	Ile	Ile	Glu
Trp	Lys	Asn 755	Leu	Asn	Glu 760	Asp	Gly 760	Glu	Ile	Lys	Trp	Leu 765	Arg	Ile	Ser
Ser	Ser	Val	Lys	Lys	Tyr	Tyr	Ile	His	Asp	His	Phe	Ile	Pro	Ile	Glu

-continued

770	775	780
Lys Tyr Gln Phe Ser Leu Tyr Pro Ile Phe Met Glu Gly Val Gly Lys		
785	790	795 800
Pro Lys Ile Ile Asn Ser Phe Thr Gln Asp Asp Ile Glu Lys His Gln		
	805	810 815
Ser Asp Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu		
	820	825 830
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr		
	835	840 845
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val		
	850	855 860
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val		
	865	870 875 880
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser		
	885	890 895
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu		
	900	905 910
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala		
	915	920 925
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro		
	930	935 940
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln		
	945	950 955 960
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala		
	965	970 975
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr		
	980	985 990
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu		
	995	1000 1005
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys		
	1010	1015 1020
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser		
	1025	1030 1035
Leu Ser Leu Ser Pro Gly Lys		
	1040	1045

<210> SEQ ID NO 93

<211> LENGTH: 844

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: MfLEPR-mmh aa 1-816: Macaca fascicularis LEPR
(F22-D837 of XP_005543194.1 with a T827A substitution) aa 817-844:
myc-myc-hexahistidine tag

<400> SEQUENCE: 93

Phe Asn Leu Ser Tyr Pro Ile Thr Pro Trp Arg Phe Lys Leu Ser Cys
1 5 10 15
Met Pro Pro Asn Ser Thr Tyr Asp Tyr Phe Leu Leu Pro Ala Gly Leu
20 25 30
Ser Lys Asn Thr Ser Asn Leu Asn Gly His Tyr Glu Thr Ala Val Glu
35 40 45
Phe Asn Ser Ser Asp Thr His Phe Ser Asn Leu Ser Lys Thr Thr Phe
50 55 60
His Cys Cys Phe Arg Ser Glu Gln Asp Arg Asn Cys Ser Leu Cys Ala
65 70 75 80

-continued

Asp	Asn	Ile	Glu	Gly	Lys	Thr	Phe	Val	Ser	Thr	Val	Asn	Ser	Ser	Val	85	90	95	
Phe	Gln	Gln	Met	Gly	Ala	Asn	Trp	Asn	Ile	Gln	Cys	Trp	Leu	Lys	Gly	100	105	110	
Asp	Leu	Lys	Leu	Phe	Ile	Cys	Tyr	Val	Glu	Ser	Leu	Phe	Lys	Asn	Pro	115	120	125	
Phe	Lys	Asn	Tyr	Lys	His	Lys	Val	His	Leu	Leu	Tyr	Val	Leu	Pro	Glu	130	135	140	
Val	Leu	Glu	Asp	Ser	Pro	Leu	Val	Pro	Gln	Lys	Gly	Ser	Phe	Gln	Met	145	150	155	160
Val	His	Cys	Asn	Cys	Ser	Val	His	Glu	Arg	Cys	Glu	Cys	Leu	Val	Pro	165	170	175	
Val	Pro	Thr	Ala	Lys	Leu	Asn	Asp	Thr	Leu	Leu	Met	Cys	Leu	Lys	Ile	180	185	190	
Thr	Ser	Gly	Gly	Val	Ile	Phe	Gln	Ser	Pro	Leu	Met	Ser	Val	Gln	Pro	195	200	205	
Ile	Asn	Met	Val	Lys	Pro	Asp	Pro	Pro	Leu	Gly	Leu	Arg	Met	Glu	Ile	210	215	220	
Thr	Asp	Asp	Gly	Asn	Leu	Lys	Ile	Ser	Trp	Ser	Ser	Pro	Pro	Leu	Val	225	230	235	240
Pro	Phe	Pro	Leu	Gln	Tyr	Glu	Val	Lys	Tyr	Ser	Glu	Asn	Ser	Thr	Thr	245	250	255	
Val	Ile	Arg	Glu	Ala	Asp	Lys	Ile	Val	Ser	Ala	Thr	Ser	Leu	Leu	Val	260	265	270	
Asp	Gly	Ile	Leu	Pro	Gly	Ser	Ser	Tyr	Glu	Val	Gln	Val	Arg	Gly	Lys	275	280	285	
Arg	Leu	Asp	Gly	Pro	Gly	Ile	Trp	Ser	Asp	Trp	Ser	Thr	Pro	His	Val	290	295	300	
Phe	Thr	Thr	Gln	Asp	Val	Ile	Tyr	Phe	Pro	Pro	Lys	Ile	Leu	Thr	Ser	305	310	315	320
Val	Gly	Ser	Asn	Val	Ser	Phe	His	Cys	Ile	Tyr	Lys	Asn	Glu	Asn	Lys	325	330	335	
Ile	Val	Ser	Ser	Lys	Lys	Ile	Val	Trp	Trp	Met	Asn	Leu	Ala	Glu	Lys	340	345	350	
Ile	Pro	Gln	Ser	Gln	Tyr	Asp	Val	Val	Ser	Asp	His	Val	Ser	Lys	Val	355	360	365	
Thr	Phe	Phe	Asn	Leu	Asn	Glu	Thr	Lys	Pro	Arg	Gly	Lys	Phe	Thr	Tyr	370	375	380	
Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	His	Glu	Cys	His	His	Arg	Tyr	Ala	385	390	395	400
Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile	Asn	Ile	Ser	Cys	Glu	Thr	Asp	405	410	415	
Gly	His	Leu	Thr	Lys	Met	Thr	Cys	Arg	Trp	Ser	Thr	Asn	Thr	Ile	Gln	420	425	430	
Ser	Leu	Ala	Gly	Ser	Thr	Leu	Gln	Leu	Arg	Tyr	Arg	Arg	Ser	Ser	Leu	435	440	445	
Tyr	Cys	Phe	Asp	Ile	Pro	Ser	Ile	His	Pro	Ile	Ser	Lys	Pro	Lys	Asp	450	455	460	
Cys	Tyr	Leu	Gln	Ser	Asp	Gly	Phe	Tyr	Glu	Cys	Val	Phe	Gln	Pro	Ile	465	470	475	480
Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp	Ile	Arg	Ile	Asn	His	Pro	Leu	485	490	495	

-continued

Gly Ser Leu Asp Ser Pro Pro Thr Cys Val Leu Pro Asp Ser Val Val
 500 505 510
 Lys Pro Leu Pro Pro Ser Ser Val Lys Ala Glu Ile Ile Lys Asn Ile
 515 520 525
 Gly Leu Leu Lys Ile Ser Trp Glu Lys Pro Val Phe Pro Glu Asn Asn
 530 535 540
 Leu Gln Phe Gln Ile Arg Tyr Gly Leu Ser Gly Lys Glu Ile Gln Trp
 545 550 555 560
 Lys Met Tyr Asp Val Tyr Asp Ala Lys Ser Lys Ser Val Ser Leu Pro
 565 570 575
 Val Pro Asp Phe Cys Ala Val Tyr Ala Val Gln Val Arg Cys Lys Arg
 580 585 590
 Ser Asp Gly Leu Gly Leu Trp Ser Asn Trp Ser Asn Pro Ala Tyr Thr
 595 600 605
 Val Val Met Asp Ile Lys Val Pro Met Arg Gly Pro Glu Phe Trp Arg
 610 615 620
 Ile Ile Asn Gly Asp Thr Met Lys Lys Glu Lys Asn Val Thr Leu Leu
 625 630 635 640
 Trp Lys Pro Leu Met Lys Asn Asp Ser Leu Cys Ser Val Gln Arg Tyr
 645 650 655
 Val Ile Asn His His Thr Ser Cys Asn Gly Thr Trp Ser Glu Asp Val
 660 665 670
 Gly Asn His Thr Lys Phe Thr Phe Leu Trp Thr Glu Gln Ala His Thr
 675 680 685
 Val Thr Val Leu Ala Ile Asn Ser Ile Gly Ala Ser Val Ala Asn Phe
 690 695 700
 Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val Asn Ile Val Gln Ser
 705 710 715 720
 Leu Ser Ala Tyr Pro Leu Asn Ser Ser Cys Val Ile Leu Ser Trp Ile
 725 730 735
 Leu Ser Pro Ser Asp Tyr Lys Leu Met Tyr Phe Ile Ile Glu Trp Lys
 740 745 750
 Asn Leu Asn Glu Asp Gly Glu Ile Lys Trp Leu Arg Ile Ser Ser Ser
 755 760 765
 Val Lys Lys Tyr Tyr Ile His Asp His Phe Ile Pro Ile Glu Lys Tyr
 770 775 780
 Gln Phe Ser Leu Tyr Pro Ile Phe Met Glu Gly Val Gly Lys Pro Lys
 785 790 795 800
 Ile Ile Asn Ser Phe Ala Gln Asp Asn Thr Glu Lys His Gln Asn Asp
 805 810 815
 Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu Gly Gly Glu Gln Lys Leu
 820 825 830
 Ile Ser Glu Glu Asp Leu His His His His His His
 835 840

 <210> SEQ ID NO 94
 <211> LENGTH: 846
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: mLEPR-mmh aa 1-818: mouse LEPR (L22-G839 of
 NP_666258.2) aa 819-846: myc-myc-hexahistidine tag

 <400> SEQUENCE: 94

 Leu Asn Leu Ala Tyr Pro Ile Ser Pro Trp Lys Phe Lys Leu Phe Cys
 1 5 10 15

Gly	Pro	Pro	Asn	Thr	Thr	Asp	Asp	Ser	Phe	Leu	Ser	Pro	Ala	Gly	Ala
			20				25					30			
Pro	Asn	Asn	Ala	Ser	Ala	Leu	Lys	Gly	Ala	Ser	Glu	Ala	Ile	Val	Glu
			35			40					45				
Ala	Lys	Phe	Asn	Ser	Ser	Gly	Ile	Tyr	Val	Pro	Glu	Leu	Ser	Lys	Thr
			50			55				60					
Val	Phe	His	Cys	Cys	Phe	Gly	Asn	Glu	Gln	Gly	Gln	Asn	Cys	Ser	Ala
			65		70				75						80
Leu	Thr	Asp	Asn	Thr	Glu	Gly	Lys	Thr	Leu	Ala	Ser	Val	Val	Lys	Ala
			85					90					95		
Ser	Val	Phe	Arg	Gln	Leu	Gly	Val	Asn	Trp	Asp	Ile	Glu	Cys	Trp	Met
			100				105					110			
Lys	Gly	Asp	Leu	Thr	Leu	Phe	Ile	Cys	His	Met	Glu	Pro	Leu	Pro	Lys
			115			120					125				
Asn	Pro	Phe	Lys	Asn	Tyr	Asp	Ser	Lys	Val	His	Leu	Leu	Tyr	Asp	Leu
			130			135					140				
Pro	Glu	Val	Ile	Asp	Asp	Ser	Pro	Leu	Pro	Pro	Leu	Lys	Asp	Ser	Phe
			145		150				155						160
Gln	Thr	Val	Gln	Cys	Asn	Cys	Ser	Leu	Arg	Gly	Cys	Glu	Cys	His	Val
			165					170					175		
Pro	Val	Pro	Arg	Ala	Lys	Leu	Asn	Tyr	Ala	Leu	Leu	Met	Tyr	Leu	Glu
			180				185					190			
Ile	Thr	Ser	Ala	Gly	Val	Ser	Phe	Gln	Ser	Pro	Leu	Met	Ser	Leu	Gln
			195			200					205				
Pro	Met	Leu	Val	Val	Lys	Pro	Asp	Pro	Pro	Leu	Gly	Leu	His	Met	Glu
			210		215					220					
Val	Thr	Asp	Asp	Gly	Asn	Leu	Lys	Ile	Ser	Trp	Asp	Ser	Gln	Thr	Met
			225		230			235						240	
Ala	Pro	Phe	Pro	Leu	Gln	Tyr	Gln	Val	Lys	Tyr	Leu	Glu	Asn	Ser	Thr
			245				250						255		
Ile	Val	Arg	Glu	Ala	Ala	Glu	Ile	Val	Ser	Ala	Thr	Ser	Leu	Leu	Val
			260				265					270			
Asp	Ser	Val	Leu	Pro	Gly	Ser	Ser	Tyr	Glu	Val	Gln	Val	Arg	Ser	Lys
			275			280					285				
Arg	Leu	Asp	Gly	Ser	Gly	Val	Trp	Ser	Asp	Trp	Ser	Ser	Pro	Gln	Val
			290		295					300					
Phe	Thr	Thr	Gln	Asp	Val	Val	Tyr	Phe	Pro	Pro	Lys	Ile	Leu	Thr	Ser
			305		310			315						320	
Val	Gly	Ser	Asn	Ala	Ser	Phe	His	Cys	Ile	Tyr	Lys	Asn	Glu	Asn	Gln
			325				330					335			
Ile	Ile	Ser	Ser	Lys	Gln	Ile	Val	Trp	Trp	Arg	Asn	Leu	Ala	Glu	Lys
			340				345					350			
Ile	Pro	Glu	Ile	Gln	Tyr	Ser	Ile	Val	Ser	Asp	Arg	Val	Ser	Lys	Val
			355			360					365				
Thr	Phe	Ser	Asn	Leu	Lys	Ala	Thr	Arg	Pro	Arg	Gly	Lys	Phe	Thr	Tyr
			370		375										

Ser	Leu	Val	Gly	Ser	Thr	Val	Gln	Leu	Arg	Tyr	His	Arg	Arg	Ser	Leu
		435													
Tyr	Cys	Pro	Asp	Ser	Pro	Ser	Ile	His	Pro	Thr	Ser	Glu	Pro	Lys	Asn
		450													
Cys	Val	Leu	Gln	Arg	Asp	Gly	Phe	Tyr	Glu	Cys	Val	Phe	Gln	Pro	Ile
		465													
Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp	Ile	Arg	Ile	Asn	His	Ser	Leu
					485										
Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys	Val	Leu	Pro	Asp	Ser	Val	Val
					500										
Lys	Pro	Leu	Pro	Pro	Ser	Asn	Val	Lys	Ala	Glu	Ile	Thr	Val	Asn	Thr
					515										
Gly	Leu	Leu	Lys	Val	Ser	Trp	Glu	Lys	Pro	Val	Phe	Pro	Glu	Asn	Asn
					530										
Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu	Ser	Gly	Lys	Glu	Ile	Gln	Trp
					550										
Lys	Thr	His	Glu	Val	Phe	Asp	Ala	Lys	Ser	Lys	Ser	Ala	Ser	Leu	Leu
					565										
Val	Ser	Asp	Leu	Cys	Ala	Val	Tyr	Val	Val	Gln	Val	Arg	Cys	Arg	Arg
					580										
Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn	Trp	Ser	Ser	Pro	Ala	Tyr	Thr
					595										
Leu	Val	Met	Asp	Val	Lys	Val	Pro	Met	Arg	Gly	Pro	Glu	Phe	Trp	Arg
					610										
Lys	Met	Asp	Gly	Asp	Val	Thr	Lys	Lys	Glu	Arg	Asn	Val	Thr	Leu	Leu
					625										
Trp	Lys	Pro	Leu	Thr	Lys	Asn	Asp	Ser	Leu	Cys	Ser	Val	Arg	Arg	Tyr
					645										
Val	Val	Lys	His	Arg	Thr	Ala	His	Asn	Gly	Thr	Trp	Ser	Glu	Asp	Val
					660										
Gly	Asn	Arg	Thr	Asn	Leu	Thr	Phe	Leu	Trp	Thr	Glu	Pro	Ala	His	Thr
					675										
Val	Thr	Val	Leu	Ala	Val	Asn	Ser	Leu	Gly	Ala	Ser	Leu	Val	Asn	Phe
					690										
Asn	Leu	Thr	Phe	Ser	Trp	Pro	Met	Ser	Lys	Val	Ser	Ala	Val	Glu	Ser
					705										
Leu	Ser	Ala	Tyr	Pro	Leu	Ser	Ser	Ser	Cys	Val	Ile	Leu	Ser	Trp	Thr
					725										
Leu	Ser	Pro	Asp	Asp	Tyr	Ser	Leu	Leu	Tyr	Leu	Val	Ile	Glu	Trp	Lys
					740										
Ile	Leu	Asn	Glu	Asp	Asp	Gly	Met	Lys	Trp	Leu	Arg	Ile	Pro	Ser	Asn
					755										
Val	Lys	Lys	Phe	Tyr	Ile	His	Asp	Asn	Phe	Ile	Pro	Ile	Glu	Lys	Tyr
					770										
Gln	Phe	Ser	Leu	Tyr	Pro	Val	Phe	Met	Glu	Gly	Val	Gly	Lys	Pro	Lys
					785										
Ile	Ile	Asn	Gly	Phe	Thr	Lys	Asp	Ala	Ile	Asp	Lys	Gln	Gln	Asn	Asp
					805										
Ala	Gly	Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Gly	Gly	Glu	Gln
					820										
Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	His	His	His	His	His	His		
					835										

-continued

```

<210> SEQ ID NO 95
<211> LENGTH: 846
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: rLEPR-mmh aa 1-818: rat LEPR (L22-G839 of
      NP_036728.1) aa 819-846: myc-myc-hexahistidine tag

```

```

<400> SEQUENCE: 95

```

```

Leu Asn Leu Ala Tyr Pro Thr Ser Pro Trp Arg Phe Lys Leu Phe Cys
 1             5             10             15

Ala Pro Pro Ser Thr Thr Asp Asp Ser Phe Leu Ser Pro Ala Gly Val
      20             25             30

Pro Asn Asn Thr Ser Ser Leu Lys Gly Ala Ser Glu Ala Leu Val Glu
      35             40             45

Ala Lys Phe Asn Ser Thr Gly Ile Tyr Val Ser Glu Leu Ser Lys Thr
 50             55             60

Ile Phe His Cys Cys Phe Gly Asn Glu Gln Gly Gln Asn Cys Ser Ala
 65             70             75             80

Leu Thr Gly Asn Thr Glu Gly Lys Thr Leu Ala Ser Val Val Lys Pro
      85             90             95

Leu Val Phe Arg Gln Leu Gly Val Asn Trp Asp Ile Glu Cys Trp Met
      100            105            110

Lys Gly Asp Leu Thr Leu Phe Ile Cys His Met Glu Pro Leu Leu Lys
      115            120            125

Asn Pro Phe Lys Asn Tyr Asp Ser Lys Val His Leu Leu Tyr Asp Leu
      130            135            140

Pro Glu Val Ile Asp Asp Leu Pro Leu Pro Pro Leu Lys Asp Ser Phe
      145            150            155            160

Gln Thr Val Gln Cys Asn Cys Ser Val Arg Glu Cys Glu Cys His Val
      165            170            175

Pro Val Pro Arg Ala Lys Val Asn Tyr Ala Leu Leu Met Tyr Leu Glu
      180            185            190

Ile Thr Ser Ala Gly Val Ser Phe Gln Ser Pro Leu Met Ser Leu Gln
      195            200            205

Pro Met Leu Val Val Lys Pro Asp Pro Pro Leu Gly Leu Arg Met Glu
      210            215            220

Val Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp Asp Ser Gln Thr Lys
      225            230            235            240

Ala Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr Leu Glu Asn Ser Thr
      245            250            255

Ile Val Arg Glu Ala Ala Glu Ile Val Ser Asp Thr Ser Leu Leu Val
      260            265            270

Asp Ser Val Leu Pro Gly Ser Ser Tyr Glu Val Gln Val Arg Ser Lys
      275            280            285

Arg Leu Asp Gly Ser Gly Val Trp Ser Asp Trp Ser Leu Pro Gln Leu
      290            295            300

Phe Thr Thr Gln Asp Val Met Tyr Phe Pro Pro Lys Ile Leu Thr Ser
      305            310            315            320

Val Gly Ser Asn Ala Ser Phe Cys Cys Ile Tyr Lys Asn Glu Asn Gln
      325            330            335

Thr Ile Ser Ser Lys Gln Ile Val Trp Trp Met Asn Leu Ala Glu Lys
      340            345            350

Ile Pro Glu Thr Gln Tyr Asn Thr Val Ser Asp His Ile Ser Lys Val
      355            360            365

```

-continued

Thr	Phe	Ser	Asn	Leu	Lys	Ala	Thr	Arg	Pro	Arg	Gly	Lys	Phe	Thr	Tyr
370						375					380				
Asp	Ala	Val	Tyr	Cys	Cys	Asn	Glu	Gln	Ala	Cys	His	His	Arg	Tyr	Ala
385					390					395					400
Glu	Leu	Tyr	Val	Ile	Asp	Val	Asn	Ile	Asn	Ile	Ser	Cys	Glu	Thr	Asp
			405						410					415	
Gly	Tyr	Leu	Thr	Lys	Met	Thr	Cys	Arg	Trp	Ser	Pro	Ser	Thr	Ile	Gln
			420						425				430		
Ser	Leu	Val	Gly	Ser	Thr	Val	Gln	Leu	Arg	Tyr	His	Arg	Arg	Ser	Leu
		435					440					445			
Tyr	Cys	Pro	Asp	Asn	Pro	Ser	Ile	Arg	Pro	Thr	Ser	Glu	Leu	Lys	Asn
	450					455					460				
Cys	Val	Leu	Gln	Thr	Asp	Gly	Phe	Tyr	Glu	Cys	Val	Phe	Gln	Pro	Ile
465					470					475					480
Phe	Leu	Leu	Ser	Gly	Tyr	Thr	Met	Trp	Ile	Arg	Ile	Asn	His	Ser	Leu
			485						490					495	
Gly	Ser	Leu	Asp	Ser	Pro	Pro	Thr	Cys	Val	Leu	Pro	Asp	Ser	Val	Val
			500					505					510		
Lys	Pro	Leu	Pro	Pro	Ser	Asn	Val	Lys	Ala	Glu	Ile	Thr	Ile	Asn	Thr
		515					520						525		
Gly	Leu	Leu	Lys	Val	Ser	Trp	Glu	Lys	Pro	Val	Phe	Pro	Glu	Asn	Asn
	530					535					540				
Leu	Gln	Phe	Gln	Ile	Arg	Tyr	Gly	Leu	Asn	Gly	Lys	Glu	Ile	Gln	Trp
545					550					555					560
Lys	Thr	His	Glu	Val	Phe	Asp	Ala	Lys	Ser	Lys	Ser	Ala	Ser	Leu	Pro
			565					570						575	
Val	Ser	Asp	Leu	Cys	Ala	Val	Tyr	Val	Val	Gln	Val	Arg	Cys	Arg	Arg
			580					585					590		
Leu	Asp	Gly	Leu	Gly	Tyr	Trp	Ser	Asn	Trp	Ser	Ser	Pro	Ala	Tyr	Thr
	595					600						605			
Leu	Val	Met	Asp	Val	Lys	Val	Pro	Met	Arg	Gly	Pro	Glu	Phe	Trp	Arg
	610					615					620				
Ile	Met	Asp	Gly	Asp	Ile	Thr	Lys	Lys	Glu	Arg	Asn	Val	Thr	Leu	Leu
625					630					635					640
Trp	Lys	Pro	Leu	Met	Lys	Asn	Asp	Ser	Leu	Cys	Ser	Val	Arg	Arg	Tyr
			645						650					655	
Val	Val	Lys	His	Arg	Thr	Ala	His	Asn	Gly	Thr	Trp	Ser	Gln	Asp	Val
			660					665					670		
Gly	Asn	Gln	Thr	Asn	Leu	Thr	Phe	Leu	Trp	Ala	Glu	Ser	Ala	His	Thr
	675						680					685			
Val	Thr	Val	Leu	Ala	Ile	Asn	Ser	Ile	Gly	Ala	Ser	Leu	Val	Asn	Phe
	690					695					700				
Asn	Leu	Thr	Phe	Ser	Trp	Pro	Met	Ser	Lys	Val	Asn	Ala	Val	Gln	Ser
705					710					715					720
Leu	Ser	Ala	Tyr	Pro	Leu	Ser	Ser	Ser	Cys	Val	Ile	Leu	Ser	Trp	Thr
			725						730					735	
Leu	Ser	Pro	Asn	Asp	Tyr	Ser	Leu	Leu	Tyr	Leu	Val	Ile	Glu	Trp	Lys
			740					745					750		
Asn	Leu	Asn	Asp	Asp	Asp	Gly	Met	Lys	Trp	Leu	Arg	Ile	Pro	Ser	Asn
		755					760					765			
Val	Asn	Lys	Tyr	Tyr	Ile	His	Asp	Asn	Phe	Ile	Pro	Ile	Glu	Lys	Tyr
770						775						780			

-continued

Gln	Phe	Ser	Leu	Tyr	Pro	Val	Phe	Met	Glu	Gly	Val	Gly	Lys	Pro	Lys
785					790					795					800
Ile	Ile	Asn	Gly	Phe	Thr	Lys	Asp	Asp	Ile	Ala	Lys	Gln	Gln	Asn	Asp
			805						810					815	
Ala	Gly	Glu	Gln	Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	Gly	Gly	Glu	Gln
			820					825					830		
Lys	Leu	Ile	Ser	Glu	Glu	Asp	Leu	His	His	His	His	His	His		
	835						840					845			

What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof that binds human leptin receptor (LEPR), wherein the antibody or antigen-binding fragment thereof comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) that comprises an amino acid sequence set forth in a SEQ ID NO selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 42, and SEQ ID NO: 58 and (b) the CDRs of a light chain variable region (LCVR) that comprises the amino acid sequence set forth in SEQ ID NO: 10.

2. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12; an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14, and an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16; and

a heavy chain variable region comprising:

(i) an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 4; an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 6; and an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 8;

(ii) an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 44; an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 46; and an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 48; or

(iii) an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 60; an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 62; and an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 64.

3. The isolated antibody or antigen-binding fragment thereof of claim 2, which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

4. The isolated antibody or antigen-binding fragment thereof of claim 2 which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 42 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

5. The isolated antibody or antigen-binding fragment thereof of claim 2 which is an antibody comprising a heavy chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 58 and a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 10.

6. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier or diluent.

7. The antibody of claim 3 wherein the heavy chain variable region is linked to a human IgG4 Fc.

8. The antibody of claim 4 wherein the heavy chain variable region is linked to a human IgG4 Fc.

9. The antibody of claim 5 wherein the heavy chain variable region is linked to a human IgG4 Fc.

10. A pharmaceutical composition comprising the antibody of claim 7, and a pharmaceutically acceptable carrier or diluent.

11. A pharmaceutical composition comprising the antibody of claim 8, and a pharmaceutically acceptable carrier or diluent.

12. A pharmaceutical composition comprising the antibody of claim 9, and a pharmaceutically acceptable carrier or diluent.

13. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;

an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14; and

an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16;

and a heavy chain variable region comprising:

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 4;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 6; and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 8.

14. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;

an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14; and

an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16; and

a heavy chain variable region comprising:

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 44;

117

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 46; and
an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 48.

15. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising:

an LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 12;

an LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 14; and

an LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 16; and

a heavy chain variable region comprising:

an HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 60;

an HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 62; and

an HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 64.

118

16. An autoinjector that comprises the antibody of claim 3.

17. An autoinjector that comprises the antibody of claim 4.

18. An autoinjector that comprises the antibody of claim 5.

19. A pen delivery device that comprises the antibody of claim 3.

20. A pen delivery device that comprises the antibody of claim 4.

21. A pen delivery device that comprises the antibody of claim 5.

22. The antibody of claim 7 wherein the light chain variable region is linked to a kappa light chain constant domain.

23. The antibody of claim 8 wherein the light chain variable region is linked to a kappa light chain constant domain.

24. The antibody of claim 9 wherein the light chain variable region is linked to a kappa light chain constant domain.

* * * * *

**Traducción al castellano de todas las reivindicaciones
determinadas como patentables como aparecen en la publicación
de la patente No. US 10,550, 192 B2**

Lo reivindicado es:

1. Un anticuerpo aislado o fragmento de unión a antígeno del mismo que se une al receptor de leptina humana (LEPR), en el que el anticuerpo o fragmento de unión a antígeno del mismo comprende: (a) las regiones determinantes de complementariedad (CDR) de una región variable de cadena pesada (HCVR) que comprende una secuencia de aminoácidos establecida en una SEQ ID NO seleccionada del grupo que consiste en SEQ ID NO: 2, SEQ ID NO: 42 y SEQ ID NO: 58 y (b) los CDRs de una región variable de cadena ligera (LCVR) que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

2. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **1**, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 12; una LCDR2 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 14, y una LCDR3 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 16; y

una región variable de cadena pesada que comprende:

(i)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8;

(ii)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 44;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:46; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48;

o

(iii)

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO:62; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.

3. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **2**, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 2 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

4. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **2**, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 42 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

5. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **2**, que es un anticuerpo que comprende una región variable de cadena pesada que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 58 y una región variable de cadena ligera que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 10.

6. Una composición farmacéutica que comprende el anticuerpo o fragmento de unión a antígeno del mismo según la reivindicación **1**, y un vehículo o diluyente farmacéuticamente aceptable.

7. El anticuerpo según la reivindicación **3**, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

8. El anticuerpo según la reivindicación **4**, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

9. El anticuerpo según la reivindicación **5**, en el que la región variable de la cadena pesada está unida a un IgG4 Fc humano.

10. Una composición farmacéutica que comprende el anticuerpo según la reivindicación **7**, y un vehículo o diluyente farmacéuticamente aceptable.

11. Una composición farmacéutica que comprende el anticuerpo según la reivindicación **8**, y un vehículo o diluyente farmacéuticamente aceptable.

12. Una composición farmacéutica que comprende el anticuerpo según la reivindicación **9**, y un vehículo o diluyente farmacéuticamente aceptable.

13. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **1**, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12;

una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16;

y una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 4;

un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 6; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 8.

14. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **1**, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de la cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos expuesta en la SEQ ID NO: 12;

una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y

una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en la SEQ ID NO: 44; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 46; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 48.

15. El anticuerpo aislado o fragmento de unión a antígeno del mismo según la reivindicación **1**, en donde el anticuerpo o fragmento de unión a antígeno comprende una región variable de cadena ligera que comprende:

una LCDR1 que comprende la secuencia de aminoácidos expuesta en SEQ ID NO: 12;

una LCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 14; y

una LCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 16; y

una región variable de cadena pesada que comprende:

un HCDR1 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 60; un HCDR2 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 62; y

un HCDR3 que comprende la secuencia de aminoácidos establecida en SEQ ID NO: 64.

- 16.** Un autoinyector que comprende el anticuerpo según la reivindicación **3**.
- 17.** Un autoinyector que comprende el anticuerpo según la reivindicación **4**.
- 18.** Un autoinyector que comprende el anticuerpo según la reivindicación **5**.
- 19.** Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación **3**.
- 20.** Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación **4**.
- 21.** Un dispositivo de entrega de pluma que comprende el anticuerpo según la reivindicación **5**.
- 22.** El anticuerpo según la reivindicación **7** en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.
- 23.** El anticuerpo según la reivindicación **8** en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.
- 24.** El anticuerpo según la reivindicación **9** en el que la región variable de la cadena ligera está unida a un dominio constante de la cadena ligera kappa.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		15807426
	Filing Date		2017-11-08
	First Named Inventor	Jesper Gromada	
	Art Unit	1647	
	Examiner Name	SHAFER, SHULAMITH H.	
	Attorney Docket Number	09774.271US1/10271US01	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6005080		1999-12-21	SNODGRASS, et al.	
	2	6380363		2002-04-30	TARTAGLIA, et al.	
	3	7575878		2009-08-18	TAVERNIER, et al.	
	4	7863240		2011-01-04	ILAN, et al.	
	5	8969291		2015-03-03	ILAN, et al.	
	6	10023644		2018-07-17	GROMADA, et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15807426
Filing Date	2017-11-08
First Named Inventor	Jesper Gromada
Art Unit	1647
Examiner Name	SHAHER, SHULAMITH H.
Attorney Docket Number	09774.271US1/10271US01

1	20180037648	2018-02-08	ILAN, et al.
2	20190002569	2019-01-03	BELAID-CHOUCAIR, et al.
3	USSN16/222,800	2018-12-17	GROMADA, et al.

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	AU2004201496	AU	C1	2018-08-11	THE ROCKEFELLER UNIVERSITY		☐
	2	EP0730606	EP	B1	2005-11-05	INDEVUS PHARMACEUTICALS, INC.		☐
	3	EP1019432	EP	B1	2012-01-11	MILLENNIUM PHARMACEUTICALS, INC.		☐
	4	EP1619250	EP	B1	2009-11-25	GENENTECH, INC.		☐
	5	EP885299	EP	B1	2005-10-26	GENENTECH, INC.		☐
	6	EP981365	EP	B1	2004-12-01	YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.		☐

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		15807426
Filing Date		2017-11-08
First Named Inventor	Jesper Gromada	
Art Unit	1647	
Examiner Name	SHAHER, SHULAMITH H.	
Attorney Docket Number	09774.271US1/10271US01	

7	1996/08510	WO		1996-03-21	PROGENITOR, INC.		☐
8	1997/019952	WO		1997-06-05	MILLENNIUM PHARMACEUTICALS, INC.		☐
9	1997/025425	WO		1997-07-17	GENENTECH, INC.		☐
10	1997/26272	WO		1997-07-24	PROGENITOR, INC.		☐
11	1997/26370	WO		1997-07-24	PROGENITOR, INC.		☐
12	1997/26523	WO		1997-07-24	PROGENITOR, INC.		☐
13	1997/27286	WO		1997-07-31	PROGENITOR, INC.		☐
14	1997/41263	WO		1997-11-06	PROGENITOR, INC.		☐
15	1998/48831	WO		1998-11-05	YEDA RESEARCH & DEVELOPMENT COMPANY, LTD.		☐
16	2006/053883	WO		2006-05-26	VIB, VZW; UNIVERSITEIT, GENT		☐
17	2015/124588	WO		2015-08-27	INSERM (INSTITUT NATIONAL DE LA SANTÉ ...		☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		15807426
	Filing Date		2017-11-08
	First Named Inventor	Jesper Gromada	
	Art Unit	1647	
	Examiner Name	SHAHER, SHULAMITH H.	
	Attorney Docket Number	09774.271US1/10271US01	

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	TARTAGLIA et al., (1995) "Identification and Expression Cloning of a Leptin Receptor, OB-R", Cell, 83(7):1263-1271	☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE 10/02/2019

Examiner Signature	/SHULAMITH H SHAHER/	Date Considered	/SHULAMITH H SHAHER/
--------------------	----------------------	-----------------	----------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	15807426
Filing Date	2017-11-08
First Named Inventor	Jesper Gromada
Art Unit	1647
Examiner Name	SHAHER, SHULAMITH H.
Attorney Docket Number	09774.271US1/10271US01

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☒ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☒ The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Cara L. Crowley-Weber, Ph.D., J.D./	Date (YYYY-MM-DD)	2019-02-28
Name/Print	Cara L. Crowley-Weber, Ph.D., J.D.	Registration Number	58174

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.